

116TH CONGRESS  
2D SESSION

**S.** \_\_\_\_\_

To provide emergency assistance and health care response for individuals, families, and businesses affected by the 2020 coronavirus pandemic.

---

IN THE SENATE OF THE UNITED STATES

---

Mr. MCCONNELL (for himself, Mr. ALEXANDER, Mr. CRAPO, Mr. GRASSLEY, Mr. RUBIO, Mr. SHELBY, and Mr. WICKER) introduced the following bill; which was read twice and referred to the Committee on

---

## **A BILL**

To provide emergency assistance and health care response for individuals, families, and businesses affected by the 2020 coronavirus pandemic.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Coronavirus Aid, Re-  
5 lief, and Economic Security Act” or the “CARES Act”.

6 **SEC. 2. TABLE OF CONTENTS.**

7 The table of contents for this Act is as follows:

Sec. 1. Short title.

Sec. 2. Table of contents.

## 2

## DIVISION A—SMALL BUSINESS INTERRUPTION LOANS

- Sec. 1101. Definitions.
- Sec. 1102. 7(a) loan program.
- Sec. 1103. Entrepreneurial development.
- Sec. 1104. Waiver of matching funds requirement under the women's business center program.
- Sec. 1105. Loan forgiveness.
- Sec. 1106. Direct appropriations.
- Sec. 1107. Minority business development agency.
- Sec. 1108. Waiver of prepayment penalty.
- Sec. 1109. United States Treasury Program Management Authority.

## DIVISION B—RELIEF FOR INDIVIDUALS, FAMILIES, AND BUSINESSES

## TITLE I—REBATES AND OTHER INDIVIDUAL PROVISIONS

- Sec. 2101. 2020 recovery rebates for individuals.
- Sec. 2102. Delay of certain deadlines.
- Sec. 2103. Special rules for use of retirement funds.
- Sec. 2104. Allowance of partial above the line deduction for charitable contributions.
- Sec. 2105. Modification of limitations on charitable contributions during 2020.

## TITLE II—BUSINESS PROVISIONS

- Sec. 2201. Delay of estimated tax payments for corporations.
- Sec. 2202. Delay of payment of employer payroll taxes.
- Sec. 2203. Modifications for net operating losses.
- Sec. 2204. Modification of limitation on losses for taxpayers other than corporations.
- Sec. 2205. Modification of credit for prior year minimum tax liability of corporations.
- Sec. 2206. Modification of limitation on business interest.
- Sec. 2207. Technical amendments regarding qualified improvement property.
- Sec. 2208. Installments not to prevent credit or refund of overpayments or increase estimated taxes.
- Sec. 2209. Restoration of limitation on downward attribution of stock ownership in applying constructive ownership rules.

## DIVISION C—ASSISTANCE TO SEVERELY DISTRESSED SECTORS OF THE UNITED STATES ECONOMY

## TITLE I—ECONOMIC STABILIZATION

- Sec. 3101. Short title.
- Sec. 3102. Emergency relief through loans and loan guarantees.
- Sec. 3103. Limitation on certain employee compensation.
- Sec. 3104. Continuation of certain air service.
- Sec. 3105. Reports.
- Sec. 3106. Coordination with Secretary of Transportation.
- Sec. 3107. Definitions.
- Sec. 3108. Rule of construction.

## TITLE II—AVIATION EXCISE TAXES

- Sec. 3201. Suspension of certain aviation excise taxes.

## 3

## DIVISION D—HEALTH CARE RESPONSE

## TITLE I—HEALTH PROVISIONS

## Subtitle A—Addressing Supply Shortages

## PART I—MOVING THE STRATEGIC NATIONAL STOCKPILE TO ASPR

Sec. 4101. Moving the strategic national stockpile to ASPR.

## PART II—MEDICAL PRODUCT SUPPLIES

Sec. 4111. National Academies report on America’s medical product supply chain security.

Sec. 4112. Requiring the strategic national stockpile to include certain types of medical supplies.

Sec. 4113. Treatment of respiratory protective devices as covered counter-measures.

## PART III—MITIGATING EMERGENCY DRUG SHORTAGES

Sec. 4121. Prioritize reviews of drug applications; incentives.

Sec. 4122. Additional manufacturer reporting requirements in response to drug shortages.

Sec. 4123. GAO report on intra-agency coordination.

Sec. 4124. Report.

Sec. 4125. Safe harbor provision.

## PART IV—PREVENTING ESSENTIAL MEDICAL DEVICE SHORTAGES

Sec. 4131. Discontinuance or interruption in the production of medical devices.

Sec. 4132. GAO report on intra-agency coordination.

## PART V—EMERGENCY USE OF LABORATORY DEVELOPED TESTS

Sec. 4141. Emergency use of laboratory developed tests.

## Subtitle B—Access to Health Care for COVID-19 Patients

## PART I—COVERAGE OF TESTING AND PREVENTIVE SERVICES

Sec. 4201. Coverage of diagnostic testing for COVID-19.

Sec. 4202. Pricing of diagnostic testing.

Sec. 4203. Rapid coverage of preventive services and vaccines for coronavirus.

## PART II—SUPPORT FOR HEALTH CARE PROVIDERS

Sec. 4211. Supplemental awards for health centers.

Sec. 4212. Allowing permanent direct hire of NDMS health care professionals.

Sec. 4213. Telehealth network and telehealth resource centers grant programs.

Sec. 4214. Rural health care services outreach, rural health network development, and small health care provider quality improvement grant programs.

Sec. 4215. United States Public Health Service Modernization.

Sec. 4216. Limitation on liability for volunteer health care professionals during covid-19 emergency response.

## PART III—MISCELLANEOUS PROVISIONS

## 4

- Sec. 4221. Confidentiality and disclosure of records relating to substance use disorder.
- Sec. 4222. Nutrition services.
- Sec. 4223. Guidance on protected health information.
- Sec. 4224. Reauthorization of healthy start program.

## Subtitle C—Innovation

- Sec. 4301. Removing the cap on OTA.
- Sec. 4302. Extending the priority review program for agents that present national security threats.
- Sec. 4303. Priority zoonotic animal drugs.

## Subtitle D—Finance Committee

- Sec. 4401. Exemption for telehealth services.
- Sec. 4402. Inclusion of certain over-the-counter medical products as qualified medical expenses.
- Sec. 4403. Treatment of direct primary care service arrangements.
- Sec. 4404. Increasing Medicare telehealth flexibilities during emergency period.
- Sec. 4405. Enhancing Medicare telehealth services for Federally qualified health centers and rural health clinics during emergency period.
- Sec. 4406. Temporary waiver of requirement for face-to-face visits between home dialysis patients and physicians.
- Sec. 4407. Improving care planning for Medicare home health services.
- Sec. 4408. Adjustment of sequestration.
- Sec. 4409. Medicare hospital inpatient prospective payment system add-on payment for covid-19 patients during emergency period.
- Sec. 4410. Revising payment rates for durable medical equipment under the Medicare program through duration of emergency period.
- Sec. 4411. Providing home and community-based services in acute care hospitals.
- Sec. 4412. Treatment of technology-enabled collaborative learning and capacity building models as medical assistance.
- Sec. 4413. Encouraging the development and use of DISARM antimicrobial drugs.
- Sec. 4414. Novel medical products.

## TITLE II—EDUCATION PROVISIONS

- Sec. 4501. Short title.
- Sec. 4502. Definitions.
- Sec. 4503. Campus-based aid waivers.
- Sec. 4504. Use of supplemental educational opportunity grants for emergency aid.
- Sec. 4505. Federal work-study during a qualifying emergency.
- Sec. 4506. Adjustment of subsidized loan usage limits.
- Sec. 4507. Exclusion from Federal Pell Grant duration limit.
- Sec. 4508. Institutional refunds and Federal student loan flexibility.
- Sec. 4509. Satisfactory progress.
- Sec. 4510. Continuing education at affected foreign institutions.
- Sec. 4511. National emergency educational waivers.
- Sec. 4512. HBCU Capital financing.
- Sec. 4513. Temporary relief for federal student loan borrowers.

- Sec. 4514. Provisions related to the Corporation for National and Community Service.
- Sec. 4515. Workforce response activities.
- Sec. 4516. Technical amendments.

#### TITLE III—LABOR PROVISIONS

- Sec. 4601. Limitation on paid leave.
- Sec. 4602. Emergency Paid Sick Leave Act Limitation.
- Sec. 4603. Regulatory Authorities under the Emergency Paid Sick Leave Act.
- Sec. 4604. Unemployment insurance.
- Sec. 4605. OMB Waiver of Paid Family and Paid Sick Leave.
- Sec. 4606. Paid leave for rehired employees.
- Sec. 4607. Advance refunding of credits.

#### DIVISION E—TEMPORARY PERMIT USE TO GUARANTEE MONEY MARKET MUTUAL FUNDS

- Sec. 5001. Non-applicability of restrictions on ESF during national emergency.

#### DIVISION F—BUDGETARY PROVISIONS

- Sec. 6001. Emergency designation.

## 1 **DIVISION A—SMALL BUSINESS** 2 **INTERRUPTION LOANS**

### 3 **SEC. 1101. DEFINITIONS.**

4 In this division—

5 (1) the terms “Administration” and “Adminis-  
6 trator” mean the Small Business Administration  
7 and the Administrator thereof; and

8 (2) the term “small business concern” has the  
9 meaning given the term in section 3 of the Small  
10 Business Act (15 U.S.C. 632).

### 11 **SEC. 1102. 7(a) LOAN PROGRAM.**

12 (a) DEFINITION OF COVERED PERIOD.—In this sec-  
13 tion, the term “covered period” means the period begin-  
14 ning on March 1, 2020 and ending on December 31, 2020.

1 (b) INCREASED ELIGIBILITY FOR CERTAIN SMALL  
2 BUSINESSES AND ORGANIZATIONS.—

3 (1) IN GENERAL.—During the covered period,  
4 any business concern, private nonprofit organization,  
5 or public nonprofit organization which employs not  
6 more than 500 employees shall be eligible to receive  
7 a loan made under section 7(a) of the Small Busi-  
8 ness Act (15 U.S.C. 636(a)), in addition to small  
9 business concerns.

10 (2) EXCLUSION OF NONPROFITS RECEIVING  
11 MEDICAID EXPENDITURES.—Paragraph (1) shall not  
12 apply to a nonprofit entity eligible for payment for  
13 items or services furnished under a State plan under  
14 title XIX of the Social Security Act (42 U.S.C. 1396  
15 et seq.) or under a waiver of such plan.

16 (c) MAXIMUM LOAN AMOUNT.—During the covered  
17 period, with respect to any loan guaranteed under section  
18 7(a) of the Small Business Act (15 U.S.C. 636(a)) for  
19 which an application is approved or pending approval on  
20 or after the date of enactment of this Act, the maximum  
21 loan amount shall be the lesser of—

22 (1) the product obtained by multiplying—

23 (A) the average total monthly payments by  
24 the applicant for payroll, mortgage payments,  
25 rent payments, and payments on any other debt

1 obligations incurred during the 1 year period  
2 before the date on which the loan is made, ex-  
3 cept that, in the case of an applicant that is  
4 seasonal employer, as determined by the Ad-  
5 ministrator, the average total monthly pay-  
6 ments for payroll shall be for the period begin-  
7 ning March 1, 2019 and ending June 30, 2019;  
8 by

9 (B) 4; or  
10 (2) \$10,000,000.

11 (d) ALLOWABLE USES OF PROGRAM LOANS.—

12 (1) IN GENERAL.—During the covered period, a  
13 recipient of a loan made under section 7(a) of the  
14 Small Business Act (15 U.S.C. 636(a)) (including a  
15 recipient of assistance under the Community Advan-  
16 tage Pilot Program of the Administration) may, in  
17 addition to the allowable uses of such a loan, use the  
18 proceeds of the loan for—

19 (A) payroll support, including paid sick,  
20 medical, or family leave, and costs related to  
21 the continuation of group health care benefits  
22 during those periods of leave;

23 (B) employee salaries;

24 (C) mortgage payments;

1 (D) rent (including rent under a lease  
2 agreement);

3 (E) utilities; and

4 (F) any other debt obligations that were  
5 incurred before the covered period.

6 (2) DELEGATED AUTHORITY.—

7 (A) IN GENERAL.—For purposes of mak-  
8 ing loans for the purposes described in para-  
9 graph (1), a lender under section 7(a) of the  
10 Small Business Act (15 U.S.C. 636(a)) shall be  
11 considered to have delegated authority to make  
12 and approve loans under such section 7(a)  
13 based on an evaluation of the eligibility of the  
14 borrower.

15 (B) CONSIDERATIONS.—In evaluating the  
16 eligibility of a borrower for a loan under section  
17 7(a) of the Small Business Act (15 U.S.C.  
18 636(a)) with the terms described in this sub-  
19 section and subsection (c), a lender shall only  
20 consider whether the borrower—

21 (i) was in operation on March 1,  
22 2020; and

23 (ii) had employees for whom the bor-  
24 rower paid salaries and payroll taxes.



1           (3) LIMITATION.—A borrower that receives as-  
2           sistance under section 7(b)(2) of the Small Business  
3           Act (15 U.S.C. 636(b)(2)) related to COVID–19 for  
4           purposes of paying payroll and providing payroll  
5           support shall not be eligible for a loan described in  
6           paragraph (1) for the same purpose.

7           (e) FEE WAIVER FOR 7(A) LOANS.—During the cov-  
8           ered period, with respect to each loan guaranteed under  
9           section 7(a) of the Small Business Act (15 U.S.C.  
10          636(a))—

11           (1) in lieu of the fee otherwise applicable under  
12           section 7(a)(23)(A) of the Small Business Act (15  
13           U.S.C. 636(a)(23)(A)), the Administrator shall col-  
14           lect no fee or reduce fees to the maximum extent  
15           possible; and

16           (2) for which the application is approved on or  
17           after the date of enactment of this Act, the Adminis-  
18           trator shall, in lieu of the fee otherwise applicable  
19           under section 7(a)(18)(A) of the Small Business Act  
20           (15 U.S.C. 636(a)(18)(A)), collect no fee or reduce  
21           fees to the maximum extent possible.

22          (f) GUARANTEE AMOUNT FOR 7(A) LOANS.—

23           (1) IN GENERAL.—Section 7(a)(2)(A) of the  
24           Small Business Act (15 U.S.C. 636(a)(2)(A)) is  
25           amended by striking “equal to—” and all that fol-

1        lows through the end of the subparagraph and in-  
2        sserting “equal to 100 percent of the balance of the  
3        financing outstanding at the time of disbursement of  
4        the loan.”.

5            (2) PROSPECTIVE REPEAL.—Effective on Janu-  
6        ary 1, 2021, section 7(a)(2)(A) of the Small Busi-  
7        ness Act (15 U.S.C. 636(a)(2)(A)) is amended by  
8        striking “equal to 100 percent of the balance of fi-  
9        nancing outstanding at the time of disbursement of  
10       the loan” and inserting “equal to—

11                    “(i) 75 percent of the balance of the  
12                    financing outstanding at the time of dis-  
13                    bursement of the loan, if such balance ex-  
14                    ceeds \$150,000; or

15                    “(ii) 85 percent of the balance of the  
16                    financing outstanding at the time of dis-  
17                    bursement of the loan, if such balance is  
18                    less than or equal to \$150,000.”.

19        (g) DEFERMENT OF 7(A) LOANS.—

20            (1) DEFINITIONS .—

21                    (A) ELIGIBLE BORROWER.—The term “eli-  
22                    gible borrower” means—

23                            (i) a small business concern; or

24                            (ii) an organization made eligible by  
25                    subsection (b) of this section for a loan

1 under section 7(a) of the Small Business  
2 Act (15 U.S.C. 636(a)).

3 (B) IMPACTED BORROWER.—

4 (i) IN GENERAL.—In this subsection,  
5 the term “impacted borrower” means an  
6 eligible borrower that—

7 (I) is in operation on March 1,  
8 2020; and

9 (II) has an application for a loan  
10 made under section 7(a) of the Small  
11 Business Act (15 U.S.C. 636(a)) that  
12 is approved or pending approval on or  
13 after the date of enactment of this  
14 Act.

15 (ii) PRESUMPTION.—For purposes of  
16 this subsection, an impacted borrower is  
17 presumed to have been adversely impacted  
18 by COVID–19.

19 (2) DEFERRAL.—During the covered period,  
20 the Administrator shall—

21 (A) consider each eligible borrower that  
22 applies for a loan under section 7(a) of the  
23 Small Business Act (15 U.S.C. 636(a)) to be an  
24 impacted borrower; and

1 (B) require lenders under such section 7(a)  
2 to provide complete payment deferment relief  
3 for impacted borrowers with loans guaranteed  
4 under such section 7(a) for a period of not  
5 more than 1 year.

6 (3) SECONDARY MARKET.—During the covered  
7 period, with respect to a loan made under 7(a) of  
8 the Small Business Act (15 U.S.C. 636(a)) that is  
9 sold on the secondary market, if an investor declines  
10 to approve a deferral requested by a lender under  
11 paragraph (2), the Administrator shall exercise the  
12 authority to purchase the loan so that the impacted  
13 borrower may receive a deferral for a period of not  
14 more than 1 year.

15 (4) GUIDANCE.—Not later than 30 days after  
16 the date of enactment of this Act, the Administrator  
17 shall provide guidance to lenders under section 7(a)  
18 of the Small Business Act (15 U.S.C. 636(a)) on the  
19 deferment process described in this subsection.

20 (h) COMMITMENTS FOR 7(A) LOANS.—During the  
21 covered period—

22 (1) there shall be no limitation on the commit-  
23 ments for general business loans authorized under  
24 section 7(a) of the Small Business Act (15 U.S.C.  
25 636(a)); and

1           (2) the amount authorized for commitments for  
2 such loans under the heading “BUSINESS LOANS  
3 PROGRAM ACCOUNT” under the heading “SMALL  
4 BUSINESS ADMINISTRATION” under title V of the  
5 Consolidated Appropriations Act, 2020 (Public Law  
6 116–93; 133 Stat. 2475) shall not apply.

7           (i) EXPRESS LOANS.—

8           (1) IN GENERAL.—Section 7(a)(31)(D) of the  
9 Small Business Act (15 U.S.C. 636(a)(31)(D)) is  
10 amended by striking “\$350,000” and inserting  
11 “\$1,000,000”.

12           (2) PROSPECTIVE REPEAL.—Effective on Janu-  
13 ary 1, 2021, section 7(a)(31)(D) of the Small Busi-  
14 ness Act (15 U.S.C. 636(a)(31)(D)) is amended by  
15 striking “\$1,000,000” and inserting “\$350,000”.

16 **SEC. 1103. ENTREPRENEURIAL DEVELOPMENT.**

17           (a) DEFINITIONS.—In this section—

18           (1) the term “covered small business concern”  
19 means a small business concern that is located in an  
20 area that is substantially affected by the COVID–19;

21           (2) the term “resource partner” means—

22                   (A) a small business development center;

23                   and

24                   (B) a women’s business center;

1           (3) the term “small business development cen-  
2           ter” has the meaning given the term in section 3 of  
3           the Small Business Act (15 U.S.C. 632);

4           (4) the term “substantially affected by COVID-  
5           19” means, with respect to a covered small business  
6           concern, that the covered small business concern has  
7           experienced—

8                   (A) supply chain disruptions, including  
9                   changes in—

10                           (i) quantity and lead time, including  
11                           the number of shipments of components  
12                           and delays in shipments;

13                           (ii) quality, including shortages in  
14                           supply for quality control reasons; and

15                           (iii) technology, including a com-  
16                           promised payment network;

17                   (B) staffing challenges;

18                   (C) a decrease in sales or customers; or

19                   (D) shuttered businesses; and

20           (5) the term “women’s business center” means  
21           a women’s business center described in section 29 of  
22           the Small Business Act (15 U.S.C. 656).

23           (b) EDUCATION, TRAINING, AND ADVISING  
24           GRANTS.—

1           (1) IN GENERAL.—The Administration may  
2 provide financial assistance in the form of grants to  
3 resource partners to provide education, training, and  
4 advising to covered small business concerns.

5           (2) USE OF FUNDS.—Grants under this sub-  
6 section shall be used for the education, training, and  
7 advising of covered small business concerns and  
8 their employees on—

9           (A) accessing and applying for resources  
10 provided by the Administration and other Fed-  
11 eral resources relating to access to capital and  
12 business resiliency;

13           (B) the hazards and prevention of the  
14 transmission and communication of COVID–19  
15 and other communicable diseases;

16           (C) the potential effects of COVID–19 on  
17 the supply chains, distribution, and sale of  
18 products of covered small business concerns and  
19 the mitigation of those effects;

20           (D) the management and practice of  
21 telework to reduce possible transmission of  
22 COVID–19;

23           (E) the management and practice of re-  
24 mote customer service by electronic or other  
25 means;

1 (F) the risks of and mitigation of cyber  
2 threats in remote customer service or telework  
3 practices;

4 (G) the mitigation of the effects of reduced  
5 travel or outside activities on covered small  
6 business concerns during COVID–19 or similar  
7 occurrences; and

8 (H) any other relevant business practices  
9 necessary to mitigate the economic effects of  
10 COVID–19 or similar occurrences.

11 (3) GRANT DETERMINATION.—

12 (A) SMALL BUSINESS DEVELOPMENT CEN-  
13 TERS.—The Administration shall award 80 per-  
14 cent of funds authorized to carry out this sub-  
15 section to small business development centers,  
16 which shall be awarded pursuant to a formula  
17 jointly developed, negotiated, and agreed upon,  
18 with full participation of both parties, between  
19 the association formed under section  
20 21(a)(3)(A) of the Small Business Act (15  
21 U.S.C. 648(a)(3)(A)) and the Administration.

22 (B) WOMEN’S BUSINESS CENTERS.—The  
23 Administration shall award 20 percent of funds  
24 authorized to carry out this subsection to wom-  
25 en’s business centers, which shall be awarded



1           pursuant to a process established by the Ad-  
2           ministration in consultation with recipients of  
3           assistance.

4           (C) NO MATCHING FUNDS REQUIRED.—  
5           Matching funds shall not be required for any  
6           grant under this subsection.

7           (4) GOALS AND METRICS.—

8           (A) IN GENERAL.—Goals and metrics for  
9           the funds made available under this subsection  
10          shall be jointly developed, negotiated, and  
11          agreed upon, with full participation of both par-  
12          ties, between the resource partners and the Ad-  
13          ministrator, which shall—

14                 (i) take into consideration the extent  
15                 of the circumstances relating to the spread  
16                 of COVID–19, or similar occurrences, that  
17                 affect covered small business concerns lo-  
18                 cated in the areas covered by the resource  
19                 partner, particularly in rural areas or eco-  
20                 nomically distressed areas;

21                 (ii) generally follow the use of funds  
22                 outlined in paragraph (2), but shall not re-  
23                 strict the activities of resource partners in  
24                 responding to unique situations; and

1 (iii) encourage resource partners to  
2 develop and provide services to covered  
3 small business concerns.

4 (B) PUBLIC AVAILABILITY.—The Adminis-  
5 trator shall make publicly available the method-  
6 ology by which the Administrator and resource  
7 partners jointly develop the metrics and goals  
8 described in subparagraph (A).

9 (c) RESOURCE PARTNER ASSOCIATION GRANTS.—

10 (1) IN GENERAL.—The Administrator may pro-  
11 vide grants to an association or associations rep-  
12 resenting resource partners to establish a centralized  
13 hub for COVID–19 information, which shall in-  
14 clude—

15 (A) an online platform that consolidates  
16 resources and information available across mul-  
17 tiple Federal agencies for small business con-  
18 cerns related to COVID–19; and

19 (B) a training program to educate resource  
20 partner counselors on the resources and infor-  
21 mation described in subparagraph (A).

22 (2) GOALS AND METRICS.—Goals and metrics  
23 for the funds made available under this subsection  
24 shall be jointly developed, negotiated, and agreed  
25 upon, with full participation of both parties, between

1 the association or associations receiving a grant  
2 under this subsection and the Administrator.

3 (d) REPORT.—Not later than 6 months after the date  
4 of enactment of this Act, and annually thereafter, the Ad-  
5 ministrator shall submit to the Committee on Small Busi-  
6 ness and Entrepreneurship of the Senate and the Com-  
7 mittee on Small Business of the House of Representatives  
8 a report—

9 (1) that describes, with respect to the initial  
10 year covered by the report—

11 (A) the programs and services developed  
12 and provided by the Administration and re-  
13 source partners under subsection (b);

14 (B) the initial efforts to provide those serv-  
15 ices under subsection (b); and

16 (C) the online platform and training devel-  
17 oped and provided by the Administration and  
18 the association or associations under subsection  
19 (c); and

20 (2) that describes, with respect to the subse-  
21 quent years covered by the report—

22 (A) with respect to the grant program  
23 under subsection (b)—

1 (i) the efforts of the Administrator  
2 and resource partners to develop services  
3 to assist covered small business concerns;

4 (ii) the challenges faced by owners of  
5 covered small business concerns in access-  
6 ing services provided by the Administration  
7 and resource partners;

8 (iii) the number of unique covered  
9 small business concerns that were served  
10 by the Administration and resource part-  
11 ners; and

12 (iv) other relevant outcome perform-  
13 ance data with respect to covered small  
14 business concerns, including the number of  
15 employees affected, the effect on sales, the  
16 disruptions of supply chains, and the ef-  
17 forts made by the Administration and re-  
18 source partners to mitigate these effects;  
19 and

20 (B) with respect to the grant program  
21 under subsection (c)—

22 (i) the efforts of the Administrator  
23 and the association or associations to de-  
24 velop and evolve an online resource for  
25 small business concerns; and

1 (ii) the efforts of the Administrator  
2 and the association or associations to de-  
3 velop a training program for resource part-  
4 ner counselors, including the number of  
5 counselors trained.

6 **SEC. 1104. WAIVER OF MATCHING FUNDS REQUIREMENT**  
7 **UNDER THE WOMEN'S BUSINESS CENTER**  
8 **PROGRAM.**

9 During the 3-month period beginning on the date of  
10 enactment of this Act, the requirement relating to obtain-  
11 ing cash contributions from non-Federal sources under  
12 section 29(c)(1) of the Small Business Act (15 U.S.C.  
13 656(c)(1)) is waived for any recipient of assistance under  
14 such section 29.

15 **SEC. 1105. LOAN FORGIVENESS.**

16 (a) DEFINITIONS.—In this section—

17 (1) the term “covered 7(a) loan” means a loan  
18 guaranteed under section 7(a) of the Small Business  
19 Act (15 U.S.C. 636(a)) that is made during the cov-  
20 ered period;

21 (2) the term “covered period” means the period  
22 beginning on March 1, 2020 and ending on June 30,  
23 2020;

24 (3) the term “eligible recipient” means the re-  
25 cipient of a covered 7(a) loan; and

1 (4) the term “payroll costs” shall not include—

2 (A) the compensation of an individual em-  
3 ployee in excess of \$33,333 during the covered  
4 period;

5 (B) qualified sick leave wages for which a  
6 credit is allowed under section 7001 of the  
7 Families First Coronavirus Response Act; or

8 (C) qualified family leave wages for which  
9 a credit is allowed under section 7003 of the  
10 Families First Coronavirus Response Act.

11 (b) FORGIVENESS.—An eligible recipient shall be eli-  
12 gible for forgiveness of indebtedness on a covered 7(a) loan  
13 in an amount equal to the cost of maintaining payroll con-  
14 tinuity during the covered period.

15 (c) TREATMENT OF AMOUNTS FORGIVEN.—

16 (1) IN GENERAL.—Amounts which have been  
17 forgiven under this section shall be considered can-  
18 celed indebtedness by lenders authorized under sec-  
19 tion 7(a) of the Small Business Act (15 U.S.C.  
20 636(a)).

21 (2) FOR PURPOSES OF REDEMPTION OF GUAR-  
22 ANTEES.—For purposes of the redemption of a  
23 guarantee by the lender for a covered 7(a) loan,  
24 amounts which are forgiven under this section shall  
25 be treated as a default, in accordance with the pro-

1 cedures that are otherwise applicable to a default on  
2 a loan guaranteed under section 7(a) of the Small  
3 Business Act (15 U.S.C. 636(a)).

4 (d) LIMITS ON AMOUNT OF FORGIVENESS.—

5 (1) IN GENERAL.—The amount of loan forgive-  
6 ness under this section for an eligible recipient shall  
7 not exceed the sum of—

8 (A) the total payroll costs incurred by the  
9 eligible recipient during the covered period; and

10 (B) the amount of payments made during  
11 the covered period on debt obligations that were  
12 incurred before the covered period.

13 (2) REDUCTION BASED ON REDUCTION IN NUM-  
14 BER OF EMPLOYEES.—

15 (A) IN GENERAL.—The amount of loan  
16 forgiveness under this section shall be reduced  
17 by the percentage equal to the difference ob-  
18 tained by subtracting—

19 (i) the quotient obtained by dividing—

20 (I) the average number of full-  
21 time equivalent employees per month  
22 employed by the eligible recipient dur-  
23 ing the covered period; by

24 (II)(aa) the average number of  
25 full time equivalent employees per

1 month employed by the eligible recipi-  
2 ent during the period beginning on  
3 March 1, 2019 and ending on June  
4 30, 2019; or

5 (bb) in the case of an eligible re-  
6 cipient that is seasonal employer, as  
7 determined by the Administrator, the  
8 average number of full-time equivalent  
9 employees per month employed by the  
10 eligible recipient during the period be-  
11 ginning on March 1, 2019 and ending  
12 on June 30, 2019; from

13 (ii) 1.

14 (B) CALCULATION OF AVERAGE NUMBER  
15 OF EMPLOYEES.—The average number of full-  
16 time equivalent employees shall be determined  
17 by calculating the average number of employees  
18 for each pay period falling within a month.

19 (3) REDUCTION RELATING TO COMPENSA-  
20 TION.—The amount of loan forgiveness under this  
21 section shall also be reduced by the amount of any  
22 reduction in excess of 25 percent of compensation in  
23 the most recent full quarter in which the employee  
24 was paid in compensation during the covered period  
25 of any employee who was compensated—



1           (A) in an amount less than \$33,333 during  
2           the period beginning on March 1, 2019 and  
3           ending on June 30, 2019; or

4           (B) not more than \$100,000 on annualized  
5           basis during 2019.

6           (4) EXCEPTION FOR TIPPED WORKERS.—An el-  
7           igible recipient with tipped employees described in  
8           section 3(m)(2)(A) of the Fair Labor Standards Act  
9           of 1938 (29 U.S.C. 203(m)(2)(A)) may receive for-  
10          giveness for additional wages paid to those employ-  
11          ees.

12          (e) APPLICATION.—An eligible recipient seeking loan  
13          forgiveness under this section shall submit to the lender  
14          that originated the covered 7(a) loan an application, which  
15          shall include documentation verifying the number of full-  
16          time equivalent employees on payroll and pay rates for the  
17          periods described in subsection (d), including—

18               (1) payroll tax filings reported to the Internal  
19               Revenue Service;

20               (2) State income, payroll, and unemployment  
21               insurance filings;

22               (3) financial statements verifying payment on  
23               debt obligations incurred before the covered period;  
24               and

1           (4) any other documentation the Administrator  
2 determines necessary.

3           (f) CERTIFICATION.—An eligible recipient receiving  
4 loan forgiveness under this section shall make a good faith  
5 certification that the uncertainty of current economic con-  
6 ditions justifies the loan request to support the ongoing  
7 operations of the borrower, and acknowledges that funds  
8 will be used to retain workers and maintain payroll.

9           (g) PROHIBITION ON FORGIVENESS WITHOUT DOCU-  
10 MENTATION.—No eligible recipient shall receive forgive-  
11 ness under this section without submitting to the lender  
12 that originated the covered 7(a) loan the documentation  
13 required under subsection (e).

14          (h) DECISION.—Not later than 15 days after the date  
15 on which a lender receives an application for loan forgive-  
16 ness under this section from an eligible recipient, the lend-  
17 er shall issue a decision on the an application.

18          (i) TAXABILITY.—Canceled indebtedness under this  
19 section shall be excluded from gross income for purposes  
20 of the Internal Revenue Code of 1986.

21          (j) RULE OF CONSTRUCTION.—The cancellation of  
22 indebtedness on a covered 7(a) loan under this section  
23 shall not otherwise modify the terms and conditions of the  
24 covered 7(a) loan.

1 (k) REGULATIONS.—Not later than 30 days after the  
2 date of enactment of this Act, the Administrator shall  
3 issue guidance and regulations implementing this section.

4 **SEC. 1106. DIRECT APPROPRIATIONS.**

5 (a) IN GENERAL.—There is appropriated, out of  
6 amounts in the Treasury not otherwise appropriated, for  
7 the fiscal year ending September 30, 2020, to remain  
8 available until September 30, 2021, for additional  
9 amounts—

10 (1) \$299,400,000,000 under the heading  
11 “Small Business Administration—Business Loans  
12 Program Account” for the cost of guaranteed loans  
13 as authorized under section 7(a) of the Small Busi-  
14 ness Act (15 U.S.C. 636(a));

15 (2) \$300,000,000 under the heading “Small  
16 Business Administration—Salaries and Expenses”  
17 for salaries and expenses of the Administration;

18 (3) \$25,000,000 under the heading “Small  
19 Business Administration—Office of Inspector Gen-  
20 eral” for necessary expenses of the Office of Inspec-  
21 tor General of the Administration in carrying out  
22 the provisions of the Inspector General Act of 1978  
23 (5 U.S.C. App.);

1           (4) \$265,000,000 under the heading “Small  
2 Business Administration—Entrepreneurial Develop-  
3 ment Programs”, of which—

4           (A) \$240,000,000 shall be for carrying sec-  
5 tion 1103(b) of this Act; and

6           (B) \$25,000,000 shall be for carrying out  
7 section 1103(e) of this Act; and

8           (5) \$10,000,000 under the heading “Depart-  
9 ment of Commerce—Minority Business Development  
10 Agency” for minority business centers of the Minor-  
11 ity Business Development Agency to provide tech-  
12 nical assistance to small business concerns.

13       (b) REPORTS.—Not later than 180 days after the  
14 date of enactment of this Act, the Administrator shall sub-  
15 mit to the Committee on Appropriations of the Senate and  
16 the Committee on Appropriations of the House of Rep-  
17 resentatives a detailed expenditure plan for using the  
18 amounts appropriated under subsection (a).

19 **SEC. 1107. MINORITY BUSINESS DEVELOPMENT AGENCY.**

20       (a) DEFINITIONS.—In this section—

21           (1) the term “Agency” means the Minority  
22 Business Development Agency of the Department of  
23 Commerce;

24           (2) the term “covered small business concern”  
25 means a small business concern (as defined in sec-

1 tion 3 of the Small Business Act (15 U.S.C. 632)  
2 that is located in an area that is substantially af-  
3 fected by the COVID-19;

4 (3) the term “minority business center” means  
5 a Business Center of the Agency; and

6 (4) the term “substantially affected by COVID-  
7 19” means, with respect to a covered small business  
8 concern, that the covered small business concern has  
9 experienced—

10 (A) supply chain disruptions, including  
11 changes in—

12 (i) quantity and lead time, including  
13 the number of shipments of components  
14 and delays in shipments;

15 (ii) quality, including shortages in  
16 supply for quality control reasons; and

17 (iii) technology, including a com-  
18 promised payment network;

19 (B) staffing challenges;

20 (C) a decrease in sales or customers; or

21 (D) shuttered businesses.

22 (b) EDUCATION, TRAINING, AND ADVISING  
23 GRANTS.—

24 (1) IN GENERAL.—The Agency may provide fi-  
25 nancial assistance in the form of grants to minority

1 business centers to provide education, training, and  
2 advising to covered small business concerns.

3 (2) USE OF FUNDS.—Grants under this section  
4 shall be used for the education, training, and advis-  
5 ing of covered small business concerns and their em-  
6 ployees on—

7 (A) accessing and applying for resources  
8 provided by the Agency and other Federal re-  
9 sources relating to access to capital and busi-  
10 ness resiliency;

11 (B) the hazards and prevention of the  
12 transmission and communication of COVID–19  
13 and other communicable diseases;

14 (C) the potential effects of COVID–19 on  
15 the supply chains, distribution, and sale of  
16 products of covered small business concerns and  
17 the mitigation of those effects;

18 (D) the management and practice of  
19 telework to reduce possible transmission of  
20 COVID–19;

21 (E) the management and practice of re-  
22 mote customer service by electronic or other  
23 means;

1 (F) the risks of and mitigation of cyber  
2 threats in remote customer service or telework  
3 practices;

4 (G) the mitigation of the effects of reduced  
5 travel or outside activities on covered small  
6 business concerns during COVID–19 or similar  
7 occurrences; and

8 (H) any other relevant business practices  
9 necessary to mitigate the economic effects of  
10 COVID–19 or similar occurrences.

11 (3) NO MATCHING FUNDS REQUIRED.—Match-  
12 ing funds shall not be required for any grant under  
13 this section.

14 (4) GOALS AND METRICS.—

15 (A) IN GENERAL.—Goals and metrics for  
16 the funds made available under this section  
17 shall be jointly developed, negotiated, and  
18 agreed upon, with full participation of both par-  
19 ties, between the minority business centers and  
20 the Agency, which shall—

21 (i) take into consideration the extent  
22 of the circumstances relating to the spread  
23 of COVID–19, or similar occurrences, that  
24 affect covered small business concerns lo-  
25 cated in the areas covered by the minority

1 business centers, particularly in rural areas  
2 or economically distressed areas;

3 (ii) generally follow the use of funds  
4 outlined in paragraph (2), but shall not re-  
5 strict the activities of minority business  
6 centers in responding to unique situations;  
7 and

8 (iii) encourage minority business cen-  
9 ters to develop and provide services to cov-  
10 ered small business concerns.

11 (B) PUBLIC AVAILABILITY.—The Agency  
12 shall make publicly available the methodology  
13 by which the Agency and minority business cen-  
14 ters jointly develop the metrics and goals de-  
15 scribed in subparagraph (A).

16 (5) AUTHORIZATION OF APPROPRIATIONS.—  
17 There is authorized to be appropriated \$10,000,000  
18 to carry out this section, to remain available until  
19 expended.

20 **SEC. 1108. WAIVER OF PREPAYMENT PENALTY.**

21 Notwithstanding any other provision of law, for a  
22 loan made under the authority under this division or an  
23 amendment made by this division, there shall be no pre-  
24 payment penalty for any payment on the loan made on  
25 or before December 31, 2020.



1 **SEC. 1109. UNITED STATES TREASURY PROGRAM MANAGE-**  
2 **MENT AUTHORITY.**

3 (a) **AUTHORITY TO INCLUDE ADDITIONAL FINAN-**  
4 **CIAL INSTITUTIONS.**—The Department of the Treasury,  
5 in consultation with the Administration and the other  
6 Federal financial regulatory agencies (as defined in section  
7 313(r) of title 31, United States Code), shall establish cri-  
8 teria for insured depository institutions (as defined in sec-  
9 tion 3 of the Federal Deposit Insurance Act (12 U.S.C.  
10 1813)) and other specialized lenders, that do not already  
11 participate in lending under programs of the Administra-  
12 tion, to participate in a small business interruption loans  
13 program to provide loans under section 7(a) of the Small  
14 Business Act (15 U.S.C. 636(a)) in accordance with this  
15 section until the date on which the national emergency de-  
16 clared by the President under the National Emergencies  
17 Act (50 U.S.C. 1601 et seq.) with respect to the  
18 Coronavirus Disease 2019 (COVID–19) expires.

19 (b) **CRITERIA.**—Due to exigent circumstances, the  
20 eligibility criteria that would otherwise be applicable a loan  
21 made under section 7(a) of the Small Business Act (15  
22 U.S.C. 636(a)) shall not apply to a loan made under this  
23 section.

24 (c) **SAFETY AND SOUNDNESS.**—An insured depository  
25 institution (as defined in section 3 of the Federal De-  
26 posit Insurance Act (12 U.S.C. 1813)) or other specialized

1 lender may only participate in the program established  
2 under this section if participation does not affect the safe-  
3 ty and soundness of the institution or lender.

4 (d) ADDITIONAL REGULATIONS.—The Secretary of  
5 the Treasury, in consultation with the Administrator, shall  
6 issue regulations and guidance in order to direct addi-  
7 tional lenders under this section and establish additional  
8 terms that set out compensation, underwriting standards,  
9 interest rates, maturity, and other relevant terms and con-  
10 ditions.

11 (e) PROGRAM ADMINISTRATION.—Under the infra-  
12 structure of the Department of the Treasury and with  
13 guidance from the Secretary of the Treasury, the Adminis-  
14 tration shall administer the program established under  
15 this section until the date on which the national emergency  
16 declared by the President under the National Emergencies  
17 Act (50 U.S.C. 1601 et seq.) with respect to the  
18 Coronavirus Disease 2019 (COVID–19) expires.

1 **DIVISION B—RELIEF FOR INDI-**  
2 **VIDUALS, FAMILIES, AND**  
3 **BUSINESSES**

4 **TITLE I—REBATES AND OTHER**  
5 **INDIVIDUAL PROVISIONS**

6 **SEC. 2101. 2020 RECOVERY REBATES FOR INDIVIDUALS.**

7 (a) IN GENERAL.—Subchapter B of chapter 65 of  
8 subtitle F of the Internal Revenue Code of 1986 is amend-  
9 ed by inserting after section 6427 the following new sec-  
10 tion:

11 **“SEC. 6428. 2020 RECOVERY REBATES FOR INDIVIDUALS.**

12 “(a) IN GENERAL.—In the case of an eligible indi-  
13 vidual, there shall be allowed as a credit against the tax  
14 imposed by subtitle A for the first taxable year beginning  
15 in 2020 an amount equal to the lesser of—

16 “(1) net income tax liability, or

17 “(2) \$1,200 (\$2,400 in the case of a joint re-  
18 turn).

19 “(b) SPECIAL RULES.—

20 “(1) IN GENERAL.—In the case of a taxpayer  
21 described in paragraph (2)—

22 “(A) the amount determined under sub-  
23 section (a) shall not be less than \$600 (\$1,200  
24 in the case of a joint return), and

1           “(B) the amount determined under sub-  
2           section (a) (after the application of subpara-  
3           graph (A)) shall be increased by the product of  
4           \$500 multiplied by the number of qualifying  
5           children (within the meaning of section 24(e))  
6           of the taxpayer.

7           “(2) TAXPAYER DESCRIBED.—A taxpayer is de-  
8           scribed in this paragraph if the taxpayer—

9           “(A) has qualifying income of at least  
10          \$2,500, or

11          “(B) has—

12                  “(i) net income tax liability which is  
13                  greater than zero, and

14                  “(ii) gross income which is greater  
15                  than the basic standard deduction.

16          “(c) TREATMENT OF CREDIT.—The credit allowed by  
17          subsection (a) shall be treated as allowed by subpart C  
18          of part IV of subchapter A of chapter 1.

19          “(d) LIMITATION BASED ON ADJUSTED GROSS IN-  
20          COME.—The amount of the credit allowed by subsection  
21          (a) (determined without regard to this subsection and sub-  
22          section (f)) shall be reduced (but not below zero) by 5 per-  
23          cent of so much of the taxpayer’s adjusted gross income  
24          as exceeds \$75,000 (\$150,000 in the case of a joint re-  
25          turn).

1 “(e) DEFINITIONS.—For purposes of this section—

2 “(1) QUALIFYING INCOME.—The term ‘quali-  
3 fying income’ means—

4 “(A) earned income,

5 “(B) social security benefits (within the  
6 meaning of section 86(d)), and

7 “(C) any compensation or pension received  
8 under chapter 11, chapter 13, or chapter 15 of  
9 title 38, United States Code.

10 “(2) NET INCOME TAX LIABILITY.—The term  
11 ‘net income tax liability’ means the excess of—

12 “(A) the sum of the taxpayer’s regular tax  
13 liability (within the meaning of section 26(b))  
14 and the tax imposed by section 55 for the tax-  
15 able year, over

16 “(B) the credits allowed by part IV (other  
17 than section 24 and subpart C thereof) of sub-  
18 chapter A of chapter 1.

19 “(3) ELIGIBLE INDIVIDUAL.—The term ‘eligible  
20 individual’ means any individual other than—

21 “(A) any nonresident alien individual,

22 “(B) any individual with respect to whom  
23 a deduction under section 151 is allowable to  
24 another taxpayer for a taxable year beginning

1           in the calendar year in which the individual's  
2           taxable year begins, and

3                   “(C) an estate or trust.

4           “(4) EARNED INCOME.—The term ‘earned in-  
5           come’ has the meaning set forth in section 32(e)(2)  
6           except that such term shall not include net earnings  
7           from self-employment which are not taken into ac-  
8           count in computing taxable income.

9           “(5) BASIC STANDARD DEDUCTION.—The term  
10          ‘basic standard deduction’ shall have the same  
11          meaning as when used in section 63 (as modified by  
12          subsection (c)(7) of such section).

13          “(f) COORDINATION WITH ADVANCE REFUNDS OF  
14          CREDIT.—

15               “(1) IN GENERAL.—The amount of credit  
16               which would (but for this paragraph) be allowable  
17               under this section shall be reduced (but not below  
18               zero) by the aggregate refunds and credits made or  
19               allowed to the taxpayer under subsection (g). Any  
20               failure to so reduce the credit shall be treated as  
21               arising out of a mathematical or clerical error and  
22               assessed according to section 6213(b)(1).

23               “(2) JOINT RETURNS.—In the case of a refund  
24               or credit made or allowed under subsection (g) with  
25               respect to a joint return, half of such refund or cred-

1 it shall be treated as having been made or allowed  
2 to each individual filing such return.

3 “(g) ADVANCE REFUNDS AND CREDITS.—

4 “(1) IN GENERAL.—Subject to paragraph (5),  
5 each individual who was an eligible individual for  
6 such individual’s first taxable year beginning in  
7 2018 shall be treated as having made a payment  
8 against the tax imposed by chapter 1 for such first  
9 taxable year in an amount equal to the advance re-  
10 fund amount for such taxable year.

11 “(2) ADVANCE REFUND AMOUNT.—For pur-  
12 poses of paragraph (1), the advance refund amount  
13 is the amount that would have been allowed as a  
14 credit under this section for such first taxable year  
15 if this section (other than subsection (f) and this  
16 subsection) had applied to such taxable year.

17 “(3) TIMING OF PAYMENTS.—The Secretary  
18 shall, subject to the provisions of this title, refund  
19 or credit any overpayment attributable to this sec-  
20 tion as rapidly as possible. No refund or credit shall  
21 be made or allowed under this subsection after De-  
22 cember 31, 2020.

23 “(4) NO INTEREST.—No interest shall be al-  
24 lowed on any overpayment attributable to this sec-  
25 tion.

1           “(5) ALTERNATE TAXABLE YEAR.—In the case  
2 of an individual who, at the time of any determina-  
3 tion made pursuant to paragraph (3), has not filed  
4 a tax return for the year described in paragraph (1),  
5 the Secretary may apply such paragraph by sub-  
6 stituting ‘2019’ for ‘2018’.

7           “(h) IDENTIFICATION NUMBER REQUIREMENT.—

8           “(1) IN GENERAL.—No credit shall be allowed  
9 under subsection (a) to an eligible individual who  
10 does not include on the return of tax for the taxable  
11 year—

12                   “(A) such individual’s valid identification  
13 number,

14                   “(B) in the case of a joint return, the valid  
15 identification number of such individual’s  
16 spouse, and

17                   “(C) in the case of any qualifying child  
18 taken into account under subsection (b)(1)(B),  
19 the valid identification number of such quali-  
20 fying child.

21           “(2) VALID IDENTIFICATION NUMBER.—

22                   “(A) IN GENERAL.—For purposes of para-  
23 graph (1), the term ‘valid identification num-  
24 ber’ means a social security number (as such  
25 term is defined in section 24(h)(7)).



1           “(B) ADOPTION TAXPAYER IDENTIFICA-  
2           TION NUMBER.—For purposes of paragraph  
3           (1)(C), in the case of a qualifying child who is  
4           adopted, the term ‘valid identification number’  
5           shall include the adoption taxpayer identifica-  
6           tion number of such child.

7           “(i) REGULATIONS.—The Secretary shall prescribe  
8           such regulations or other guidance as may be necessary  
9           to carry out the purposes of this section.”.

10          (b) ADMINISTRATIVE AMENDMENTS.—

11           (1) DEFINITION OF DEFICIENCY.—Section  
12           6211(b)(4)(A) of the Internal Revenue Code of 1986  
13           is amended by striking “and 36B, 168(k)(4)” and  
14           inserting “36B, and 6428”.

15           (2) MATHEMATICAL OR CLERICAL ERROR AU-  
16           THORITY.—Section 6213(g)(2)(L) of such Code is  
17           amended by striking “or 32” and inserting “32, or  
18           6428”.

19          (c) TREATMENT OF POSSESSIONS.—

20           (1) PAYMENTS TO POSSESSIONS.—

21           (A) MIRROR CODE POSSESSION.—The Sec-  
22           retary of the Treasury shall pay to each posses-  
23           sion of the United States which has a mirror  
24           code tax system amounts equal to the loss (if  
25           any) to that possession by reason of the amend-

1           ments made by this section. Such amounts shall  
2           be determined by the Secretary of the Treasury  
3           based on information provided by the govern-  
4           ment of the respective possession.

5                   (B) OTHER POSSESSIONS.—The Secretary  
6           of the Treasury shall pay to each possession of  
7           the United States which does not have a mirror  
8           code tax system amounts estimated by the Sec-  
9           retary of the Treasury as being equal to the ag-  
10          gregate benefits (if any) that would have been  
11          provided to residents of such possession by rea-  
12          son of the amendments made by this section if  
13          a mirror code tax system had been in effect in  
14          such possession. The preceding sentence shall  
15          not apply unless the respective possession has a  
16          plan, which has been approved by the Secretary  
17          of the Treasury, under which such possession  
18          will promptly distribute such payments to its  
19          residents.

20                   (2) COORDINATION WITH CREDIT ALLOWED  
21          AGAINST UNITED STATES INCOME TAXES.—No cred-  
22          it shall be allowed against United States income  
23          taxes under section 6428 of the Internal Revenue  
24          Code of 1986 (as added by this section) to any per-  
25          son—

1 (A) to whom a credit is allowed against  
2 taxes imposed by the possession by reason of  
3 the amendments made by this section, or

4 (B) who is eligible for a payment under a  
5 plan described in paragraph (1)(B).

6 (3) DEFINITIONS AND SPECIAL RULES.—

7 (A) POSSESSION OF THE UNITED  
8 STATES.—For purposes of this subsection, the  
9 term “possession of the United States” includes  
10 the Commonwealth of Puerto Rico and the  
11 Commonwealth of the Northern Mariana Is-  
12 lands.

13 (B) MIRROR CODE TAX SYSTEM.—For pur-  
14 poses of this subsection, the term “mirror code  
15 tax system” means, with respect to any posses-  
16 sion of the United States, the income tax sys-  
17 tem of such possession if the income tax liabil-  
18 ity of the residents of such possession under  
19 such system is determined by reference to the  
20 income tax laws of the United States as if such  
21 possession were the United States.

22 (C) TREATMENT OF PAYMENTS.—For pur-  
23 poses of section 1324 of title 31, United States  
24 Code, the payments under this section shall be  
25 treated in the same manner as a refund due

1 from a credit provision referred to in subsection  
2 (b)(2) of such section.

3 (d) EXCEPTION FROM TREASURY OFFSET PRO-  
4 GRAM.—Any credit or refund allowed or made to any indi-  
5 vidual by reason of section 6428 of the Internal Revenue  
6 Code of 1986 (as added by this section) or by reason of  
7 subsection (c) of this section shall not be subject to reduc-  
8 tion or offset pursuant to—

9 (1) section 3716 or 3720A of title 31, United  
10 States Code, or

11 (2) subsection (d), (e), or (f) of section 6402 of  
12 the Internal Revenue Code of 1986.

13 (e) APPROPRIATIONS TO CARRY OUT REBATES.—

14 (1) IN GENERAL.—Immediately upon the enact-  
15 ment of this Act, the following sums are appro-  
16 priated, out of any money in the Treasury not other-  
17 wise appropriated, for the fiscal year ending Sep-  
18 tember 30, 2020:

19 (A) DEPARTMENT OF THE TREASURY.—

20 (i) For an additional amount for “De-  
21 partment of the Treasury—Bureau of the  
22 Fiscal Service—Salaries and Expenses”,  
23 \$78,650,000, to remain available until  
24 September 30, 2021.

1 (ii) For an additional amount for  
2 “Department of the Treasury—Internal  
3 Revenue Service—Taxpayer Services”,  
4 \$70,200,000, to remain available until  
5 September 30, 2021.

6 (iii) For an additional amount for  
7 “Department of the Treasury—Internal  
8 Revenue Service—Operations Support”,  
9 \$209,600,000, to remain available until  
10 September 30, 2021.

11 (B) SOCIAL SECURITY ADMINISTRATION.—  
12 For an additional amount for “Social Security  
13 Administration—Limitation on Administrative  
14 Expenses”, \$38,000,000, to remain available  
15 until September 30, 2020.

16 (2) REPORTS.—No later than 15 days after en-  
17 actment of this Act, the Secretary of the Treasury  
18 shall submit a plan to the Committees on Appropria-  
19 tions of the House of Representatives and the Sen-  
20 ate detailing the expected use of the funds provided  
21 by paragraph (1)(A). Beginning 90 days after enact-  
22 ment of this Act, the Secretary of the Treasury shall  
23 submit a quarterly report to the Committees on Ap-  
24 propriations of the House of Representatives and the  
25 Senate detailing the actual expenditure of funds pro-

1 vided by paragraph (1)(A) and the expected expendi-  
2 ture of such funds in the subsequent quarter.

3 (f) CONFORMING AMENDMENTS.—

4 (1) Paragraph (2) of section 1324(b) of title  
5 31, United States Code, is amended by inserting  
6 “6428,” after “54B(h),”.

7 (2) The table of sections for subchapter B of  
8 chapter 65 of subtitle F of the Internal Revenue  
9 Code of 1986 is amended by inserting after the item  
10 relating to section 6427 the following:

“Sec. 6428. 2020 Recovery Rebates for individuals.”.

11 **SEC. 2102. DELAY OF CERTAIN DEADLINES.**

12 (a) FILING DEADLINES FOR 2019.—

13 (1) IN GENERAL.—In the case of returns for  
14 taxable year 2019, including for purposes of section  
15 6151(a) of the Internal Revenue Code of 1986, sec-  
16 tion 6072(a) of such Code shall be applied—

17 (A) by substituting “July” for “April”,

18 and

19 (B) by substituting “the seventh month”  
20 for “the fourth month”.

21 (2) EFFECTIVE DATE.—Paragraph (1) shall  
22 apply to all returns required to be filed for taxable  
23 year 2019.

24 (b) ESTIMATED TAX PAYMENTS FOR INDIVID-  
25 UALS.—

1           (1) IN GENERAL.—In the case of an individual,  
2           the due date for any required installment under sec-  
3           tion 6654 of the Internal Revenue Code of 1986  
4           which (but for the application of this section) would  
5           be due during the applicable period shall not be due  
6           before October 15, 2020, and all such installments  
7           shall be treated as one installment due on such date.  
8           The Secretary of the Treasury (or the Secretary’s  
9           delegate) shall prescribe such regulations or other  
10          guidance as may be necessary to carry out the pur-  
11          poses of this subsection.

12          (2) APPLICABLE PERIOD.—For purposes of this  
13          subsection, the applicable period is the period begin-  
14          ning on the date of the enactment of this Act and  
15          ending before October 15, 2020.

16 **SEC. 2103. SPECIAL RULES FOR USE OF RETIREMENT**  
17 **FUNDS.**

18          (a) TAX-FAVORED WITHDRAWALS FROM RETIRE-  
19          MENT PLANS.—

20               (1) IN GENERAL.—Section 72(t) of the Internal  
21               Revenue Code of 1986 shall not apply to any  
22               coronavirus-related distribution.

23               (2) AGGREGATE DOLLAR LIMITATION.—

24                       (A) IN GENERAL.—For purposes of this  
25                       subsection, the aggregate amount of distribu-

1 tions received by an individual which may be  
2 treated as coronavirus-related distributions for  
3 any taxable year shall not exceed \$100,000.

4 (B) TREATMENT OF PLAN DISTRIBUTIONS.—If a distribution to an individual would  
5 (without regard to subparagraph (A)) be a  
6 coronavirus-related distribution, a plan shall not  
7 be treated as violating any requirement of the  
8 Internal Revenue Code of 1986 merely because  
9 the plan treats such distribution as a  
10 coronavirus-related distribution, unless the ag-  
11 gregate amount of such distributions from all  
12 plans maintained by the employer (and any  
13 member of any controlled group which includes  
14 the employer) to such individual exceeds  
15 \$100,000.  
16

17 (C) CONTROLLED GROUP.—For purposes  
18 of subparagraph (B), the term “controlled  
19 group” means any group treated as a single  
20 employer under subsection (b), (c), (m), or (o)  
21 of section 414 of the Internal Revenue Code of  
22 1986.

23 (3) AMOUNT DISTRIBUTED MAY BE REPAYED.—

24 (A) IN GENERAL.—Any individual who re-  
25 ceives a coronavirus-related distribution may, at



1 any time during the 3-year period beginning on  
2 the day after the date on which such distribu-  
3 tion was received, make 1 or more contributions  
4 in an aggregate amount not to exceed the  
5 amount of such distribution to an eligible retire-  
6 ment plan of which such individual is a bene-  
7 ficiary and to which a rollover contribution of  
8 such distribution could be made under section  
9 402(c), 403(a)(4), 403(b)(8), 408(d)(3), or  
10 457(e)(16), of the Internal Revenue Code of  
11 1986, as the case may be.

12 (B) TREATMENT OF REPAYMENTS OF DIS-  
13 TRIBUTIONS FROM ELIGIBLE RETIREMENT  
14 PLANS OTHER THAN IRAS.—For purposes of  
15 the Internal Revenue Code of 1986, if a con-  
16 tribution is made pursuant to subparagraph (A)  
17 with respect to a coronavirus-related distribu-  
18 tion from an eligible retirement plan other than  
19 an individual retirement plan, then the taxpayer  
20 shall, to the extent of the amount of the con-  
21 tribution, be treated as having received the  
22 coronavirus-related distribution in an eligible  
23 rollover distribution (as defined in section  
24 402(c)(4) of such Code) and as having trans-  
25 ferred the amount to the eligible retirement

1 plan in a direct trustee to trustee transfer with-  
2 in 60 days of the distribution.

3 (C) TREATMENT OF REPAYMENTS OF DIS-  
4 TRIBUTIONS FROM IRAS.—For purposes of the  
5 Internal Revenue Code of 1986, if a contribu-  
6 tion is made pursuant to subparagraph (A)  
7 with respect to a coronavirus-related distribu-  
8 tion from an individual retirement plan (as de-  
9 fined by section 7701(a)(37) of such Code),  
10 then, to the extent of the amount of the con-  
11 tribution, the coronavirus-related distribution  
12 shall be treated as a distribution described in  
13 section 408(d)(3) of such Code and as having  
14 been transferred to the eligible retirement plan  
15 in a direct trustee to trustee transfer within 60  
16 days of the distribution.

17 (4) DEFINITIONS.—For purposes of this sub-  
18 section—

19 (A) CORONAVIRUS-RELATED DISTRIBUTION.—Except as provided in paragraph (2),  
20 the term “coronavirus-related distribution”  
21 means any distribution from an eligible retire-  
22 ment plan made—  
23

1 (i) on or after the date of the enact-  
2 ment of this Act and before December 31,  
3 2020,

4 (ii) to an individual—

5 (I) who is diagnosed with the  
6 virus SARS-CoV-2 or with  
7 coronavirus disease 2019 (COVID-19)  
8 by a test approved by the Centers for  
9 Disease Control and Prevention,

10 (II) whose spouse or dependent  
11 (as defined in section 152 of the In-  
12 ternal Revenue Code of 1986) is diag-  
13 nosed with such virus or disease by  
14 such a test, or

15 (III) who experiences adverse fi-  
16 nancial consequences as a result of  
17 being quarantined, being furloughed  
18 or laid off or having work hours re-  
19 duced due to such virus or disease,  
20 being unable to work due to lack of  
21 child care due to such virus or dis-  
22 ease, closing or reducing hours of a  
23 business owned or operated by the in-  
24 dividual due to such virus or disease,  
25 or other factors as determined by the

1 Secretary of the Treasury (or the Sec-  
2 retary's delegate).

3 (B) ELIGIBLE RETIREMENT PLAN.—The  
4 term “eligible retirement plan” has the meaning  
5 given such term by section 402(c)(8)(B) of the  
6 Internal Revenue Code of 1986.

7 (5) INCOME INCLUSION SPREAD OVER 3-YEAR  
8 PERIOD.—

9 (A) IN GENERAL.—In the case of any  
10 coronavirus-related distribution, unless the tax-  
11 payer elects not to have this paragraph apply  
12 for any taxable year, any amount required to be  
13 included in gross income for such taxable year  
14 shall be so included ratably over the 3-taxable-  
15 year period beginning with such taxable year.

16 (B) SPECIAL RULE.—For purposes of sub-  
17 paragraph (A), rules similar to the rules of sub-  
18 paragraph (E) of section 408A(d)(3) of the In-  
19 ternal Revenue Code of 1986 shall apply.

20 (6) SPECIAL RULES.—

21 (A) EXEMPTION OF DISTRIBUTIONS FROM  
22 TRUSTEE TO TRUSTEE TRANSFER AND WITH-  
23 HOLDING RULES.—For purposes of sections  
24 401(a)(31), 402(f), and 3405 of the Internal  
25 Revenue Code of 1986, coronavirus-related dis-

1           tributions shall not be treated as eligible roll-  
2           over distributions.

3           (B) CORONAVIRUS-RELATED DISTRIBUTIONS TREATED AS MEETING PLAN DISTRIBUTION REQUIREMENTS.—For purposes of the Internal Revenue Code of 1986, a coronavirus-related distribution shall be treated as meeting the requirements of sections 401(k)(2)(B)(i), 403(b)(7)(A)(i), 403(b)(11), and 457(d)(1)(A) of such Code.

11       (b) LOANS FROM QUALIFIED PLANS.—

12           (1) INCREASE IN LIMIT ON LOANS NOT TREATED AS DISTRIBUTIONS.—In the case of any loan from a qualified employer plan (as defined under section 72(p)(4) of the Internal Revenue Code of 1986) to a qualified individual made during the 180-day period beginning on the date of the enactment of this Act—

19           (A) clause (i) of section 72(p)(2)(A) of such Code shall be applied by substituting “\$100,000” for “\$50,000”, and

22           (B) clause (ii) of such section shall be applied by substituting “the present value of the nonforfeitable accrued benefit of the employee under the plan” for “one-half of the present

1 value of the nonforfeitable accrued benefit of  
2 the employee under the plan”.

3 (2) DELAY OF REPAYMENT.—In the case of a  
4 qualified individual with an outstanding loan (on or  
5 after the date of the enactment of this Act) from a  
6 qualified employer plan (as defined in section  
7 72(p)(4) of the Internal Revenue Code of 1986)—

8 (A) if the due date pursuant to subpara-  
9 graph (B) or (C) of section 72(p)(2) of such  
10 Code for any repayment with respect to such  
11 loan occurs during the period beginning on the  
12 date of the enactment of this Act and ending on  
13 December 31, 2020, such due date shall be de-  
14 layed for 1 year (or, if later, until the date  
15 which is 180 days after the date of the enact-  
16 ment of this Act),

17 (B) any subsequent repayments with re-  
18 spect to any such loan shall be appropriately  
19 adjusted to reflect the delay in the due date  
20 under subparagraph (A) and any interest accru-  
21 ing during such delay, and

22 (C) in determining the 5-year period and  
23 the term of a loan under subparagraph (B) or  
24 (C) of section 72(p)(2) of such Code, the period

1 described in subparagraph (A) of this para-  
2 graph shall be disregarded.

3 (3) QUALIFIED INDIVIDUAL.—For purposes of  
4 this subsection, the term “qualified individual”  
5 means any individual who is described in subsection  
6 (a)(4)(A)(ii).

7 (c) PROVISIONS RELATING TO PLAN AMEND-  
8 MENTS.—

9 (1) IN GENERAL.—If this subsection applies to  
10 any amendment to any plan or annuity contract,  
11 such plan or contract shall be treated as being oper-  
12 ated in accordance with the terms of the plan during  
13 the period described in paragraph (2)(B)(i).

14 (2) AMENDMENTS TO WHICH SUBSECTION AP-  
15 PLIES.—

16 (A) IN GENERAL.—This subsection shall  
17 apply to any amendment to any plan or annuity  
18 contract which is made—

19 (i) pursuant to any provision of this  
20 section, or pursuant to any regulation  
21 issued by the Secretary of the Treasury or  
22 the Secretary of Labor (or the delegate of  
23 either such Secretary) under any provision  
24 of this section, and

1 (ii) on or before the last day of the  
2 first plan year beginning on or after Janu-  
3 ary 1, 2020, or such later date as the Sec-  
4 retary of the Treasury (or the Secretary's  
5 delegate) may prescribe.

6 In the case of a governmental plan (as defined  
7 in section 414(d) of the Internal Revenue Code  
8 of 1986), clause (ii) shall be applied by sub-  
9 stituting the date which is 2 years after the  
10 date otherwise applied under clause (ii).

11 (B) CONDITIONS.—This subsection shall  
12 not apply to any amendment unless—

13 (i) during the period—

14 (I) beginning on the date that  
15 this section or the regulation de-  
16 scribed in subparagraph (A)(i) takes  
17 effect (or in the case of a plan or con-  
18 tract amendment not required by this  
19 section or such regulation, the effec-  
20 tive date specified by the plan), and

21 (II) ending on the date described  
22 in subparagraph (A)(ii) (or, if earlier,  
23 the date the plan or contract amend-  
24 ment is adopted),



1           the plan or contract is operated as if such  
 2           plan or contract amendment were in effect,  
 3           and

4                   (ii) such plan or contract amendment  
 5           applies retroactively for such period.

6 **SEC. 2104. ALLOWANCE OF PARTIAL ABOVE THE LINE DE-**  
 7 **DUCTION FOR CHARITABLE CONTRIBUTIONS.**

8           (a) IN GENERAL.—Section 62(a) of the Internal Rev-  
 9 enue Code of 1986 is amended by inserting after para-  
 10 graph (21) the following new paragraph:

11                   “(22) CHARITABLE CONTRIBUTIONS.—In the  
 12 case of taxable years beginning in 2020, the amount  
 13 (not to exceed \$300) of qualified charitable contribu-  
 14 tions made by an eligible taxpayer during the tax-  
 15 able year .”.

16           (b) DEFINITIONS.—Section 62 of such Code is  
 17 amended by adding at the end the following new sub-  
 18 section:

19                   “(f) DEFINITIONS RELATING TO QUALIFIED CHARI-  
 20 TABLE CONTRIBUTIONS.—For purposes of subsection  
 21 (a)(22)—

22                           “(1) ELIGIBLE TAXPAYER.—The term ‘eligible  
 23 taxpayer’ means any individual who does not elect to  
 24 itemize deductions.

1           “(2) QUALIFIED CHARITABLE CONTRIBU-  
2           TIONS.—The term ‘qualified charitable contribution’  
3           means a charitable contribution (as defined in sec-  
4           tion 170(c))—

5                   “(A) which is made in cash,

6                   “(B) for which a deduction is allowable  
7           under section 170 (determined without regard  
8           to subsection (b) thereof), and

9                   “(C) which is—

10                   “(i) made to an organization de-  
11           scribed in section 170(b)(1)(A), and

12                   “(ii) not—

13                   “(I) to an organization described  
14           in section 509(a)(3), or

15                   “(II) for the establishment of a  
16           new, or maintenance of an existing,  
17           donor advised fund (as defined in sec-  
18           tion 4966(d)(2)).

19           Such term shall not include any amount  
20           which is treated as a charitable contribu-  
21           tion made in such taxable year under sub-  
22           section (b)(1)(G) or (d)(1) of section  
23           170.”.

1 (c) EFFECTIVE DATE.—The amendments made by  
2 this section shall apply to taxable years beginning after  
3 December 31, 2019.

4 **SEC. 2105. MODIFICATION OF LIMITATIONS ON CHARITABLE CONTRIBUTIONS DURING 2020.**

5 (a) TEMPORARY SUSPENSION OF LIMITATIONS ON  
6 CERTAIN CASH CONTRIBUTIONS.—

7 (1) IN GENERAL.—Except as otherwise provided in paragraph (2), qualified contributions shall  
8 be disregarded in applying subsections (b) and (d) of  
9 section 170 of the Internal Revenue Code of 1986.

10 (2) TREATMENT OF EXCESS CONTRIBUTIONS.—  
11 For purposes of section 170 of the Internal Revenue  
12 Code of 1986—

13 (A) INDIVIDUALS.—In the case of an individual—

14 (i) LIMITATION.—Any qualified contribution shall be allowed as a deduction  
15 only to the extent that the aggregate of  
16 such contributions does not exceed the excess of the taxpayer's contribution base (as  
17 defined in subparagraph (H) of section  
18 170(b)(1) of such Code) over the amount  
19 of all other charitable contributions allowed  
20 under section 170(b)(1) of such Code.

1                   (ii) CARRYOVER.—If the aggregate  
2                   amount of qualified contributions made in  
3                   the contribution year (within the meaning  
4                   of section 170(d)(1) of such Code) exceeds  
5                   the limitation of clause (i), such excess  
6                   shall be added to the excess described in  
7                   section 170(b)(1)(G)(ii).

8                   (B) CORPORATIONS.—In the case of a cor-  
9                   poration—

10                   (i) LIMITATION.—Any qualified con-  
11                   tribution shall be allowed as a deduction  
12                   only to the extent that the aggregate of  
13                   such contributions does not exceed the ex-  
14                   cess of 25 percent of the taxpayer's taxable  
15                   income (as determined under paragraph  
16                   (2) of section 170(b) of such Code) over  
17                   the amount of all other charitable con-  
18                   tributions allowed under such paragraph.

19                   (ii) CARRYOVER.—If the aggregate  
20                   amount of qualified contributions made in  
21                   the contribution year (within the meaning  
22                   of section 170(d)(2) of such Code) exceeds  
23                   the limitation of clause (i), such excess  
24                   shall be appropriately taken into account

1 under section 170(d)(2) subject to the limi-  
2 tations thereof.

3 (3) QUALIFIED CONTRIBUTIONS.—

4 (A) IN GENERAL.—For purposes of this  
5 subsection, the term “qualified contribution”  
6 means any charitable contribution (as defined  
7 in section 170(c) of the Internal Revenue Code  
8 of 1986) if—

9 (i) such contribution is paid in cash  
10 during calendar year 2020 to an organiza-  
11 tion described in section 170(b)(1)(A) of  
12 such Code, and

13 (ii) the taxpayer has elected the appli-  
14 cation of this section with respect to such  
15 contribution.

16 (B) EXCEPTION.—Such term shall not in-  
17 clude a contribution by a donor if the contribu-  
18 tion is—

19 (i) to an organization described in sec-  
20 tion 509(a)(3) of the Internal Revenue  
21 Code of 1986, or

22 (ii) for the establishment of a new, or  
23 maintenance of an existing, donor advised  
24 fund (as defined in section 4966(d)(2) of  
25 such Code).

1 (C) APPLICATION OF ELECTION TO PART-  
2 NERSHIPS AND S CORPORATIONS.—In the case  
3 of a partnership or S corporation, the election  
4 under subparagraph (A)(ii) shall be made sepa-  
5 rately by each partner or shareholder.

6 (b) INCREASE IN LIMITS ON CONTRIBUTIONS OF  
7 FOOD INVENTORY.—In the case of any charitable con-  
8 tribution of food during 2020 to which section  
9 170(e)(3)(C) of the Internal Revenue Code of 1986 ap-  
10 plies, subclauses (I) and (II) of clause (ii) thereof shall  
11 each be applied by substituting “25 percent” for “15 per-  
12 cent.”

13 (c) EFFECTIVE DATE.—This section shall apply to  
14 taxable years ending after December 31, 2019.

## 15 **TITLE II—BUSINESS PROVISIONS**

### 16 **SEC. 2201. DELAY OF ESTIMATED TAX PAYMENTS FOR COR-** 17 **PORATIONS.**

18 (a) IN GENERAL.—In the case of a corporation, the  
19 due date for any required installment under section 6655  
20 of the Internal Revenue Code of 1986 which (but for the  
21 application of this section) would be due during the appli-  
22 cable period shall not be due before October 15, 2020, and  
23 all such installments shall be treated as one installment  
24 due on such date. The Secretary of the Treasury (or the  
25 Secretary’s delegate) shall prescribe such regulations or

1 other guidance as may be necessary to carry out the pur-  
2 poses of this section.

3 (b) **APPLICABLE PERIOD.**—For purposes of this sec-  
4 tion, the applicable period is the period beginning on the  
5 date of the enactment of this Act and ending before Octo-  
6 ber 15, 2020.

7 **SEC. 2202. DELAY OF PAYMENT OF EMPLOYER PAYROLL**  
8 **TAXES.**

9 (a) **IN GENERAL.**—

10 (1) **TAXES.**—Notwithstanding any other provi-  
11 sion of law, the payment for applicable employment  
12 taxes for the payroll tax deferral period shall not be  
13 due before the applicable date.

14 (2) **DEPOSITS.**—Notwithstanding section 6302  
15 of the Internal Revenue Code of 1986, an employer  
16 shall be treated as having timely made all deposits  
17 of applicable employment taxes that are required to  
18 be made (without regard to this section) for such  
19 taxes during the payroll tax deferral period if all  
20 such deposits are made not later than the applicable  
21 date.

22 (3) **EXCEPTION.**—This subsection shall not  
23 apply to any taxpayer if such taxpayer has had in-  
24 debtedness forgiven under section 1105 of this Act

1 with respect to a loan under section 7(a) of the  
2 Small Business Act (15 U.S.C. 636(a)).

3 (b) SECA.—

4 (1) IN GENERAL.—Notwithstanding any other  
5 provision of law, the payment for 50 percent of the  
6 taxes imposed under section 1401(a) of the Internal  
7 Revenue Code of 1986 for the payroll tax deferral  
8 period shall not be due before the applicable date.

9 (2) ESTIMATED TAXES.—For purposes of ap-  
10 plying section 6654 of the Internal Revenue Code of  
11 1986 to any taxable year which includes any part of  
12 the payroll tax deferral period, 50 percent of the of  
13 the taxes imposed under section 1401(a) of such  
14 Code for the payroll tax deferral period shall not be  
15 treated as taxes to which such section 6654 applies.

16 (c) DEFINITIONS.—For purposes of this section—

17 (1) APPLICABLE EMPLOYMENT TAXES.—The  
18 term “applicable employment taxes” means the fol-  
19 lowing:

20 (A) The taxes imposed under section  
21 3111(a) of the Internal Revenue Code of 1986.

22 (B) So much of the taxes imposed under  
23 section 3211(a) of such Code as are attrib-  
24 utable to the rate in effect under section  
25 3111(a) of such Code.



1           (C) So much of the taxes imposed under  
2           section 3221(a) of such Code as are attrib-  
3           utable to the rate in effect under section  
4           3111(a) of such Code.

5           (2) PAYROLL TAX DEFERRAL PERIOD.—The  
6           term “payroll tax deferral period” means the period  
7           beginning on the date of the enactment of this Act  
8           and ending before January 1, 2021.

9           (3) APPLICABLE DATE.—The term “applicable  
10          date” means—

11           (A) December 31, 2021, with respect to 50  
12           percent of the amounts to which subsection (a)  
13           or (b), as the case may be, apply, and

14           (B) December 31, 2022, with respect to  
15           the remaining such amounts.

16          (d) TRUST FUNDS HELD HARMLESS.—There are  
17          hereby appropriated (out of any money in the Treasury  
18          not otherwise appropriated) for each fiscal year to the  
19          Federal Old-Age and Survivors Insurance Trust Fund and  
20          the Federal Disability Insurance Trust Fund established  
21          under section 201 of the Social Security Act (42 U.S.C.  
22          401) and the Social Security Equivalent Benefit Account  
23          established under section 15A(a) of the Railroad Retire-  
24          ment Act of 1974 (45 U.S.C. 231n–1(a)) an amount equal  
25          to the reduction in the transfers to such fund for such

1 fiscal year by reason of this section. Amounts appropriated  
2 by the preceding sentence shall be transferred from the  
3 general fund at such times and in such manner as to rep-  
4 licate to the extent possible the transfers which would have  
5 occurred to such Trust Fund had such amendments not  
6 been enacted.

7 (e) REGULATORY AUTHORITY.—The Secretary of the  
8 Treasury (or the Secretary’s delegate) shall issue such  
9 regulations or other guidance as necessary to carry out  
10 the purposes of this section.

11 **SEC. 2203. MODIFICATIONS FOR NET OPERATING LOSSES.**

12 (a) TEMPORARY REPEAL OF TAXABLE INCOME LIM-  
13 ITATION.—

14 (1) IN GENERAL.—The first sentence of section  
15 172(a) of the Internal Revenue Code of 1986 is  
16 amended by striking “an amount equal to” and all  
17 that follows and inserting “an amount equal to—

18 “(1) in the case of a taxable year beginning be-  
19 fore January 1, 2021, the aggregate of the net oper-  
20 ating loss carryovers to such year, plus the net oper-  
21 ating loss carrybacks to such year, and

22 “(2) in the case of a taxable year beginning  
23 after December 31, 2020, the sum of—

24 “(A) the aggregate amount of net oper-  
25 ating losses arising in taxable years beginning

1 before January 1, 2018, carried to such taxable  
2 year, plus

3 “(B) the lesser of—

4 “(i) the aggregate amount of net op-  
5 erating losses arising in taxable years be-  
6 ginning after December 31, 2017, carried  
7 to such taxable year, or

8 “(ii) 80 percent of the excess (if any)  
9 of—

10 “(I) taxable income computed  
11 without regard to the deductions  
12 under this section and sections 199A  
13 and 250, over

14 “(II) the amount determined  
15 under subparagraph (A).”.

16 (2) CONFORMING AMENDMENTS.—

17 (A) Section 172(b)(2)(C) of such Code is  
18 amended to read as follows:

19 “(C) for taxable years beginning after De-  
20 cember 31, 2020, be reduced by 20 percent of  
21 the excess (if any) described in subsection  
22 (a)(2)(B)(ii) for such taxable year.”.

23 (B) Section 172(d)(6)(C) of such Code is  
24 amended by striking “subsection (a)(2)” and  
25 inserting “subsection (a)(2)(B)(ii)(I)”.

1           (C) Section 860E(a)(3)(B) of such Code is  
2           amended by striking all that follows “for pur-  
3           poses of” and inserting “subsection  
4           (a)(2)(B)(ii)(I) and the second sentence of sub-  
5           section (b)(2) of section 172.”.

6           (b) MODIFICATION OF RULES RELATING TO  
7 CARRYBACKS.—

8           (1) IN GENERAL.—Section 172(b)(1) of the In-  
9           ternal Revenue Code of 1986 is amended by adding  
10          at the end the following new subparagraph:

11                   “(D) SPECIAL RULE FOR LOSSES ARISING  
12                   IN 2018, 2019, AND 2020.—

13                           “(i) IN GENERAL.—In the case of any  
14                           net operating loss arising in a taxable year  
15                           beginning after December 31, 2017, and  
16                           before January 1, 2020—

17                                   “(I) such loss shall be a net oper-  
18                                   ating loss carryback to each of the 5  
19                                   taxable years preceding the taxable  
20                                   year of such loss, and

21   “(II) subparagraphs (B) and  
22   (C)(i) shall not apply.

23                           “(ii) SPECIAL RULES FOR REIT’S.—  
24                           For purposes of this subparagraph—

1                   “(I) IN GENERAL.—A net oper-  
2                   ating loss for a REIT year shall not  
3                   be a net operating loss carryback to  
4                   any taxable year preceding the taxable  
5                   year of such loss.

6                   “(II) SPECIAL RULE.—In the  
7                   case of any net operating loss for a  
8                   taxable year which is not a REIT  
9                   year, such loss shall not be carried  
10                  back to any taxable year which is a  
11                  REIT year.

12                  “(III) REIT YEAR.—For pur-  
13                  poses of this subparagraph, the term  
14                  ‘REIT year’ means any taxable year  
15                  for which the provisions of part II of  
16                  subchapter M (relating to real estate  
17                  investment trusts) apply to the tax-  
18                  payer.

19                  “(iii) ELECTION.—A taxpayer may  
20                  elect not to have clause (i) apply for any  
21                  taxable year. Such election shall be made  
22                  in such manner as prescribed by the Sec-  
23                  retary and shall be made—

24                                 “(I) in the case of any election  
25                                 relating to a net operating loss arising

1 in a taxable year beginning in 2018 or  
2 2019, by the due date (including ex-  
3 tensions of time) for filing the tax-  
4 payer’s return for the first taxable  
5 year ending after the date of the en-  
6 actment of this subparagraph, and

7 “(II) in the case of any election  
8 relating to a net operating loss arising  
9 in a taxable year beginning in 2020,  
10 by the due date (including extensions  
11 of time) for such taxable year.

12 Such election, once made for any taxable  
13 year, shall be irrevocable for such taxable  
14 year.”.

15 (2) CONFORMING AMENDMENT.—Section  
16 170(b)(1)(A) of such Code, as amended by sub-  
17 section (c)(2), is amended by striking “and (C)(i)”  
18 and inserting “, (C)(i), and (D)”.

19 (c) TECHNICAL AMENDMENT RELATING TO SECTION  
20 13302 OF PUBLIC LAW 115–97.—

21 (1) Section 13302(e) of Public Law 115–97 is  
22 amended to read as follows:

23 “(e) EFFECTIVE DATES.—

1           “(1) NET OPERATING LOSS LIMITATION.—The  
2           amendments made by subsections (a) and (d)(2)  
3           shall apply to—

4                   “(A) taxable years beginning after Decem-  
5                   ber 31, 2017, and

6                   “(B) taxable years beginning on or before  
7                   December 31, 2017, to which net operating  
8                   losses arising in taxable years beginning after  
9                   December 31, 2017, are carried.

10           “(2) CARRYFORWARDS AND CARRYBACKS.—The  
11           amendments made by subsections (b), (c), and  
12           (d)(1) shall apply to net operating losses arising in  
13           taxable years beginning after December 31, 2017.”.

14           (2) Section 172(b)(1)(A) of the Internal Rev-  
15           enue Code of 1986 is amended to read as follows:

16                   “(A) GENERAL RULE.—A net operating  
17                   loss for any taxable year—

18                           “(i) shall be a net operating loss  
19                           carryback to the extent provided in sub-  
20                           paragraphs (B) and (C)(i), and

21                           “(ii) except as provided in subpara-  
22                           graph (C)(ii), shall be a net operating loss  
23                           carryover—

24                                   “(I) in the case of a net oper-  
25                                   ating loss arising in a taxable year be-

1                   ginning before January 1, 2018, to  
2                   each of the 20 taxable years following  
3                   the taxable year of the loss, and

4                   “(II) in the case of a net oper-  
5                   ating loss arising in a taxable year be-  
6                   ginning after December 31, 2017, to  
7                   each taxable year following the tax-  
8                   able year of the loss.”.

9                   (d) EFFECTIVE DATES.—

10                   (1) NET OPERATING LOSS LIMITATION.—The  
11                   amendments made by subsection (a) shall apply—

12                   (A) to taxable years beginning after De-  
13                   cember 31, 2017, and

14                   (B) taxable years beginning on or before  
15                   December 31, 2017, to which net operating  
16                   losses arising in taxable years beginning after  
17                   December 31, 2017, are carried.

18                   (2) CARRYFORWARDS AND CARRYBACKS.—The  
19                   amendment made by subsection (b) shall apply to  
20                   net operating losses arising in taxable years begin-  
21                   ning after December 31, 2017.

22                   (3) TECHNICAL AMENDMENTS.—The amend-  
23                   ments made by subsection (c) shall take effect as if  
24                   included in the provisions of Public Law 115–97 to  
25                   which they relate.



1           (4) SPECIAL RULE.—In the case of a net oper-  
2           ating loss arising in a taxable year beginning before  
3           January 1, 2018, and ending after December 31,  
4           2017—

5                   (A) an application under section 6411(a)  
6                   of the Internal Revenue Code of 1986 with re-  
7                   spect to the carryback of such net operating  
8                   loss shall not fail to be treated as timely filed  
9                   if filed not later than the date which is 120  
10                  days after the date of the enactment of this  
11                  Act, and

12                  (B) an election to—

13                          (i) forgo any carryback of such net  
14                          operating loss,

15                          (ii) reduce any period to which such  
16                          net operating loss may be carried back, or

17                          (iii) revoke any election made under  
18                          section 172(b) to forgo any carryback of  
19                          such net operating loss,

20                  shall not fail to be treated as timely made if  
21                  made not later than the date which is 120 days  
22                  after the date of the enactment of this Act.

1 **SEC. 2204. MODIFICATION OF LIMITATION ON LOSSES FOR**  
2 **TAXPAYERS OTHER THAN CORPORATIONS.**

3 (a) IN GENERAL.—Section 461(l)(1) of the Internal  
4 Revenue Code of 1986 is amended by striking “December  
5 31, 2017” and inserting “December 31, 2020”.

6 (b) TECHNICAL AMENDMENTS RELATING TO SEC-  
7 TION 11012 OF PUBLIC LAW 115–97.—

8 (1) Section 461(l)(2) of the Internal Revenue  
9 Code of 1986 is amended by striking “a net oper-  
10 ating loss carryover to the following taxable year  
11 under section 172” and inserting “a net operating  
12 loss for the taxable year for purposes of determining  
13 any net operating loss carryover under section  
14 172(b) for subsequent taxable years”.

15 (2) Section 461(l)(3)(A) of such Code is  
16 amended—

17 (A) in clause (i), by inserting “and without  
18 regard to any deduction allowable under section  
19 172 or 199A” after “under paragraph (1)”,  
20 and

21 (B) by adding at the end the following  
22 flush sentence:

23 “Such excess shall be determined without regard to  
24 any deductions, gross income, or gains attributable  
25 to any trade or business of performing services as an  
26 employee.”.

1           (3) Section 461(l)(3) of such Code is amended  
2           by redesignating subparagraph (B) as subparagraph  
3           (C) and by inserting after subparagraph (A) the fol-  
4           lowing new subparagraph:

5                   “(B) TREATMENT OF CAPITAL GAINS AND  
6           LOSSES.—

7                   “(i) LOSSES.—Deductions for losses  
8                   from sales or exchanges of capital assets  
9                   shall not be taken into account under sub-  
10                  paragraph (A)(i).

11                  “(ii) GAINS.—The amount of gains  
12                  from sales or exchanges of capital assets  
13                  taken into account under subparagraph  
14                  (A)(ii) shall not exceed the lesser of—

15                   “(I) the capital gain net income  
16                   determined by taking into account  
17                   only gains and losses attributable to a  
18                   trade or business, or

19                   “(II) the capital gain net in-  
20                   come.”.

21           (c) EFFECTIVE DATES.—

22                   (1) IN GENERAL.—The amendments made by  
23                   subsection (a) shall apply to taxable years beginning  
24                   after December 31, 2017.

1           (2) TECHNICAL AMENDMENTS.—The amend-  
2           ments made by subsection (b) shall take effect as if  
3           included in the provisions of Public Law 115–97 to  
4           which they relate.

5 **SEC. 2205. MODIFICATION OF CREDIT FOR PRIOR YEAR**  
6                                   **MINIMUM TAX LIABILITY OF CORPORATIONS.**

7           (a) IN GENERAL.—Section 53(e) of the Internal Rev-  
8           enue Code of 1986 is amended to read as follows:

9           “(e) CREDIT TREATED AS REFUNDABLE FOR CER-  
10          TAIN TAXPAYERS.—In the case of the first taxable year  
11          of a corporation beginning in 2018—

12                           “(1) subsection (e) shall not apply, and

13                           “(2) for purposes of this title (other than this  
14          section), the credit allowed by reason of this sub-  
15          section shall be treated as allowed under subpart C  
16          (and not this subpart).”.

17          (b) EFFECTIVE DATE.—The amendment made by  
18          this section shall apply to taxable years beginning after  
19          December 31, 2017.

20 **SEC. 2206. MODIFICATION OF LIMITATION ON BUSINESS IN-**  
21                                   **TEREST.**

22          (a) IN GENERAL.—Section 163(j) of the Internal  
23          Revenue Code of 1986 is amended by redesignating para-  
24          graph (10) as paragraph (11) and by inserting after para-  
25          graph (9) the following new paragraph:

1           “(10) SPECIAL RULE FOR TAXABLE YEARS BE-  
2           GINNING IN 2019 AND 2020.—

3           “(A) IN GENERAL.—In the case of any  
4           taxable year beginning in 2019 or 2020, para-  
5           graph (1)(B) shall be applied by substituting  
6           ‘50 percent’ for ‘30 percent’.

7           “(B) ELECTION TO USE 2019 INCOME FOR  
8           TAXABLE YEARS BEGINNING IN 2020.—

9           “(i) IN GENERAL.—Subject to clause  
10           (ii), in the case of any taxable year begin-  
11           ning in 2020, the taxpayer may elect to  
12           apply this subsection by substituting the  
13           adjusted taxable income of the taxpayer for  
14           the last taxable year beginning in 2019 for  
15           the adjusted taxable income for such tax-  
16           able year.

17           “(ii) SPECIAL RULE FOR SHORT TAX-  
18           ABLE YEARS.—No election may be made  
19           under clause (i) with respect to any taxable  
20           year beginning in 2020 if such taxable  
21           year is a short taxable year.”.

22           (b) EFFECTIVE DATE.—The amendments made by  
23           this section shall apply to taxable years beginning after  
24           December 31, 2018.

1 **SEC. 2207. TECHNICAL AMENDMENTS REGARDING QUALI-**  
2 **FIED IMPROVEMENT PROPERTY.**

3 (a) IN GENERAL.—Section 168 of the Internal Rev-  
4 enue Code of 1986 is amended—

5 (1) in subsection (e)—

6 (A) in paragraph (3)(E), by striking “and”  
7 at the end of clause (v), by striking the period  
8 at the end of clause (vi) and inserting “, and”,  
9 and by adding at the end the following new  
10 clause:

11 “(vii) any qualified improvement prop-  
12 erty.”, and

13 (B) in paragraph (6)(A), by inserting  
14 “made by the taxpayer” after “any improve-  
15 ment”, and

16 (2) in the table contained in subsection  
17 (g)(3)(B)—

18 (A) by striking the item relating to sub-  
19 paragraph (D)(v), and

20 (B) by inserting after the item relating to  
21 subparagraph (E)(vi) the following new item:  
22 “(E)(vii) ..... 20”.

23 (b) EFFECTIVE DATE.—The amendments made by  
24 this section shall take effect as if included in section  
13204 of Public Law 115–97.

1 **SEC. 2208. INSTALLMENTS NOT TO PREVENT CREDIT OR**  
2 **REFUND OF OVERPAYMENTS OR INCREASE**  
3 **ESTIMATED TAXES.**

4 (a) IN GENERAL.—Section 965(h) of the Internal  
5 Revenue Code of 1986 is amended by adding at the end  
6 the following new paragraph:

7 “(7) INSTALLMENTS NOT TO PREVENT CREDIT  
8 OR REFUND OF OVERPAYMENTS OR INCREASE ESTI-  
9 MATED TAXES.—If an election is made under para-  
10 graph (1) to pay the net tax liability under this sec-  
11 tion in installments—

12 “(A) no installment of such net tax liabil-  
13 ity shall—

14 “(i) in the case of a request for credit  
15 or refund, be taken into account as a li-  
16 ability for purposes of determining whether  
17 an overpayment exists for purposes of sec-  
18 tion 6402 before the date on which such  
19 installment is due, or

20 “(ii) for purposes of sections 6425,  
21 6654, and 6655, be treated as a tax im-  
22 posed by section 1, section 11, or sub-  
23 chapter L of chapter 1, and

24 “(B) the first sentence of section 6403  
25 shall not apply with respect to any such install-  
26 ment.”.

1 (b) LIMITATION ON PAYMENT OF INTEREST.—In the  
2 case of the portion of any overpayment which exists by  
3 reason of the application of section 965(h)(7) of the Inter-  
4 nal Revenue Code of 1986 (as added by this section)—

5 (1) if credit or refund of such portion is made  
6 on or before the date which is 45 days after the date  
7 of the enactment of this Act, no interest shall be al-  
8 lowed or paid under section 6611 of such Code with  
9 respect to such portion; and

10 (2) if credit or refund of such portion is made  
11 after the date which is 45 days after the date of the  
12 enactment of this Act, no interest shall be allowed  
13 or paid under section 6611 of such Code with re-  
14 spect to such portion for any period before the date  
15 of the enactment of this Act.

16 (c) EFFECTIVE DATE.—The amendment made by  
17 subsection (a) shall take effect as if included in section  
18 14103 of Public Law 115–97.

19 **SEC. 2209. RESTORATION OF LIMITATION ON DOWNWARD**  
20 **ATTRIBUTION OF STOCK OWNERSHIP IN AP-**  
21 **PLYING CONSTRUCTIVE OWNERSHIP RULES.**

22 (a) IN GENERAL.—Section 958(b) of the Internal  
23 Revenue Code of 1986 is amended—

24 (1) by inserting after paragraph (3) the fol-  
25 lowing:



1           “(4) Subparagraphs (A), (B), and (C) of sec-  
2           tion 318(a)(3) shall not be applied so as to consider  
3           a United States person as owning stock which is  
4           owned by a person who is not a United States per-  
5           son.”, and

6           (2) by striking “Paragraph (1)” in the last sen-  
7           tence and inserting “Paragraphs (1) and (4)”.

8           (b) FOREIGN CONTROLLED UNITED STATES SHARE-  
9           HOLDERS.—Subpart F of part III of subchapter N of  
10          chapter 1 of such Code is amended by inserting after sec-  
11          tion 951A the following new section:

12         **“SEC. 951B. AMOUNTS INCLUDED IN GROSS INCOME OF**  
13                         **FOREIGN CONTROLLED UNITED STATES**  
14                         **SHAREHOLDERS.**

15         “(a) IN GENERAL.—In the case of any foreign con-  
16          trolled United States shareholder of a foreign controlled  
17          foreign corporation—

18                 “(1) this subpart (other than sections 951A,  
19                 951(b), 957, and 965) shall be applied with respect  
20                 to such shareholder (separately from, and in addi-  
21                 tion to, the application of this subpart without re-  
22                 gard to this section)—

23                         “(A) by substituting ‘foreign controlled  
24                         United States shareholder’ for ‘United States  
25                         shareholder’ each place it appears therein, and

1           “(B) by substituting ‘foreign controlled  
2           foreign corporation’ for ‘controlled foreign cor-  
3           poration’ each place it appears therein, and

4           “(2) sections 951A and 965 shall be applied  
5           with respect to such shareholder —

6           “(A) by treating each reference to ‘United  
7           States shareholder’ in such sections as includ-  
8           ing a reference to such shareholder, and

9           “(B) by treating each reference to ‘con-  
10          trolled foreign corporation’ in such sections as  
11          including a reference to such foreign controlled  
12          foreign corporation.

13          “(b) FOREIGN CONTROLLED UNITED STATES  
14          SHAREHOLDER.—For purposes of this section, the term  
15          ‘foreign controlled United States shareholder’ means, with  
16          respect to any foreign corporation, any United States per-  
17          son which would be a United States shareholder with re-  
18          spect to such foreign corporation if—

19                 “(1) section 951(b) were applied by substituting  
20                 ‘more than 50 percent’ for ‘10 percent or more’, and

21                 “(2) section 958(b) were applied without regard  
22                 to paragraph (4) thereof.

23          “(c) FOREIGN CONTROLLED FOREIGN CORPORA-  
24          TION.—For purposes of this section, the term ‘foreign con-  
25          trolled foreign corporation’ means a foreign corporation,

1 other than a controlled foreign corporation, which would  
2 be a controlled foreign corporation if section 957(a) were  
3 applied—

4 “(1) by substituting ‘foreign controlled United  
5 States shareholders’ for ‘United States share-  
6 holders’, and

7 “(2) by substituting ‘section 958(b) (other than  
8 paragraph (4) thereof)’ for ‘section 958(b)’.

9 “(d) REGULATIONS.—The Secretary shall prescribe  
10 such regulations or other guidance as may be necessary  
11 or appropriate to carry out the purposes of this section,  
12 including regulations or other guidance—

13 “(1) to treat a foreign controlled United States  
14 shareholder or a foreign controlled foreign corpora-  
15 tion as a United States shareholder or as a con-  
16 trolled foreign corporation, respectively, for purposes  
17 of provisions of this title other than this subpart,  
18 and

19 “(2) to prevent the avoidance of the purposes of  
20 this section.”.

21 (c) CLERICAL AMENDMENT.—The table of sections  
22 for subpart F of part III of subchapter N of chapter 1  
23 of such Code is amended by inserting after the item relat-  
24 ing to section 951A the following new item:

“Sec. 951B. Amounts included in gross income of foreign controlled United States shareholders.”.

1 (d) EFFECTIVE DATE.—The amendments made by  
2 this section shall apply to—

3 (1) the last taxable year of foreign corporations  
4 beginning before January 1, 2018, and each subse-  
5 quent taxable year of such foreign corporations, and

6 (2) taxable years of United States persons in  
7 which or with which such taxable years of foreign  
8 corporations end.

9 **DIVISION C—ASSISTANCE TO SE-**  
10 **VERELY DISTRESSED SEC-**  
11 **TORS OF THE UNITED STATES**  
12 **ECONOMY**

13 **TITLE I—ECONOMIC**  
14 **STABILIZATION**

15 **SEC. 3101. SHORT TITLE.**

16 This title may be cited as the “Coronavirus Economic  
17 Stabilization Act of 2020”.

18 **SEC. 3102. EMERGENCY RELIEF THROUGH LOANS AND**  
19 **LOAN GUARANTEES.**

20 (a) IN GENERAL.—Notwithstanding any other provi-  
21 sion of law, to provide liquidity to eligible businesses re-  
22 lated to losses incurred as a direct result of coronavirus,  
23 the Secretary is authorized to make or guarantee loans  
24 to eligible businesses that do not, in the aggregate, exceed  
25 \$208,000,000,000 and provide the subsidy amounts nec-

1    essary for such loans and loan guarantees in accordance  
2    with the provisions of the Federal Credit Reform Act of  
3    1990 (2 U.S.C. 661 et seq.).

4           (b) DISTRIBUTION OF LOANS AND LOAN GUARAN-  
5    TEES.—Loans and loan guarantees made pursuant to sub-  
6    section (a) shall be made available to eligible business as  
7    follows:

8           (1) Not more than \$50,000,000,000 shall be  
9    available for passenger air carriers.

10          (2) Not more than \$8,000,000,000 shall be  
11   available for cargo air carriers.

12          (3) Not more than \$150,000,000,000 shall be  
13   available for other eligible businesses.

14          (c) LOANS AND LOAN GUARANTEES.—

15           (1) IN GENERAL.—The Secretary shall review  
16   and decide on applications for loans and loan guar-  
17   antees under this section and may enter into agree-  
18   ments to make or guarantee loans to one or more  
19   obligors if the Secretary determines, in the Sec-  
20   retary's discretion, that—

21           (A) the obligor is a eligible business for  
22   which credit is not reasonably available at the  
23   time of the transaction;

24           (B) the intended obligation by the obligor  
25   is prudently incurred; and

1 (C) the loan is sufficiently secured.

2 (2) TERMS AND LIMITATIONS.—

3 (A) FORMS; TERMS AND CONDITIONS.—A  
4 loan or loan guarantee shall be issued under  
5 this section in such form and on such terms  
6 and conditions and contain such covenants, rep-  
7 resentatives, warranties, and requirements (in-  
8 cluding requirements for audits) as the Sec-  
9 retary determines appropriate. Any loans made  
10 by the Secretary under this section shall be at  
11 a rate not less than a rate determined by the  
12 Secretary taking into consideration the current  
13 average yield on outstanding marketable obliga-  
14 tions of the United States of comparable matu-  
15 rity.

16 (B) PROCEDURES.—As soon as prac-  
17 ticable, but in no case later than 10 days after  
18 the date of enactment of this Act, the Secretary  
19 shall publish procedures for application and  
20 minimum requirements, which may be supple-  
21 mented by the Secretary in the Secretary's dis-  
22 cretion, for the making of loans and loan guar-  
23 antees under this section.

24 (d) FINANCIAL PROTECTION OF GOVERNMENT.—

1           (1) IN GENERAL.—To the extent feasible and  
2           practicable, the Secretary shall ensure that the Fed-  
3           eral Government is compensated for the risk as-  
4           sumed in making loans and loan guarantees under  
5           this section.

6           (2) GOVERNMENT PARTICIPATION IN GAINS.—If  
7           an eligible business receives a loan or loan guarantee  
8           from the Federal Government under this section, the  
9           Secretary is authorized to enter into contracts under  
10          which the Federal Government, contingent on the fi-  
11          nancial success of the eligible business, would par-  
12          ticipate in the gains of the eligible business or its se-  
13          curity holders through the use of such instruments  
14          as warrants, stock options, common or preferred  
15          stock, or other appropriate equity instruments.

16          (e) DEPOSIT OF PROCEEDS.—Amounts collected by  
17          the Secretary under this section, including the proceeds  
18          of investments, earnings, and interest collected, shall be  
19          deposited as follows:

20                 (1) Amounts collected from eligible businesses  
21                 that received loans or loan guarantees under para-  
22                 graph (1) or (2) of subsection (b) shall be deposited  
23                 in the Airport and Airway Trust Fund under section  
24                 9502 of the Internal Revenue Code of 1986.

1           (2) Amounts collected from eligible businesses  
2           that received loans or loan guarantees under para-  
3           graph (3) of subsection (b) shall be deposited in the  
4           Treasury as miscellaneous receipts.

5           (f) ADMINISTRATIVE EXPENSES.—Notwithstanding  
6 any other provision of law, the Secretary may use  
7 \$100,000,000 of the funds made available under this sec-  
8 tion to pay costs and administrative expenses associated  
9 with the provision of direct loans or guarantees authorized  
10 under this section.

11          (g) CONFORMING AMENDMENT.—Section 10(a) of  
12 the Gold Reserve Act of 1934 (31 U.S.C. 5302(a)) is  
13 amended—

14           (1) by striking “and” before “section 3”; and

15           (2) by inserting “and the Coronavirus Eco-  
16           nomic Stabilization Act of 2020,” before “and for  
17           investing”.

18 **SEC. 3103. LIMITATION ON CERTAIN EMPLOYEE COM-**  
19 **PENSATION.**

20          (a) IN GENERAL.—The Secretary may only enter into  
21 a loan or loan agreement under section 3102(a) with an  
22 eligible business after the eligible business enters into a  
23 legally binding agreement with the Secretary that, during  
24 the 2-year period beginning March 1, 2020, and ending  
25 March 1, 2022, no officer or employee of the eligible busi-



1 ness whose total compensation exceeded \$425,000 in cal-  
2 endar year 2019 (other than an employee whose com-  
3 pensation is determined through an existing collective bar-  
4 gaining agreement entered into prior to March 1, 2020)—

5 (1) will receive from the eligible business total  
6 compensation which exceeds, during any 12 consecu-  
7 tive months of such 2-year period, the total com-  
8 pensation received by the officer or employee from  
9 the eligible business in calendar year 2019; and

10 (2) will receive from the eligible business sever-  
11 ance pay or other benefits upon termination of em-  
12 ployment with the eligible business which exceeds  
13 twice the maximum total compensation received by  
14 the officer or employee from the eligible business in  
15 calendar year 2019.

16 (b) **TOTAL COMPENSATION DEFINED.**—In this sec-  
17 tion, the term “total compensation” includes salary, bo-  
18 nuses, awards of stock, and other financial benefits pro-  
19 vided by an eligible business to an officer or employee of  
20 the eligible business.

21 **SEC. 3104. CONTINUATION OF CERTAIN AIR SERVICE.**

22 The Secretary of Transportation is authorized to re-  
23 quire, to the extent reasonable and practicable, an air car-  
24 rier receiving loans and loan guarantees under section  
25 3102 to maintain scheduled air transportation service as

1 the Secretary of Transportation deems necessary to ensure  
2 services to any point served by that carrier before March  
3 1, 2020. When considering whether to exercise the author-  
4 ity granted by this section, the Secretary of Transpor-  
5 tation shall take into consideration the air transportation  
6 needs of small and remote communities.

7 **SEC. 3105. REPORTS.**

8 (a) SECRETARY.—The Secretary shall, with respect  
9 to the loans and loan guarantees provided under section  
10 3102, make such reports as are required under section  
11 5302 or title 31, United States Code.

12 (b) GOVERNMENT ACCOUNTABILITY OFFICE.—

13 (1) STUDY.—The Comptroller General of the  
14 United States shall conduct a study on the loans  
15 and loan guarantees provided under section 3102.

16 (2) REPORT.—Not later than 9 months after  
17 the date of enactment of this Act, and annually  
18 thereafter through the year succeeding the last year  
19 for which loans or loan guarantees provided under  
20 section 3102 are in effect, the Comptroller General  
21 shall submit to the Committee on Transportation  
22 and Infrastructure, the Committee on Appropria-  
23 tions, and the Committee on the Budget of the  
24 House of Representatives and the Committee on  
25 Commerce, Science, and Transportation, the Com-



1 operations of the business are jeopardized, as  
2 determined by the Secretary, and that has not  
3 otherwise applied for or received economic relief  
4 in the form of loans or loan guarantees pro-  
5 vided under any other provision of law.

6 (5) SECRETARY.—The term “Secretary” means  
7 the Secretary of the Treasury, or the designee of the  
8 Secretary of the Treasury.

9 **SEC. 3108. RULE OF CONSTRUCTION.**

10 Nothing in this title shall be construed to allow the  
11 Secretary to provide relief to eligible businesses except in  
12 the form of secured loans and loan guarantees as provided  
13 in this title and under terms and conditions that are in  
14 the interest of the Federal Government.

15 **TITLE II—AVIATION EXCISE**  
16 **TAXES**

17 **SEC. 3201. SUSPENSION OF CERTAIN AVIATION EXCISE**  
18 **TAXES.**

19 (a) TRANSPORTATION BY AIR.—In the case of any  
20 payment for transportation by air (including any amount  
21 treated as paid for transportation by air by reason of sec-  
22 tion 4261(e)(3) of the Internal Revenue Code of 1986)  
23 during the excise tax holiday period, no tax shall be im-  
24 posed under section 4261 or 4271 of such Code. The pre-  
25 ceding sentence shall not apply to amounts paid for trans-

1 portation on or before the date of the enactment of this  
2 Act.

3 (b) USE OF KEROSENE IN COMMERCIAL AVIATION.—

4 In the case of kerosene used in commercial aviation (as  
5 defined in section 4083 of the Internal Revenue Code of  
6 1986) during the excise tax holiday period—

7 (1) no tax shall be imposed on such kerosene  
8 under—

9 (A) section 4041(c) of the Internal Rev-  
10 enue Code of 1986, or

11 (B) section 4081 of such Code (other than  
12 at the rate provided in subsection (a)(2)(B)  
13 thereof), and

14 (2) section 6427(l) of such Code shall be ap-  
15 plied—

16 (A) by treating such use as a nontaxable  
17 use, and

18 (B) without regard to paragraph (4)(A)(ii)  
19 thereof.

20 (c) EXCISE TAX HOLIDAY PERIOD.—For purposes of  
21 section, the term “excise tax holiday period” means the  
22 period beginning after the date of the enactment of this  
23 section and ending before January 1, 2021.

1       **DIVISION D—HEALTH CARE**  
2               **RESPONSE**  
3       **TITLE I—HEALTH PROVISIONS**  
4               **Subtitle A—Addressing Supply**  
5                       **Shortages**  
6       **PART I—MOVING THE STRATEGIC NATIONAL**  
7                       **STOCKPILE TO ASPR**  
8       **SEC. 4101. MOVING THE STRATEGIC NATIONAL STOCKPILE**  
9                       **TO ASPR.**

10       Section 319F–2(a)(1) of the Public Health Service  
11 Act (42 U.S.C. 247d–6b(a)(1)) is amended by striking  
12 “The Secretary, in collaboration with the Assistant Sec-  
13 retary for Preparedness and Response and the Director  
14 of the Centers for Disease Control and Prevention, and  
15 in coordination with the Secretary of Homeland Security  
16 (referred to in this section as the ‘Homeland Security Sec-  
17 retary’), shall maintain” and inserting “The Secretary, in  
18 collaboration with the Assistant Secretary for Prepared-  
19 ness and Response, and in coordination with the Secretary  
20 of Homeland Security (referred to in this section as the  
21 ‘Homeland Security Secretary’), shall maintain”.

1           **PART II—MEDICAL PRODUCT SUPPLIES**

2   **SEC. 4111. NATIONAL ACADEMIES REPORT ON AMERICA’S**  
3                   **MEDICAL PRODUCT SUPPLY CHAIN SECU-**  
4                   **RITY.**

5           (a) IN GENERAL.—Not later than 60 days after the  
6 date of enactment of this Act, the Secretary of Health and  
7 Human Services shall enter into an agreement with the  
8 National Academies of Sciences, Engineering, and Medi-  
9 cine (referred to in this section as the “National Acad-  
10 emies”) to examine, and, in a manner that does not com-  
11 promise national security, report on, the security of the  
12 United States medical product supply chain.

13           (b) PURPOSES.—The report developed under this sec-  
14 tion shall—

15                   (1) assess and evaluate the dependence of the  
16 United States, including the private commercial sec-  
17 tor, States, and the Federal Government, on critical  
18 drugs and devices that are sourced or manufactured  
19 outside of the United States, which may include an  
20 analysis of—

21                           (A) the supply chain of critical drugs and  
22 devices of greatest priority to providing health  
23 care;

24                           (B) any potential public health security or  
25 national security risks associated with reliance  
26 on critical drugs and devices sourced or manu-

1 factured outside of the United States, which  
2 may include responses to previous or existing  
3 shortages or public health emergencies, such as  
4 infectious disease outbreaks, bioterror attacks,  
5 and other public health threats;

6 (C) any existing supply chain information  
7 gaps, as applicable; and

8 (D) potential economic impact of increased  
9 domestic manufacturing; and

10 (2) provide recommendations, which may in-  
11 clude a plan to improve the resiliency of the supply  
12 chain for critical drugs and devices as described in  
13 paragraph (1), and to address any supply  
14 vulnerabilities or potential disruptions of such prod-  
15 ucts that would significantly affect or pose a threat  
16 to public health security or national security, as ap-  
17 propriate, which may include strategies to—

18 (A) promote supply chain redundancy and  
19 contingency planning;

20 (B) encourage domestic manufacturing, in-  
21 cluding consideration of economic impacts, if  
22 any;

23 (C) improve supply chain information  
24 gaps;



1           (D) improve planning considerations for  
2           medical product supply chain capacity during  
3           public health emergencies; and

4           (E) promote the accessibility of such drugs  
5           and devices.

6           (c) INPUT.—In conducting the study and developing  
7           the report under subsection (b), the National Academies  
8           shall—

9           (1) consider input from the Department of  
10          Health and Human Services, the Department of  
11          Homeland Security, the Department of Defense, the  
12          Department of Commerce, the Department of State,  
13          the Department of Veterans Affairs, the Department  
14          of Justice, and any other Federal agencies as appro-  
15          priate; and

16          (2) consult with relevant stakeholders, which  
17          may include conducting public meetings and other  
18          forms of engagement, as appropriate, with health  
19          care providers, medical professional societies, State-  
20          based societies, public health experts, State and local  
21          public health departments, State medical boards, pa-  
22          tient groups, medical product manufacturers, health  
23          care distributors, wholesalers and group purchasing  
24          organizations, pharmacists, and other entities with

1 experience in health care and public health, as ap-  
2 propriate.

3 (d) DEFINITIONS.—In this section, the terms “de-  
4 vice” and “drug” have the meanings given such terms in  
5 section 201 of the Federal Food, Drug, and Cosmetic Act  
6 (21 U.S.C. 321).

7 **SEC. 4112. REQUIRING THE STRATEGIC NATIONAL STOCK-**  
8 **PILE TO INCLUDE CERTAIN TYPES OF MED-**  
9 **ICAL SUPPLIES.**

10 Section 319F–2(a)(1) of the Public Health Service  
11 Act (42 U.S.C. 247d–6b(a)(1)) is amended by inserting  
12 “(including personal protective equipment, ancillary med-  
13 ical supplies, and other applicable supplies required for the  
14 administration of drugs, vaccines and other biological  
15 products, medical devices, and diagnostic tests in the  
16 stockpile)” after “other supplies”.

17 **SEC. 4113. TREATMENT OF RESPIRATORY PROTECTIVE DE-**  
18 **VICES AS COVERED COUNTERMEASURES.**

19 Section 319F–3(i)(1) of the Public Health Service  
20 Act (42 U.S.C. 247d–6d(i)(1)) is amended—

21 (1) in subparagraph (B), by striking “or” at  
22 the end;

23 (2) in subparagraph (C), by striking the period  
24 at the end and inserting “; or”; and

25 (3) by adding at the end the following:

1           “(D) a respiratory protective device that is  
2           approved by the National Institute for Occupa-  
3           tional Safety and Health under part 84 of title  
4           42, Code of Federal Regulations (or any suc-  
5           cessor regulations), and that the Secretary de-  
6           termines to be a priority for use during a public  
7           health emergency declared pursuant to section  
8           319.”.

9           **PART III—MITIGATING EMERGENCY DRUG**

10           **SHORTAGES**

11           **SEC. 4121. PRIORITIZE REVIEWS OF DRUG APPLICATIONS;**  
12           **INCENTIVES.**

13           Section 506C(g) of the Federal Food, Drug, and Cos-  
14           metic Act (21 U.S.C. 356c(g)) is amended—

15           (1) in paragraph (1), by striking “the Secretary  
16           may” and inserting “the Secretary shall, as appro-  
17           priate”;

18           (2) in paragraph (1), by inserting “prioritize  
19           and” before “expedite the review”; and

20           (3) in paragraph (2), by inserting “prioritize  
21           and” before “expedite an inspection”.

1 **SEC. 4122. ADDITIONAL MANUFACTURER REPORTING RE-**  
2 **QUIREMENTS IN RESPONSE TO DRUG SHORT-**  
3 **AGES.**

4 (a) EXPANSION TO INCLUDE ACTIVE PHARMA-  
5 CEUTICAL INGREDIENTS.—Subsection (a) of section 506C  
6 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
7 356c) is amended—

8 (1) in paragraph (1)(C), by inserting “or any  
9 such drug that is critical to the public health during  
10 a public health emergency determined under section  
11 319 of the Public Health Service Act” after “during  
12 surgery”; and

13 (2) in the flush text at the end—

14 (A) by inserting “, or a discontinuance or  
15 an interruption in the manufacture of the active  
16 pharmaceutical ingredients of such drug,” be-  
17 fore “that is likely”; and

18 (B) by adding at the end the following:  
19 “Notification under this subsection shall include  
20 disclosure of reasons for the discontinuation or  
21 interruption, as applicable; if an active pharma-  
22 ceutical ingredient is a reason for, or risk factor  
23 in, such discontinuation or interruption, the  
24 source of the active pharmaceutical ingredient  
25 and any alternative sources for the active phar-  
26 maceutical ingredient known by the manufac-

1           turer; whether any associated medical devices  
2           used for preparation or administration included  
3           in the finished dosage form is a reason for, or  
4           a risk factor in, such discontinuation or inter-  
5           ruption; the expected duration of the interrup-  
6           tion; and such other information as the Sec-  
7           retary may require.”.

8           (b) FOIA EXEMPTION.—Section 506C(d) of the Fed-  
9           eral Food, Drug, and Cosmetic Act (21 U.S.C. 356c(d))  
10          is amended by adding at the end the following: “Informa-  
11          tion provided by a manufacturer to the Secretary under  
12          this section shall not be subject to disclosure under section  
13          552 of title 5, United States Code.”.

14          (c) MANUFACTURING CONTINGENCY PLANS.—Sec-  
15          tion 506C of the Federal Food, Drug, and Cosmetic Act  
16          (21 U.S.C. 356c) is amended by adding at the end the  
17          following:

18          “(j) MANUFACTURER CONTINGENCY PLANS.—Each  
19          manufacturer of a drug described in subsection (a) or of  
20          any active pharmaceutical ingredient or any associated  
21          medical devices used for preparation or administration in-  
22          cluded in the finished dosage form of such a drug, shall  
23          maintain contingency and redundancy plans, as applicable,  
24          for each establishment in which such drugs or active phar-  
25          maceutical ingredients of such drugs are manufactured to

1 help prevent or mitigate interruptions in the supply of the  
2 drug or ingredient.”.

3 (d) ANNUAL NOTIFICATION.—Section 506E of the  
4 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356e)  
5 is amended by adding at the end the following:

6 “(d) INTERAGENCY NOTIFICATION.—Not later than  
7 180 days after the date of enactment of this subsection,  
8 and every 90 days thereafter, the Secretary shall transmit  
9 a report regarding the drugs of the current drug shortage  
10 list under this section to the Administrator of the Centers  
11 for Medicare & Medicaid Services.”.

12 (e) REPORTING AFTER INSPECTIONS.—Section  
13 704(b) of the Federal Food, Drug, and Cosmetic Act (21  
14 U.S.C. 374(b)) is amended—

15 (1) by redesignating paragraphs (1) and (2)  
16 and subparagraphs (A) and (B);

17 (2) by striking “(b) Upon completion” and in-  
18 serting “(b)(1) Upon completion”; and

19 (3) by adding at the end the following:

20 “(2) In carrying out this subsection with respect to  
21 any establishment manufacturing a drug approved under  
22 subsection (c) or (j) of section 505 for which a notification  
23 has been submitted in accordance with section 506C is,  
24 or has been in the last 5 years, listed on the drug shortage  
25 list under section 506E, or that is described in section

1 505(j)(11)(A), a copy of the report shall be sent promptly  
2 to the appropriate offices of the Food and Drug Adminis-  
3 tration with expertise regarding drug shortages. Such of-  
4 fices shall ensure timely and effective coordination regard-  
5 ing the reviews of such report and overseeing the align-  
6 ment of any feedback regarding such report, or corrective  
7 or preventative actions, after consideration of the system-  
8 atic benefits and risks to public health, patient safety, the  
9 drug supply and drug supply chain, and timely patient ac-  
10 cess to such drugs.”.

11 (f) EFFECTIVE DATE.—The amendments made by  
12 this section and section 4121 shall take effect on the date  
13 that is 180 days after the date of enactment of this Act.

14 **SEC. 4123. GAO REPORT ON INTRA-AGENCY COORDINA-**  
15 **TION.**

16 (a) IN GENERAL.—Not later than 2 years after the  
17 date of enactment of this Act, the Comptroller General  
18 of the United States shall submit to the Committee on  
19 Health, Education, Labor, and Pensions of the Senate and  
20 the Committee on Energy and Commerce of the House  
21 of Representatives a report examining the Food and Drug  
22 Administration’s intra-agency coordination, communica-  
23 tion, and decision making in assessing drug shortage risks,  
24 and taking corrective action.

25 (b) CONTENT.—The report shall include—

1 (1) consideration of—

2 (A) risks associated with violations of cur-  
3 rent good manufacturing practices;

4 (B) corrective and preventative actions  
5 with respect to such violations requested by the  
6 Food and Drug Administration;

7 (C) the effects of potential manufacturing  
8 slow-downs or shut-downs on potential drug  
9 shortages, including the discontinuance of drug  
10 manufacturing and marketing;

11 (D) efforts to prioritize review of applica-  
12 tions for drugs that the Secretary has deter-  
13 mined under section 506E of the Federal Food,  
14 Drug, and Cosmetic Act (21 U.S.C. 356e) to be  
15 in shortage; and

16 (E) efforts to prioritize inspections of fa-  
17 cilities necessary for approval of applications for  
18 drugs described in subparagraph (D);

19 (2) a description of how the Food and Drug  
20 Administration proactively coordinates strategies to  
21 mitigate the consequences of the violations, slow-  
22 downs, and shut-downs described in paragraph (1)  
23 across agencies; and



1           (3) an evaluation of changes in relevant Food  
2           and Drug Administration practices that such agency  
3           has proposed but not yet implemented.

4 **SEC. 4124. REPORT.**

5           Not later than 2 years after the date of enactment  
6 of this Act, the Secretary of Health and Human Services,  
7 in coordination with the Commissioner of Food and Drugs  
8 and the Administrator of the Centers for Medicare & Med-  
9 icaid Services, shall develop and submit to the Committee  
10 on Health, Education, Labor, and Pensions of the Senate  
11 and the Committee on Energy and Commerce of the  
12 House of Representatives a report containing rec-  
13 ommendations—

14           (1) for market-based incentives or other appro-  
15           priate mechanisms, sufficient to encourage the man-  
16           ufacture of drugs in shortage or at risk of shortage;  
17           and

18           (2) on how the Emerging Technology Program  
19           of the Food and Drug Administration can help fa-  
20           cilitate creating or upgrading existing technologies to  
21           address drug shortage challenges and promote mod-  
22           ern, reliable manufacturing strategies.

1 **SEC. 4125. SAFE HARBOR PROVISION.**

2 (a) IN GENERAL.—The Federal Food, Drug, and  
3 Cosmetic Act is amended by inserting after section 502  
4 (21 U.S.C. 352) the following:

5 **“SEC. 502A. SAFE HARBOR PROVISION.**

6 “(a) IN GENERAL.—The communication of informa-  
7 tion, consistent with subsection (b), with respect to the  
8 use of a drug or device authorized under section 564 pro-  
9 vided or distributed to a health care provider, shall not—

10 “(1) be a basis for treating such drug or device  
11 as misbranded under subsection (a) or (f) of section  
12 502, or in violation of section 505, 515, or 564 of  
13 this Act or subsection (a) or (k) of section 351(a)(1)  
14 of the Public Health Service Act, as applicable; or

15 “(2) be treated as evidence that such drug or  
16 device is misbranded under subsection (a) or (f) of  
17 section 502, or in violation of section 505, 513, 515,  
18 or 564 of this Act or subsection (a) or (k) of section  
19 351 of the Public Health Service Act, as applicable.

20 “(b) PROVISION OF INFORMATION.—

21 “(1) IN GENERAL.—Any information relating to  
22 a use of a drug or device authorized under section  
23 564, or for which a submission under section 564  
24 has been submitted, that—

1           “(A) is neither false nor misleading, when  
2           measured objectively against the information  
3           available at the time the statement is made;

4           “(B) is accompanied, as required, by an  
5           appropriate disclaimer, as described in para-  
6           graph (2); and

7           “(C) is based on competent and reliable  
8           scientific evidence, as described in subsection  
9           (c).

10          “(2) DISCLAIMERS.—For purposes of para-  
11          graph (1), such information shall be accompanied, as  
12          necessary, by an appropriate disclaimer, including—

13                 “(A) a statement identifying any dif-  
14                 ferences between the information and any label-  
15                 ing of the drug or device;

16                 “(B) a statement identifying contradictory  
17                 evidence; and

18                 “(C) such other information as may be re-  
19                 quired by regulation.

20          “(c) COMPETENT AND RELIABLE SCIENTIFIC EVI-  
21          DENCE.—In this section, the term ‘competent and reliable  
22          scientific evidence’ means evidence established through  
23          scientific methods that are widely accepted by experts in  
24          the relevant field and followed pursuant to a clear and  
25          well-described protocol, as scientifically appropriate. Evi-

1 dence may constitute competent and reliable scientific evi-  
2 dence within the meaning of this section—

3 “(1) regardless of whether it is supported by 2  
4 adequate and well-controlled clinical studies; and

5 “(2) may include—

6 “(A) information derived from clinical  
7 trials, observational studies, clinical studies or  
8 bench tests that describe performance, database  
9 reviews, registries, patient utilization projec-  
10 tions, and modeling techniques, and the data,  
11 inputs, and components of such information;

12 “(B) information about the effects of a  
13 drug or device in subgroups defined by demo-  
14 graphic or other variables, including groups de-  
15 fined by race, sex, risk factors, or other vari-  
16 ables, such as genomic features or disease se-  
17 verity;

18 “(C) information related to the emergency  
19 use authorization, as applicable; and

20 “(D) information relating to the safety, ef-  
21 fectiveness, or benefit of a use or treatment  
22 that is authorized under section 564 for a drug  
23 or device, including information regarding—

1                   “(i) health outcomes, patient or care-  
2                   giver experience, or other quality metrics;  
3                   and

4                   “(ii) the comparative effectiveness of  
5                   a drug or device relative to others prod-  
6                   ucts, other health care interventions, pro-  
7                   gram and quality improvement interven-  
8                   tions, or no intervention.

9           “(d) DISTRIBUTION.—Information pursuant to sub-  
10 section (b) may be distributed proactively through written  
11 or oral means, or other information platforms, to a health  
12 care provider, payor, formulary committee, or other simi-  
13 lar entity carrying out responsibilities for making drug  
14 coverage, reimbursement, or usage decisions on a popu-  
15 lation basis.

16           “(e) COVERAGE NOT EXCLUDED.—The distribution  
17 of information that otherwise meets the requirements of  
18 this section shall not fail to meet the requirements of sub-  
19 section (a) because the manufacturer or distributor of the  
20 drug or device about which information is being distrib-  
21 uted has—

22                   “(1) knowledge that such drug or device is  
23                   being used by patients or health care practitioners in  
24                   a manner not described in any labeling of the drug  
25                   or device, as applicable; or

1           “(2) objective or subjective intent that such  
2           drug or device be used in a manner inconsistent with  
3           any labeling, as applicable, of such drug or device.

4           “(f) RULE OF CONSTRUCTION.—Nothing in this sec-  
5           tion shall be construed—

6           “(1) to limit communication not specifically  
7           permitted by this section; or

8           “(2) to alter or expand the authority of the Sec-  
9           retary to enforce the provisions of this Act, except  
10          to the extent that the communication of information  
11          in accordance with this section is permitted.”.

12           **PART IV—PREVENTING ESSENTIAL MEDICAL**  
13                           **DEVICE SHORTAGES**

14           **SEC. 4131. DISCONTINUANCE OR INTERRUPTION IN THE**  
15                           **PRODUCTION OF MEDICAL DEVICES.**

16          Chapter V of the Federal Food, Drug, and Cosmetic  
17          Act (21 U.S.C. 351 et seq.) is amended by inserting after  
18          section 506I the following:

19           **“SEC. 506J. DISCONTINUANCE OR INTERRUPTION IN THE**  
20                           **PRODUCTION OF MEDICAL DEVICES.**

21          “(a) IN GENERAL.—A manufacturer of a device  
22          that—

23           “(1) is critical to public health during a public  
24          health emergency, including devices that are life-sup-

1       porting, life-sustaining, or intended for use in emer-  
2       gency medical care or during surgery; or

3               “(2) for which the Secretary determines that in-  
4       formation on potential meaningful supply interrup-  
5       tions of such device is needed during, or in advance  
6       of, a public health emergency;

7 shall, during, or in advance of, a public health emergency  
8 determined by the Secretary pursuant to section 319, no-  
9 tify the Secretary, in accordance with subsection (b), of  
10 a permanent discontinuance in the manufacture of the de-  
11 vice (except for discontinuances as a result of an approved  
12 modification of the device) or an interruption of the manu-  
13 facture of the device that is likely to lead to a meaningful  
14 disruption in the supply of that device in the United  
15 States, and the reasons for such discontinuance or inter-  
16 ruption.

17       “(b) TIMING.—A notice required under subsection (a)  
18 shall be submitted to the Secretary—

19               “(1) at least 6 months prior to the date of the  
20       discontinuance or interruption; or

21               “(2) if compliance with paragraph (1) is not  
22       possible, as soon as practicable.

23       “(c) DISTRIBUTION.—

24               “(1) PUBLIC AVAILABILITY.—To the maximum  
25       extent practicable, subject to paragraph (2), the Sec-

1       retary shall distribute, through such means as the  
2       Secretary determines appropriate, information on  
3       the discontinuance or interruption of the manufac-  
4       ture of devices reported under subsection (a) to ap-  
5       propriate organizations, including physician, health  
6       provider, patient organizations, and supply chain  
7       partners, as appropriate and applicable.

8               “(2) PUBLIC HEALTH EXCEPTION.—The Sec-  
9       retary may choose not to make information collected  
10      under this section publicly available pursuant to this  
11      section if the Secretary determines that disclosure of  
12      such information would adversely affect the public  
13      health, such as by increasing the possibility of un-  
14      necessary over purchase of product or other disrup-  
15      tion of the availability of medical products to pa-  
16      tients.

17              “(d) CONFIDENTIALITY.—Nothing in this section  
18      shall be construed as authorizing the Secretary to disclose  
19      any information that is a trade secret or confidential infor-  
20      mation subject to section 552(b)(4) of title 5, United  
21      States Code, or section 1905 of title 18, United States  
22      Code.

23              “(e) FAILURE TO MEET REQUIREMENTS.—If a per-  
24      son fails to submit information required under subsection  
25      (a) in accordance with subsection (b)—



1           “(1) the Secretary shall issue a letter to such  
2 person informing such person of such failure;

3           “(2) not later than 30 calendar days after the  
4 issuance of a letter under paragraph (1), the person  
5 who receives such letter shall submit to the Sec-  
6 retary a written response to such letter setting forth  
7 the basis for noncompliance and providing informa-  
8 tion required under subsection (a); and

9           “(3) not later than 45 calendar days after the  
10 issuance of a letter under paragraph (1), the Sec-  
11 retary shall make such letter and any response to  
12 such letter under paragraph (2) available to the pub-  
13 lic on the internet website of the Food and Drug Ad-  
14 ministration, with appropriate redactions made to  
15 protect information described in subsection (d), ex-  
16 cept that, if the Secretary determines that the letter  
17 under paragraph (1) was issued in error or, after re-  
18 view of such response, the person had a reasonable  
19 basis for not notifying as required under subsection  
20 (a), the requirements of this paragraph shall not  
21 apply.

22           “(f) EXPEDITED INSPECTIONS AND REVIEWS.—If,  
23 based on notifications described in subsection (a) or any  
24 other relevant information, the Secretary concludes that

1 there is, or is likely to be, a shortage of an device, the  
2 Secretary shall, as appropriate—

3 “(1) prioritize and expedite the review of a sub-  
4 mission under section 513(f)(2), 515, review of a no-  
5 tification under section 510(k), or 520(m) for a de-  
6 vice that could help mitigate or prevent such short-  
7 age; or

8 “(2) prioritize and expedite an inspection or re-  
9 inspection of an establishment that could help miti-  
10 gate or prevent such shortage.

11 “(g) DEVICE SHORTAGE LIST.—

12 “(1) ESTABLISHMENT.—The Secretary shall es-  
13 tablish and maintain an up-to-date list of devices  
14 that are determined by the Secretary to be in short-  
15 age in the United States.

16 “(2) CONTENTS.—For each device included on  
17 the list under paragraph (1), the Secretary shall in-  
18 clude the following information:

19 “(A) The category or name of the device in  
20 shortage.

21 “(B) The name of each manufacturer of  
22 such device.

23 “(C) The reason for the shortage, as deter-  
24 mined by the Secretary, selecting from the fol-  
25 lowing categories:

1                   “(i) Requirements related to com-  
2                   plying with good manufacturing practices.

3                   “(ii) Regulatory delay.

4                   “(iii) Shortage or discontinuance of a  
5                   component or part.

6                   “(iv) Discontinuance of the manufac-  
7                   ture of the device.

8                   “(v) Delay in shipping of the device.

9                   “(vi) Delay in sterilization of the de-  
10                  vice.

11                  “(vii) Demand increase for the device.

12                  “(D) The estimated duration of the short-  
13                  age as determined by the Secretary.

14                  “(3) PUBLIC AVAILABILITY.—

15                         “(A) IN GENERAL.—Subject to subpara-  
16                         graphs (B) and (C), the Secretary shall make  
17                         the information in the list under paragraph (1)  
18                         publicly available.

19                         “(B) TRADE SECRETS AND CONFIDENTIAL  
20                         INFORMATION.—Nothing in this subsection  
21                         shall be construed to alter or amend section  
22                         1905 of title 18, United States Code, or section  
23                         552(b)(4) of title 5 of such Code.

24                         “(C) PUBLIC HEALTH EXCEPTION.—The  
25                         Secretary may elect not to make information

1 collected under this subsection publicly available  
2 if the Secretary determines that disclosure of  
3 such information would adversely affect the  
4 public health (such as by increasing the possi-  
5 bility of hoarding or other disruption of the  
6 availability of the device to patients).

7 “(h) RULE OF CONSTRUCTION.—Nothing in this sec-  
8 tion shall be construed to affect the authority of the Sec-  
9 retary on the date of enactment of this section to expedite  
10 the review of devices under section 515 of the Federal  
11 Food, Drug, and Cosmetic Act, section 515B of such Act  
12 relating to the priority review program for devices, and  
13 section 564 of such Act relating to the emergency use au-  
14 thorization authorities.

15 “(i) DEFINITIONS.—In this section:

16 “(1) DEVICE.—The term ‘device’ means a de-  
17 vice (as defined in section 201(h)) that is intended  
18 for human use and is subject to sections 510(k),  
19 513(f)(2), 515, or 520(m).

20 “(2) MEANINGFUL DISRUPTION.—The term  
21 ‘meaningful disruption’—

22 “(A) means a change in production that is  
23 reasonably likely to lead to a reduction in the  
24 supply of a device by a manufacturer that is  
25 more than negligible and affects the ability of

1 the manufacturer to fill orders or meet expected  
2 demand for its product;

3 “(B) does not include interruptions in  
4 manufacturing due to matters such as routine  
5 maintenance or insignificant changes in manu-  
6 facturing so long as the manufacturer expects  
7 to resume operations in a reasonable or short  
8 period of time; and

9 “(C) does not include interruptions in  
10 manufacturing of components or raw materials  
11 so long as such interruptions do not result in  
12 a shortage of finished product and the manu-  
13 facturer expects to resume operations in a rea-  
14 sonable or short period of time.

15 “(3) SHORTAGE.—The term ‘shortage’, with re-  
16 spect to a device, means a period of time when the  
17 demand or projected demand for the device within  
18 the United States exceeds the supply of the device.”.

19 **SEC. 4132. GAO REPORT ON INTRA-AGENCY COORDINA-**  
20 **TION.**

21 (a) IN GENERAL.—Not later than 18 months after  
22 the date of enactment of this Act, the Comptroller General  
23 of the United States shall submit to the Committee on  
24 Health, Education, Labor, and Pensions of the Senate and  
25 the Committee on Energy and Commerce of the House

1 of Representatives a report examining the Food and Drug  
2 Administration's intra-agency coordination, communica-  
3 tion, and decision-making in assessing device shortages  
4 and risks associated with the supply of devices, and any  
5 efforts by the Food and Drug Administration to mitigate  
6 any device shortages or to take corrective actions.

7 (b) CONTENT.—The report shall include—

8 (1) consideration of—

9 (A) risks of creating, worsening, or extend-  
10 ing a shortage of a device associated with viola-  
11 tions of current good manufacturing practices;

12 (B) corrective and preventative actions  
13 with respect to such violations requested by the  
14 Food and Drug Administration;

15 (C) the effects of potential manufacturing  
16 disruptions or shut-downs on potential device  
17 shortages, which may include the discontinu-  
18 ance of device manufacturing and marketing, or  
19 the manufacturing of device components or  
20 parts;

21 (D) efforts to prioritize and expedite the  
22 review of submissions for devices that the Sec-  
23 retary has determined under section 506J(g) of  
24 the Federal Food, Drug, and Cosmetic Act (21  
25 U.S.C. 356j) to be in shortage; and

1 (E) efforts to prioritize inspections of fa-  
2 cilities necessary for approval or clearance of  
3 devices described in subparagraph (D);

4 (2) a description of how the Food and Drug  
5 Administration proactively coordinates strategies to  
6 mitigate the consequences of the violations, slow-  
7 downs, and shut-downs described in paragraph (1)  
8 across agencies; and

9 (3) an evaluation of changes in relevant Food  
10 and Drug Administration practices that such agency  
11 has proposed but not yet implemented.

12 (c) DEFINITION.—In this section, the term “device”  
13 has the meaning given such term under section 506J(i)(1)  
14 of the Federal Food, Drug, and Cosmetic Act, as added  
15 by section 4131.

16 **PART V—EMERGENCY USE OF LABORATORY**

17 **DEVELOPED TESTS**

18 **SEC. 4141. EMERGENCY USE OF LABORATORY DEVELOPED**

19 **TESTS.**

20 (a) IN GENERAL.—For the time in which the public  
21 health emergency under section 319 of the Public Health  
22 Service Act (42 U.S.C. 247d) related to the coronavirus  
23 (COVID-19), declared by the Secretary of Health and  
24 Human Services (referred to in this section as the “Sec-  
25 retary”) on January 31, 2020, is in place (or such other

1 period of time determined by the Secretary), tests in-  
2 tended to diagnose COVID–19 that are described in sub-  
3 section (b) may be lawfully marketed in accordance with  
4 this section.

5 (b) CRITERIA.—Tests described in subsection (a)  
6 may be lawfully marketed, during the period described in  
7 such subsection, if such test—

8 (1) is developed in a State that has notified the  
9 Secretary of its intention to review tests intended to  
10 diagnose COVID-19;

11 (2) is developed in a laboratory with a certifi-  
12 cate to conduct high-complexity testing pursuant to  
13 section 353 of the Public Health Service Act (42  
14 U.S.C. 263a), and the developer of such test—

15 (A) is pursuing an emergency use author-  
16 ization under section 564 of the Federal Food,  
17 Drug, and Cosmetic Act (21 U.S.C. 360bbb–3)  
18 and provides updates to the Secretary on efforts  
19 to pursue such authorization;

20 (B) validates such test prior to use;

21 (C) notifies the Secretary of the assay vali-  
22 dation; and

23 (D) includes a statement together with the  
24 results of the test that reads: “This test was  
25 developed for use as a part of a response to the



1 public health emergency declared to address the  
2 outbreak of COVID-19. This test has not been  
3 reviewed by the Food and Drug Administra-  
4 tion.”; or

5 (3) is an in vitro diagnostic test for which the  
6 developer of such test meets all of the requirements  
7 of subparagraphs (A) through (D) of paragraph (2)  
8 with respect to the test.

9 (c) DISPOSITION OF PRODUCT.—Notwithstanding  
10 the termination of a declaration under subsection (b) of  
11 section 564 of the Federal Food, Drug, and Cosmetic Act,  
12 or a revocation under subsection (g) of such section with  
13 respect to a product described in subsection (a), the Sec-  
14 retary shall consult with the developer of such in vitro di-  
15 agnostic test with respect to the appropriate disposition  
16 of such test to ensure that authorization of any in vitro  
17 diagnostic test under this section shall continue to be ef-  
18 fective to provide for continued use of such product to pre-  
19 vent or detect COVID–19.

20 (d) IN VITRO DIAGNOSTIC TEST.—In this section,  
21 the term “in vitro diagnostic test” has the meaning given  
22 the term “in vitro diagnostic product” in section 809.3(a)  
23 of title 21, Code of Federal Regulations (or successor reg-  
24 ulations).

1     **Subtitle B—Access to Health Care**  
2             **for COVID-19 Patients**

3             **PART I—COVERAGE OF TESTING AND**  
4                     **PREVENTIVE SERVICES**

5     **SEC. 4201. COVERAGE OF DIAGNOSTIC TESTING FOR**  
6             **COVID-19.**

7             (a) IN GENERAL.—A group health plan and a health  
8 insurance issuer offering group or individual health insur-  
9 ance coverage (including a grandfathered health plan (as  
10 defined in section 1251(e) of the Patient Protection and  
11 Affordable Care Act (42 U.S.C. 18011(b))) shall provide  
12 coverage, and shall not impose any cost-sharing (including  
13 deductibles, copayments, and coinsurance) requirements  
14 or prior authorization or other medical management re-  
15 quirements, for the following items and services furnished  
16 during any portion of the public health emergency de-  
17 clared by the Secretary of Health and Human Services  
18 pursuant to section 319 of the Public Health Service Act  
19 on January 31, 2020, with respect to COVID-19, begin-  
20 ning on or after the date of the enactment of this Act:

21             (1) An in vitro diagnostic product (as defined  
22 in section 809.3(a) of title 21, Code of Federal Reg-  
23 ulations) for the detection of SARS-CoV-2 or the  
24 diagnosis of the virus that causes COVID-19, and

1 the administration of such an in vitro diagnostic  
2 product, that—

3 (A) is approved, cleared, or authorized  
4 under section 510(k), 513, 515, or 564 of the  
5 Federal Food, Drug, and Cosmetic Act (21  
6 U.S.C. 360(k), 360c, 360e, 360bbb–3);

7 (B) is a clinical laboratory service per-  
8 formed in a laboratory (including a public  
9 health laboratory) certified to conduct high-  
10 complexity testing pursuant to section 353 of  
11 the Public Health Service Act (42 U.S.C. 253a)  
12 for which the developer has requested, or in-  
13 tends to request, emergency use authorization  
14 under section 564 of the Federal Food, Drug,  
15 and Cosmetic Act (21 U.S.C. 360bbb–3), unless  
16 and until the emergency use authorization re-  
17 quest under such section 564 has been denied  
18 or the developer of such test does not submit a  
19 request under such section within a reasonable  
20 timeframe; or

21 (C) is developed in a State that has noti-  
22 fied the Secretary of Health and Human Serv-  
23 ices of its intention to review tests intended to  
24 diagnose COVID-19.

1           (2) Items and services furnished to an indi-  
2           vidual during health care provider office visits, ur-  
3           gent care center visits, and emergency room visits  
4           that result in an order for or administration of an  
5           in vitro diagnostic product described in paragraph  
6           (1), but only to the extent such items and services  
7           relate to the furnishing or administration of such  
8           product or to the evaluation of such individual for  
9           purposes of determining the need of such individual  
10          for such product.

11 **SEC. 4202. PRICING OF DIAGNOSTIC TESTING.**

12          (a) REIMBURSEMENT RATES.—A group health plan  
13 or a health insurance issuer providing coverage of items  
14 and services described in section 201(a) with respect to  
15 an enrollee shall reimburse the provider of the diagnostic  
16 testing as follows:

17           (1) If the health plan or issuer has a negotiated  
18           rate for such service with such provider, such nego-  
19           tiated rate shall apply.

20           (2) If the health plan or issuer does not have  
21           a negotiated rate for such service with such provider,  
22           such plan or issuer shall reimburse the provider in  
23           an amount that equals the cash price for such serv-  
24           ice as listed by the provider on a public internet  
25           website.

1 (b) REQUIREMENT TO PUBLICIZE CASH PRICE FOR  
2 DIAGNOSTIC TESTING FOR COVID-19.—

3 (1) IN GENERAL.—Each provider of a diag-  
4 nostic test for COVID-19 shall make public the cash  
5 price for such test on a public internet website of  
6 such provider.

7 (2) CIVIL MONETARY PENALTIES.—The Sec-  
8 retary of Health and Human Services may impose a  
9 civil monetary penalty on any provider of a diag-  
10 nostic test for COVID-19 that is not in compliance  
11 with paragraph (1) and has not completed a correc-  
12 tive action plan to comply with the requirements of  
13 such paragraph, in an amount not to exceed \$300  
14 per day that the violation is ongoing.

15 **SEC. 4203. RAPID COVERAGE OF PREVENTIVE SERVICES**  
16 **AND VACCINES FOR CORONAVIRUS.**

17 (a) IN GENERAL.—Notwithstanding 2713(b) of the  
18 Public Health Service Act (42 U.S.C. 300gg–13), the Sec-  
19 retary of Health and Human Services, the Secretary of  
20 Labor, and the Secretary of the Treasury shall require  
21 group health plans and health insurance issuers offering  
22 group or individual health insurance to cover any quali-  
23 fying coronavirus preventive service, pursuant to section  
24 2713(a) of the Public Health Service Act (42 U.S.C.  
25 300gg–13(a)). The requirement described in this sub-

1 section shall take effect with respect to a qualifying  
2 coronavirus prevention service on the specified date de-  
3 scribed in subsection (b)(2).

4 (b) DEFINITIONS.—For purposes of this section:

5 (1) QUALIFYING CORONAVIRUS PREVENTIVE  
6 SERVICE.—The term “qualifying coronavirus preven-  
7 tive service” means an item, service, or immuniza-  
8 tion that is intended to prevent or mitigate  
9 coronavirus disease 2019 and that is—

10 (A) an evidence-based item or service that  
11 has in effect a rating of “A” or “B” in the cur-  
12 rent recommendations of the United States Pre-  
13 ventive Services Task Force; or

14 (B) an immunization that has in effect a  
15 recommendation from the Advisory Committee  
16 on Immunization Practices of the Centers for  
17 Disease Control and Prevention with respect to  
18 the individual involved.

19 (2) SPECIFIED DATE.—The term “specified  
20 date” means the date that is 15 business days after  
21 the date on which a recommendation is made relat-  
22 ing to the immunization as described in such para-  
23 graph.

24 (3) HEALTH INSURANCE TERMS.—In this sec-  
25 tion, the terms “group health plan”, “health insur-

1       ance issuer”, “group health insurance coverage”,  
2       and “individual health insurance coverage” have the  
3       meanings given such terms in section 2791 of the  
4       Public Health Service Act (42 U.S.C. 300gg–91).

5                   **PART II—SUPPORT FOR HEALTH CARE**  
6                                   **PROVIDERS**

7       **SEC. 4211. SUPPLEMENTAL AWARDS FOR HEALTH CEN-**  
8                   **TERS.**

9           (a) SUPPLEMENTAL AWARDS.—Section 330(r) of the  
10       Public Health Service Act (42 U.S.C. 254b(r)) is amended  
11       by adding at the end the following:

12                   “(6) ADDITIONAL AMOUNTS FOR SUPPLE-

13       MENTAL AWARDS.—In addition to any amounts  
14       made available pursuant to this subsection, section  
15       402A of this Act, or section 10503 of the Patient  
16       Protection and Affordable Care Act, there is author-  
17       ized to be appropriated, and there is appropriated,  
18       out of any monies in the Treasury not otherwise ap-  
19       propriated, \$1,320,000,000 for fiscal year 2020 for  
20       supplemental awards under subsection (d) for the  
21       detection of SARS-CoV-2 or the prevention, diag-  
22       nosis, and treatment of COVID-19.”.

23           (b) APPLICATION OF PROVISIONS.—Amounts appro-  
24       priated pursuant to the amendment made by subsection

25       (a) for fiscal year 2020 shall be subject to the require-

1 ments contained in Public Law 116–94 for funds for pro-  
2 grams authorized under sections 330 through 340 of the  
3 Public Health Service Act (42 U.S.C. 254 through 256).

4 **SEC. 4212. ALLOWING PERMANENT DIRECT HIRE OF NDMS**  
5 **HEALTH CARE PROFESSIONALS.**

6 Section 2812(c)(4) of the Public Health Service Act  
7 (42 U.S.C. 300hh–11(c)(4)) is amended to read as follows:

8 “(4) CERTAIN APPOINTMENTS.—If the Sec-  
9 retary determines that the number of intermittent  
10 disaster response personnel within the National Dis-  
11 aster Medical System under this section is insuffi-  
12 cient to address a public health emergency or poten-  
13 tial public health emergency, the Secretary may ap-  
14 point candidates directly to personnel positions for  
15 intermittent disaster response within such system.  
16 The Secretary shall provide updates on the number  
17 of vacant or unfilled positions within such system to  
18 the congressional committees of jurisdiction each  
19 quarter for which this authority is in effect.”.

20 **SEC. 4213. TELEHEALTH NETWORK AND TELEHEALTH RE-**  
21 **SOURCE CENTERS GRANT PROGRAMS.**

22 Section 330I of the Public Health Service Act (42  
23 U.S.C. 254c–14) is amended—

24 (1) in subsection (d)—

25 (A) in paragraph (1)—



- 1 (i) in the matter preceding subpara-  
2 graph (A), by striking “projects to dem-  
3 onstrate how telehealth technologies can be  
4 used through telehealth networks” and in-  
5 serting “evidence-based projects that uti-  
6 lize telehealth technologies through tele-  
7 health networks”;
- 8 (ii) in subparagraph (A)—
- 9 (I) by striking “the quality of”  
10 and inserting “access to, and the  
11 quality of,”; and
- 12 (II) by inserting “and” after the  
13 semicolon;
- 14 (iii) by striking subparagraph (B);
- 15 (iv) by redesignating subparagraph  
16 (C) as subparagraph (B); and
- 17 (v) in subparagraph (B), as so reded-  
18 icated, by striking “and patients and  
19 their families, for decisionmaking” and in-  
20 serting “, patients, and their families”;  
21 and
- 22 (B) in paragraph (2)—
- 23 (i) by striking “demonstrate how tele-  
24 health technologies can be used” and in-

1           serting “support initiatives that utilize  
2           telehealth technologies”; and

3                   (ii) by striking “, to establish tele-  
4           health resource centers”;

5           (2) in subsection (e), by striking “4 years” and  
6           inserting “5 years”;

7           (3) in subsection (f)—

8                   (A) by striking paragraph (2);

9                   (B) in paragraph (1)(B)—

10                   (i) by redesignating clauses (i)  
11           through (iii) as paragraphs (1) through  
12           (3), respectively, and adjusting the mar-  
13           gins accordingly;

14                   (ii) in paragraph (3), as so redesign-  
15           ated by clause (i), by redesignating sub-  
16           clauses (I) through (XII) as subparagraphs  
17           (A) through (L), respectively, and adjust-  
18           ing the margins accordingly; and

19                   (iii) by striking “(1) TELEHEALTH  
20           NETWORK GRANTS—” and all that follows  
21           through “(B) TELEHEALTH NETWORKS—  
22           ”; and

23                   (C) in paragraph (3)(I), as so redesign-  
24           ated, by inserting “and substance use dis-

1 order” after “mental health” each place such  
2 term appears;

3 (4) in subsection (g)(2), by striking “or im-  
4 prove” and inserting “and improve”;

5 (5) by striking subsection (h);

6 (6) by redesignating subsections (i) through (p)  
7 as subsection (h) through (o), respectively;

8 (7) in subsection (h), as so redesignated—

9 (A) in paragraph (1)—

10 (i) in subparagraph (B), by striking  
11 “mental health, public health, long-term  
12 care, home care, preventive” and inserting  
13 “mental health care, public health services,  
14 long-term care, home care, preventive  
15 care”;

16 (ii) in subparagraph (E), by inserting  
17 “and regional” after “local”; and

18 (iii) by striking subparagraph (F);

19 and

20 (B) in paragraph (2)(A), by striking  
21 “medically underserved areas or” and inserting  
22 “rural areas, medically underserved areas, or”;

23 (8) in paragraph (2) of subsection (i), as so re-  
24 designated, by striking “ensure that—” and all that  
25 follows through the end of subparagraph (B) and in-

1       serting “ensure that not less than 50 percent of the  
2       funds awarded shall be awarded for projects in rural  
3       areas.”;

4             (9) in subsection (j), as so redesignated—

5                 (A) in paragraph (1)(B), by striking “com-  
6       puter hardware and software, audio and video  
7       equipment, computer network equipment, inter-  
8       active equipment, data terminal equipment, and  
9       other”;

10             (B) in paragraph (2)(F), by striking  
11       “health care providers and”;

12             (10) in subsection (k), as so redesignated—

13                 (A) in paragraph (2), by striking “40 per-  
14       cent” and inserting “20 percent”; and

15                 (B) in paragraph (3), by striking “(such as  
16       laying cable or telephone lines, or purchasing or  
17       installing microwave towers, satellite dishes,  
18       amplifiers, or digital switching equipment)”;

19             (11) by striking subsections (q) and (r) and in-  
20       serting the following:

21             “(p) REPORT.—Not later than 4 years after the date  
22       of enactment of the CARES Act, and every 5 years there-  
23       after, the Secretary shall prepare and submit to the Com-  
24       mittee on Health, Education, Labor, and Pensions of the  
25       Senate and the Committee on Energy and Commerce of

1 the House of Representatives a report on the activities and  
 2 outcomes of the grant programs under subsection (b).”;

3 (12) by redesignating subsection (s) as sub-  
 4 section (q); and

5 (13) in subsection (q), as so redesignated, by  
 6 striking “this section—” and all that follows  
 7 through the end of paragraph (2) and inserting  
 8 “this section \$29,000,000 for each of fiscal years  
 9 2021 through 2025.”.

10 **SEC. 4214. RURAL HEALTH CARE SERVICES OUTREACH,**  
 11 **RURAL HEALTH NETWORK DEVELOPMENT,**  
 12 **AND SMALL HEALTH CARE PROVIDER QUAL-**  
 13 **ITY IMPROVEMENT GRANT PROGRAMS.**

14 Section 330A of the Public Health Service Act (42  
 15 U.S.C. 254e) is amended—

16 (1) in subsection (d)(2)—

17 (A) in subparagraph (A), by striking “es-  
 18 sential” and inserting “basic”; and

19 (B) in subparagraph (B)—

20 (i) in the matter preceding clause (i),  
 21 by inserting “to” after “grants”; and

22 (ii) in clauses (i), (ii), and (iii), by  
 23 striking “to” each place such term ap-  
 24 pears;

25 (2) in subsection (e)—

- 1 (A) in paragraph (1)—
- 2 (i) by inserting “improving and” after
- 3 “outreach by”;
- 4 (ii) by inserting “, through community
- 5 engagement and evidence-based or innova-
- 6 tive, evidence-informed models” before the
- 7 period of the first sentence; and
- 8 (iii) by striking “3 years” and insert-
- 9 ing “5 years”;
- 10 (B) in paragraph (2)—
- 11 (i) in the matter preceding subpara-
- 12 graph (A), by inserting “shall” after “enti-
- 13 ty”;
- 14 (ii) in subparagraph (A), by striking
- 15 “shall be a rural public or rural nonprofit
- 16 private entity” and inserting “be an entity
- 17 with demonstrated experience serving, or
- 18 the capacity to serve, rural underserved
- 19 populations”;
- 20 (iii) in subparagraphs (B) and (C), by
- 21 striking “shall” each place such term ap-
- 22 pears; and
- 23 (iv) in subparagraph (B)—

1 (I) in the matter preceding clause  
2 (i), by inserting “that” after “mem-  
3 bers”; and

4 (II) in clauses (i) and (ii), by  
5 striking “that” each place such term  
6 appears; and

7 (C) in paragraph (3)(C), by striking “the  
8 local community or region” and inserting “the  
9 rural underserved populations in the local com-  
10 munity or region”;

11 (3) in subsection (f)—

12 (A) in paragraph (1)—

13 (i) in subparagraph (A)—

14 (I) in the matter preceding clause  
15 (i), by striking “promote, through  
16 planning and implementation, the de-  
17 velopment of integrated health care  
18 networks that have combined the  
19 functions of the entities participating  
20 in the networks” and inserting “plan,  
21 develop, and implement integrated  
22 health care networks that collabo-  
23 rate”; and

24 (II) in clause (ii), by striking  
25 “essential health care services” and

1 inserting “basic health care services  
2 and associated health outcomes”; and

3 (ii) by amending subparagraph (B) to  
4 read as follows:

5 “(B) GRANT PERIODS.—The Director may  
6 award grants under this subsection for periods  
7 of not more than 5 years.”;

8 (B) in paragraph (2)—

9 (i) in the matter preceding subpara-  
10 graph (A), by inserting “shall” after “enti-  
11 ty”;

12 (ii) in subparagraph (A), by striking  
13 “shall be a rural public or rural nonprofit  
14 private entity” and inserting “be an entity  
15 with demonstrated experience serving, or  
16 the capacity to serve, rural underserved  
17 populations”;

18 (iii) in subparagraph (B)—

19 (I) in the matter preceding clause

20 (i)—

21 (aa) by striking “shall”; and

22 (bb) by inserting “that”

23 after “participants”; and



1 (II) in clauses (i) and (ii), by  
2 striking “that” each place such term  
3 appears; and

4 (iv) in subparagraph (C), by striking  
5 “shall”; and

6 (C) in paragraph (3)—

7 (i) by amending clause (iii) of sub-  
8 paragraph (C) to read as follows:

9 “(iii) how the rural underserved popu-  
10 lations in the local community or region to  
11 be served will benefit from and be involved  
12 in the development and ongoing operations  
13 of the network;”; and

14 (ii) in subparagraph (D), by striking  
15 “the local community or region” and in-  
16 sserting “the rural underserved populations  
17 in the local community or region”;

18 (4) in subsection (g)—

19 (A) in paragraph (1)—

20 (i) by inserting “, including activities  
21 related to increasing care coordination, en-  
22 hancing chronic disease management, and  
23 improving patient health outcomes” before  
24 the period of the first sentence; and

1 (ii) by striking “3 years” and insert-  
2 ing “5 years”;

3 (B) in paragraph (2)—

4 (i) in the matter preceding subpara-  
5 graph (A), by inserting “shall” after “enti-  
6 ty”;

7 (ii) in subparagraphs (A) and (B), by  
8 striking “shall” each place such term ap-  
9 pears; and

10 (iii) in subparagraph (A)(ii), by in-  
11 serting “or regional” after “local”; and

12 (C) in paragraph (3)(D), by striking “the  
13 local community or region” and inserting “the  
14 rural underserved populations in the local com-  
15 munity or region”;

16 (5) in subsection (h)(3), in the matter pre-  
17 ceding subparagraph (A), by inserting “, as appro-  
18 priate,” after “the Secretary”;

19 (6) by amending subsection (i) to read as fol-  
20 lows:

21 “(i) REPORT.—Not later than 4 years after the date  
22 of enactment of the CARES Act, and every 5 years there-  
23 after, the Secretary shall prepare and submit to the Com-  
24 mittee on Health, Education, Labor, and Pensions of the  
25 Senate and the Committee on Energy and Commerce of

1 the House of Representatives a report on the activities and  
2 outcomes of the grant programs under subsections (e), (f),  
3 and (g), including the impact of projects funded under  
4 such programs on the health status of rural residents with  
5 chronic conditions.”; and

6 (7) in subsection (j), by striking “\$45,000,000  
7 for each of fiscal years 2008 through 2012” and in-  
8 serting “\$79,500,000 for each of fiscal years 2021  
9 through 2025”.

10 **SEC. 4215. UNITED STATES PUBLIC HEALTH SERVICE MOD-**  
11 **ERNIZATION.**

12 (a) COMMISSIONED CORPS AND READY RESERVE  
13 CORPS.—Section 203 of the Public Health Service Act (42  
14 U.S.C. 204) is amended—

15 (1) in subsection (a)(1), by striking “a Ready  
16 Reserve Corps for service in time of national emer-  
17 gency” and inserting “, for service in time of a pub-  
18 lic health or national emergency, a Ready Reserve  
19 Corps”; and

20 (2) in subsection (c)—

21 (A) in the heading, by striking “RE-  
22 SEARCH” and inserting “RESERVE CORPS”;

23 (B) in paragraph (1), by inserting “during  
24 public health or national emergencies” before  
25 the period;

1 (C) in paragraph (2)—

2 (i) in the matter preceding subpara-  
3 graph (A), by inserting “, consistent with  
4 paragraph (1)” after “shall”;

5 (ii) in subparagraph (C), by inserting  
6 “during such emergencies” after “mem-  
7 bers”; and

8 (iii) in subparagraph (D), by inserting  
9 “, consistent with subparagraph (C)” be-  
10 fore the period; and

11 (D) by adding at the end the following:

12 “(3) STATUTORY REFERENCES TO RESERVE.—

13 A reference in any Federal statute, except in the  
14 case of subsection (b), to the ‘Reserve Corps’ of the  
15 Public Health Service or to the ‘reserve’ of the Pub-  
16 lic Health Service shall be deemed to be a reference  
17 to the Ready Reserve Corps.”.

18 (b) DEPLOYMENT READINESS.—Section  
19 203A(a)(1)(B) of the Public Health Service Act (42  
20 U.S.C. 204a(a)(1)(B)) is amended by striking “Active Re-  
21 serves” and inserting “Ready Reserve Corps”.

22 (c) RETIREMENT OF COMMISSIONED OFFICERS.—  
23 Section 211 of the Public Health Service Act (42 U.S.C.  
24 212) is amended—

1           (1) by striking “the Service” each place it ap-  
2           pears and inserting “the Regular Corps”;

3           (2) in subsection (a)(4), by striking “(in the  
4           case of an officer in the Reserve Corps)”;

5           (3) in subsection (c)—

6           (A) in paragraph (1)—

7           (i) by striking “or an officer of the  
8           Reserve Corps”; and

9           (ii) by inserting “or under section  
10           221(a)(19)” after “subsection (a)”; and

11           (B) in paragraph (2), by striking “Regular  
12           or Reserve Corps” and inserting “Regular  
13           Corps or Ready Reserve Corps”; and

14           (4) in subsection (f), by striking “the Regular  
15           or Reserve Corps of”.

16           (d) RIGHTS, PRIVILEGES, ETC. OF OFFICERS AND  
17           SURVIVING BENEFICIARIES.—Section 221 of the Public  
18           Health Service Act (42 U.S.C. 213a) is amended—

19           (1) in subsection (a), by adding at the end the  
20           following:

21           “(19) Chapter 1223, Retired Pay for Non-Reg-  
22           ular Service.

23           “(20) Section 12601, Compensation: Reserve on  
24           active duty accepting from any person.

1           “(21) Section 12684, Reserves: separation for  
2           absence without authority or sentence to imprison-  
3           ment.”; and

4           (2) in subsection (b)—

5           (A) by striking “Secretary of Health, Edu-  
6           cation, and Welfare or his designee” and insert-  
7           ing “Secretary of Health and Human Services  
8           or the designee of such secretary”;

9           (B) by striking “(b) The authority vested”  
10          and inserting the following:

11         “(b)(1) The authority vested”;

12           (C) by striking “For purposes of” and in-  
13          serting the following:

14         “(2) For purposes of”; and

15           (D) by adding at the end the following:

16         “(3) For purposes of paragraph (19) of subsection  
17 (a), the terms ‘Military department’, ‘Secretary con-  
18 cerned’, and ‘Armed forces’ in such title 10 shall be  
19 deemed to include, respectively, the Department of Health  
20 and Human Services, the Secretary of Health and Human  
21 Services, and the Commissioned Corps.”.

22         (e) TECHNICAL AMENDMENTS.—Title II of the Pub-  
23 lic Health Service Act (42 U.S.C. 202 et seq.) is amend-  
24 ed—

1 (1) in sections 204 and 207(c), by striking  
2 “Regular or Reserve Corps” each place it appears  
3 and inserting “Regular Corps or Ready Reserve  
4 Corps”;

5 (2) in section 208(a), by striking “Regular and  
6 Reserve Corps” each place it appears and inserting  
7 “Regular Corps and Ready Reserve Corps”; and

8 (3) in section 205(c), 206(c), 210, and 219,  
9 and in subsections (a), (b), and (d) of section 207,  
10 by striking “Reserve Corps” each place it appears  
11 and inserting “Ready Reserve Corps”.

12 **SEC. 4216. LIMITATION ON LIABILITY FOR VOLUNTEER**  
13 **HEALTH CARE PROFESSIONALS DURING**  
14 **COVID-19 EMERGENCY RESPONSE.**

15 (a) **LIMITATION ON LIABILITY.**—Except as provided  
16 in subsection (b), a health care professional shall not be  
17 liable under Federal or State law for any harm caused  
18 by an act or omission of the professional in the provision  
19 of health care services during the public health emergency  
20 declared by the Secretary of Health and Human Services  
21 (referred to in this section as the “Secretary”) pursuant  
22 to section 319 of the Public Health Service Act (42 U.S.C.  
23 247d) on January 31, 2020 with respect to COVID-19,  
24 if—

1           (1) the professional is providing health care  
2 services in response to such public health emergency,  
3 as a volunteer; and

4           (2) the act or omission occurs—

5                 (A) in the course of providing health care  
6 services;

7                 (B) in the health care professional's capac-  
8 ity as a volunteer;

9                 (C) in the course of providing health care  
10 services that are within the scope of the license,  
11 registration, or certification of the volunteer, as  
12 defined by the State of licensure, registration,  
13 or certification; and

14                 (D) in a good faith belief that the indi-  
15 vidual being treated is in need of health care  
16 services.

17           (b) EXCEPTIONS.—Subsection (a) does not apply if—

18                 (1) the harm was caused by an act or omission  
19 constituting willful or criminal misconduct, gross  
20 negligence, reckless misconduct, or a conscious fla-  
21 grant indifference to the rights or safety of the indi-  
22 vidual harmed by the health care professional; or

23                 (2) the health care professional rendered the  
24 health care services under the influence (as deter-



1       mined pursuant to applicable State law) of alcohol  
2       or an intoxicating drug.

3       (c) PREEMPTION.—

4           (1) IN GENERAL.—This section preempts the  
5       laws of a State or any political subdivision of a State  
6       to the extent that such laws are inconsistent with  
7       this section, unless such laws provide greater protec-  
8       tion from liability.

9           (2) VOLUNTEER PROTECTION ACT.—Protec-  
10       tions afforded by this section are in addition to those  
11       provided by the Volunteer Protection Act of 1997  
12       (Public Law 105–19).

13       (d) DEFINITIONS.—In this section—

14           (1) the term “harm” includes physical, non-  
15       physical, economic, and noneconomic losses;

16           (2) the term “health care professional” means  
17       an individual who is licensed, registered, or certified  
18       under Federal or State law to provide health care  
19       services;

20           (3) the term “health care services” means any  
21       services provided by a health care professional, or by  
22       any individual working under the supervision of a  
23       health care professional that relate to—

24           (A) the diagnosis, prevention, or treatment  
25       of COVID-19; or

1 (B) the assessment or care of the health of  
2 a human being; and

3 (4) the term “volunteer” means a health care  
4 professional who, with respect to the health care  
5 services rendered, does not receive compensation or  
6 any other thing of value in lieu of compensation,  
7 which compensation—

8 (A) includes a payment under any insur-  
9 ance policy or health plan, or under any Fed-  
10 eral or State health benefits program; and

11 (B) excludes receipt of items to be used ex-  
12 clusively for rendering health care services in  
13 the health care professional’s capacity as a vol-  
14 unteer described in subsection (a)(1).

15 (e) EFFECTIVE DATE.—This section shall take effect  
16 upon the date of enactment of this Act, and applies to  
17 a claim for harm only if the act or omission that caused  
18 such harm occurred on or after the date of enactment.

19 (f) SUNSET.—This section shall be in effect only for  
20 the length of the public health emergency declared by the  
21 Secretary of Health and Human Services (referred to in  
22 this section as the “Secretary”) pursuant to section 319  
23 of the Public Health Service Act (42 U.S.C. 247d) on Jan-  
24 uary 31, 2020 with respect to COVID-19.

1           **PART III—MISCELLANEOUS PROVISIONS**

2   **SEC. 4221. CONFIDENTIALITY AND DISCLOSURE OF**  
3                   **RECORDS RELATING TO SUBSTANCE USE DIS-**  
4                   **ORDER.**

5           (a) CONFORMING CHANGES RELATING TO SUB-  
6   STANCE USE DISORDER.—Subsections (a) and (h) of sec-  
7   tion 543 of the Public Health Service Act (42 U.S.C.  
8   290dd–2) are each amended by striking “substance  
9   abuse” and inserting “substance use disorder”.

10          (b) DISCLOSURES TO COVERED ENTITIES CON-  
11   SISTENT WITH HIPAA.—Paragraph (1) of section 543(b)  
12   of the Public Health Service Act (42 U.S.C. 290dd–2(b))  
13   is amended to read as follows:

14               “(1) CONSENT.—The following shall apply with  
15               respect to the contents of any record referred to in  
16               subsection (a):

17                       “(A) Such contents may be used or dis-  
18                       closed in accordance with the prior written con-  
19                       sent of the patient with respect to whom such  
20                       record is maintained.

21                       “(B) Once prior written consent of the pa-  
22                       tient has been obtained, such contents may be  
23                       used or disclosed by a covered entity, business  
24                       associate, or a program subject to this section  
25                       for purposes of treatment, payment, and health  
26                       care operations as permitted by the HIPAA

1 regulations. Any information so disclosed may  
2 then be redisclosed in accordance with the  
3 HIPAA regulations. Section 13405(c) of the  
4 Health Information Technology and Clinical  
5 Health Act (42 U.S.C. 17935(c)) shall apply to  
6 all disclosures pursuant to subsection (b)(1) of  
7 this section.

8 “(C) It shall be permissible for a patient’s  
9 prior written consent to be given once for all  
10 such future uses or disclosures for purposes of  
11 treatment, payment, and health care operations,  
12 until such time as the patient revokes such con-  
13 sent in writing.

14 “(D) Section 13405(a) of the Health In-  
15 formation Technology and Clinical Health Act  
16 (42 U.S.C. 17935(a)) shall apply to all disclo-  
17 sures pursuant to subsection (b)(1) of this sec-  
18 tion.”.

19 (c) DISCLOSURES OF DE-IDENTIFIED HEALTH IN-  
20 FORMATION TO PUBLIC HEALTH AUTHORITIES.—Para-  
21 graph (2) of section 543(b) of the Public Health Service  
22 Act (42 U.S.C. 290dd–2(b)), is amended by adding at the  
23 end the following:

24 “(D) To a public health authority, so long  
25 as such content meets the standards established

1 in section 164.514(b) of title 45, Code of Fed-  
2 eral Regulations (or successor regulations) for  
3 creating de-identified information.”.

4 (d) DEFINITIONS.—Section 543 of the Public Health  
5 Service Act (42 U.S.C. 290dd-2) is amended by adding  
6 at the end the following:

7 “(k) DEFINITIONS.—For purposes of this section:

8 “(1) BREACH.—The term ‘breach’ has the  
9 meaning given such term for purposes of the HIPAA  
10 regulations.

11 “(2) BUSINESS ASSOCIATE.—The term ‘busi-  
12 ness associate’ has the meaning given such term for  
13 purposes of the HIPAA regulations.

14 “(3) COVERED ENTITY.—The term ‘covered en-  
15 tity’ has the meaning given such term for purposes  
16 of the HIPAA regulations.

17 “(4) HEALTH CARE OPERATIONS.—The term  
18 ‘health care operations’ has the meaning given such  
19 term for purposes of the HIPAA regulations.

20 “(5) HIPPA REGULATIONS.—The term  
21 ‘HIPAA regulations’ has the meaning given such  
22 term for purposes of parts 160 and 164 of title 45,  
23 Code of Federal Regulations.

1           “(6) PAYMENT.—The term ‘payment’ has the  
2 meaning given such term for purposes of the HIPAA  
3 regulations.

4           “(7) PUBLIC HEALTH AUTHORITY.—The term  
5 ‘public health authority’ has the meaning given such  
6 term for purposes of the HIPAA regulations.

7           “(8) TREATMENT.—The term ‘treatment’ has  
8 the meaning given such term for purposes of the  
9 HIPAA regulations.

10           “(9) UNSECURED PROTECTED HEALTH INFOR-  
11 MATION.—The term ‘unprotected health information’  
12 has the meaning given such term for purposes of the  
13 HIPAA regulations.”.

14           (e) USE OF RECORDS IN CRIMINAL, CIVIL, OR AD-  
15 MINISTRATIVE INVESTIGATIONS, ACTIONS, OR PRO-  
16 CEEDINGS.—Subsection (c) of section 543 of the Public  
17 Health Service Act (42 U.S.C. 290dd–2(c)) is amended  
18 to read as follows:

19           “(c) USE OF RECORDS IN CRIMINAL, CIVIL, OR AD-  
20 MINISTRATIVE CONTEXTS.—Except as otherwise author-  
21 ized by a court order under subsection (b)(2)(C) or by the  
22 consent of the patient, a record referred to in subsection  
23 (a), or testimony relaying the information contained there-  
24 in, may not be disclosed or used in any civil, criminal, ad-  
25 ministrative, or legislative proceedings conducted by any

1 Federal, State, or local authority, including with respect  
2 to the following activities:

3 “(1) Such record or testimony shall not be en-  
4 tered into evidence in any criminal prosecution or  
5 civil action before a Federal or State court.

6 “(2) Such record or testimony shall not form  
7 part of the record for decision or otherwise be taken  
8 into account in any proceeding before a Federal,  
9 State, or local agency.

10 “(3) Such record or testimony shall not be used  
11 by any Federal, State, or local agency for a law en-  
12 forcement purpose or to conduct any law enforce-  
13 ment investigation.

14 “(4) Such record or testimony shall not be used  
15 in any application for a warrant.”.

16 (f) PENALTIES.—Subsection (f) of section 543 of the  
17 Public Health Service Act (42 U.S.C. 290dd–2) is amend-  
18 ed to read as follows:

19 “(f) PENALTIES.—The provisions of sections 1176  
20 and 1177 of the Social Security Act shall apply to a viola-  
21 tion of this section to the extent and in the same manner  
22 as such provisions apply to a violation of part C of title  
23 XI of such Act. In applying the previous sentence—

24 “(1) the reference to ‘this subsection’ in sub-  
25 section (a)(2) of such section 1176 shall be treated

1 as a reference to ‘this subsection (including as ap-  
 2 plied pursuant to section 543(f) of the Public Health  
 3 Service Act)’; and

4 “(2) in subsection (b) of such section 1176—

5 “(A) each reference to ‘a penalty imposed  
 6 under subsection (a)’ shall be treated as a ref-  
 7 erence to ‘a penalty imposed under subsection  
 8 (a) (including as applied pursuant to section  
 9 543(f) of the Public Health Service Act)’; and

10 “(B) each reference to ‘no damages ob-  
 11 tained under subsection (d)’ shall be treated as  
 12 a reference to ‘no damages obtained under sub-  
 13 section (d) (including as applied pursuant to  
 14 section 543(f) of the Public Health Service  
 15 Act)’.”.

16 (g) ANTIDISCRIMINATION.—Section 543 of the Public  
 17 Health Service Act (42 U.S.C. 290dd-2) is amended by  
 18 inserting after subsection (h) the following:

19 “(i) ANTIDISCRIMINATION.—

20 “(1) IN GENERAL.—No entity shall discrimi-  
 21 nate against an individual on the basis of informa-  
 22 tion received by such entity pursuant to an inad-  
 23 vertent or intentional disclosure of records, or infor-  
 24 mation contained in records, described in subsection  
 25 (a) in—



1           “(A) admission, access to, or treatment for  
2 health care;

3           “(B) hiring, firing, or terms of employ-  
4 ment, or receipt of worker’s compensation;

5           “(C) the sale, rental, or continued rental of  
6 housing;

7           “(D) access to Federal, State, or local  
8 courts; or

9           “(E) access to, approval of, or mainte-  
10 nance of social services and benefits provided or  
11 funded by Federal, State, or local governments.

12           “(2) RECIPIENTS OF FEDERAL FUNDS.—No re-  
13 cipient of Federal funds shall discriminate against  
14 an individual on the basis of information received by  
15 such recipient pursuant to an intentional or inad-  
16 vertent disclosure of such records or information  
17 contained in records described in subsection (a) in  
18 affording access to the services provided with such  
19 funds.”.

20           (h) NOTIFICATION IN CASE OF BREACH.—Section  
21 543 of the Public Health Service Act (42 U.S.C. 290dd–  
22 2), as amended by subsection (g), is further amended by  
23 inserting after subsection (i) the following:

24           “(j) NOTIFICATION IN CASE OF BREACH.—The pro-  
25 visions of section 13402 of the HITECH Act (42 U.S.C.

1 17932) shall apply to a program or activity described in  
2 subsection (a), in case of a breach of records described  
3 in subsection (a), to the same extent and in the same man-  
4 ner as such provisions apply to a covered entity in the  
5 case of a breach of unsecured protected health informa-  
6 tion.”.

7 (i) REGULATIONS.—

8 (1) IN GENERAL.—The Secretary of Health and  
9 Human Services, in consultation with appropriate  
10 Federal agencies, shall make such revisions to regu-  
11 lations as may be necessary for implementing and  
12 enforcing the amendments made by this section,  
13 such that such amendments shall apply with respect  
14 to uses and disclosures of information occurring on  
15 or after the date that is 12 months after the date  
16 of enactment of this Act.

17 (2) EASILY UNDERSTANDABLE NOTICE OF PRI-  
18 VACY PRACTICES.—Not later than 1 year after the  
19 date of enactment of this Act, the Secretary of  
20 Health and Human Services, in consultation with  
21 appropriate legal, clinical, privacy, and civil rights  
22 experts, shall update section 164.520 of title 45,  
23 Code of Federal Regulations, so that covered entities  
24 and entities creating or maintaining the records de-  
25 scribed in subsection (a) provide notice, written in

1 plain language, of privacy practices regarding pa-  
2 tient records referred to in section 543(a) of the  
3 Public Health Service Act (42 U.S.C. 290dd-2(a)),  
4 including—

5 (A) a statement of the patient’s rights, in-  
6 cluding self-pay patients, with respect to pro-  
7 tected health information and a brief descrip-  
8 tion of how the individual may exercise these  
9 rights (as required by subsection (b)(1)(iv) of  
10 such section 164.520); and

11 (B) a description of each purpose for  
12 which the covered entity is permitted or re-  
13 quired to use or disclose protected health infor-  
14 mation without the patient’s written authoriza-  
15 tion (as required by subsection (b)(2) of such  
16 section 164.520).

17 (j) RULES OF CONSTRUCTION.—Nothing in this title  
18 or the amendments made by this title shall be construed  
19 to limit—

20 (1) a patient’s right, as described in section  
21 164.522 of title 45, Code of Federal Regulations, or  
22 any successor regulation, to request a restriction on  
23 the use or disclosure of a record referred to in sec-  
24 tion 543(a) of the Public Health Service Act (42

1 U.S.C. 290dd–2(a)) for purposes of treatment, pay-  
2 ment, or health care operations; or

3 (2) a covered entity’s choice, as described in  
4 section 164.506 of title 45, Code of Federal Regula-  
5 tions, or any successor regulation, to obtain the con-  
6 sent of the individual to use or disclose a record re-  
7 ferred to in such section 543(a) to carry out treat-  
8 ment, payment, or health care operation.

9 (k) SENSE OF CONGRESS.—It is the sense of the  
10 Congress that—

11 (1) any person treating a patient through a  
12 program or activity with respect to which the con-  
13 fidentiality requirements of section 543 of the Public  
14 Health Service Act (42 U.S.C. 290dd–2) apply is en-  
15 couraged to access the applicable State-based pre-  
16 scription drug monitoring program when clinically  
17 appropriate;

18 (2) patients have the right to request a restric-  
19 tion on the use or disclosure of a record referred to  
20 in section 543(a) of the Public Health Service Act  
21 (42 U.S.C. 290dd–2(a)) for treatment, payment, or  
22 health care operations;

23 (3) covered entities should make every reason-  
24 able effort to the extent feasible to comply with a

1 patient's request for a restriction regarding such use  
2 or disclosure;

3 (4) for purposes of applying section 164.501 of  
4 title 45, Code of Federal Regulations, the definition  
5 of health care operations shall have the meaning  
6 given such term in such section, except that clause  
7 (v) of paragraph (6) shall not apply; and

8 (5) programs creating records referred to in  
9 section 543(a) of the Public Health Service Act (42  
10 U.S.C. 290dd-2(a)) should receive positive incen-  
11 tives for discussing with their patients the benefits  
12 to consenting to share such records.

13 **SEC. 4222. NUTRITION SERVICES.**

14 (a) DEFINITIONS.—In this section, the terms “As-  
15 sistant Secretary”, “Secretary”, “State agency”, and  
16 “area agency on aging” have the meanings given the  
17 terms in section 102 of the Older Americans Act of 1965  
18 (42 U.S.C. 3002).

19 (b) NUTRITION SERVICES TRANSFER CRITERIA.—  
20 During any portion of the COVID-19 public health emer-  
21 gency declared under section 319 of the Public Health  
22 Service Act (42 U.S.C. 247d), the Secretary shall allow  
23 a State agency or an area agency on aging, without prior  
24 approval, to transfer not more than 100 percent of the  
25 funds received by the State agency or area agency on

1 aging, respectively, and attributable to funds appropriated  
2 under paragraph (1) or (2) of section 303(b) of the Older  
3 Americans Act of 1965 (42 U.S.C. 3023(b)), between sub-  
4 part 1 and subpart 2 of part C (42 U.S.C. 3030d–2 et  
5 seq.) for such use as the State agency or area agency on  
6 aging, respectively, considers appropriate to meet the  
7 needs of the State or area served.

8 (c ) HOME-DELIVERED NUTRITION SERVICES WAIV-  
9 ER.—For purposes of State agencies determining the de-  
10 livery of nutrition services under section 337 of the Older  
11 Americans Act of 1965 (42 U.S.C. 3030g), during the pe-  
12 riod of the COVID–19 public health emergency declared  
13 under section 319 of the Public Health Service Act (42  
14 U.S.C. 247d), the same meaning shall be given to an indi-  
15 vidual who is unable to obtain nutrition because the indi-  
16 vidual is practicing social distancing due to the emergency  
17 as is given to an individual who is homebound by reason  
18 of illness.

19 (d) DIETARY GUIDELINES WAIVER.—To facilitate  
20 implementation of subparts 1 and 2 of part C of title III  
21 of the Older Americans Act of 1965 (42 U.S.C. 3030d–  
22 2 et seq.) during any portion of the COVID-19 public  
23 health emergency declared under section 319 of the Public  
24 Health Service Act (42 U.S.C. 247d), the Assistant Sec-  
25 retary shall waive the requirements for meals provided

1 under those subparts to comply with the requirements of  
2 clauses (i) and (ii) of section 339(2)(A) of such Act (42  
3 U.S.C. 3030g–21(2)(A)).

4 **SEC. 4223. GUIDANCE ON PROTECTED HEALTH INFORMA-**  
5 **TION.**

6 Not later than 180 days after the date of enactment  
7 of this Act, the Secretary of Health and Human Services  
8 shall issue guidance on the sharing of patients' protected  
9 health information pursuant to section 160.103 of title 45,  
10 Code of Federal Regulations (or any successor regula-  
11 tions) during the public health emergency declared by the  
12 Secretary of Health and Human Services under section  
13 319 of the Public Health Service Act (42 U.S.C. 247d)  
14 with respect to COVID-19, during the emergency involv-  
15 ing Federal primary responsibility determined to exist by  
16 the President under section 501(b) of the Robert T. Staf-  
17 ford Disaster Relief and Emergency Assistance Act (42  
18 U.S.C. 5191(b)) with respect to COVID-19, and during  
19 the national emergency declared by the President under  
20 the National Emergencies Act (50 U.S.C. 1601 et seq.)  
21 with respect to COVID-19. Such guidance shall include  
22 information on compliance with the regulations promul-  
23 gated pursuant to section 264(c) of the Health Insurance  
24 Portability and Accountability Act of 1996 (42 U.S.C.

1 1320d–2 note) and applicable policies, including such poli-  
2 cies that may come into effect during such emergencies.

3 **SEC. 4224. REAUTHORIZATION OF HEALTHY START PRO-**  
4 **GRAM.**

5 Section 330H of the Public Health Service Act (42  
6 U.S.C. 254c–8) is amended—

7 (1) in subsection (a)—

8 (A) in paragraph (1), by striking “, during  
9 fiscal year 2001 and subsequent years,”; and

10 (B) in paragraph (2), by inserting “or in-  
11 creasing above the national average” after  
12 “areas with high”;

13 (2) in subsection (b)—

14 (A) in paragraph (1), by striking “con-  
15 sumers of project services, public health depart-  
16 ments, hospitals, health centers under section  
17 330” and inserting “participants and former  
18 participants of project services, public health  
19 departments, hospitals, health centers under  
20 section 330, State substance abuse agencies”;  
21 and

22 (B) in paragraph (2)—

23 (i) in subparagraph (A), by striking  
24 “such as low birthweight” and inserting  
25 “including poor birth outcomes (such as



1 low birthweight and preterm birth) and so-  
2 cial determinants of health”;

3 (ii) by redesignating subparagraph  
4 (B) as subparagraph (C);

5 (iii) by inserting after subparagraph  
6 (A), the following:

7 “(B) Communities with—

8 “(i) high rates of infant mortality or  
9 poor perinatal outcomes; or

10 “(ii) high rates of infant mortality or  
11 poor perinatal outcomes in specific sub-  
12 populations within the community.”; and

13 (iv) in subparagraph (C) (as so redesi-  
14 gnated)—

15 (I) by redesignating clauses (i)  
16 and (ii) as clauses (ii) and (iii), re-  
17 spectively;

18 (II) by inserting before clause (ii)  
19 (as so redesignated) the following:

20 “(i) collaboration with the local com-  
21 munity in the development of the project;”;

22 (III) in clause (ii) (as so redesi-  
23 gnated), by striking “and” at the end;

1 (IV) in clause (iii) (as so redesign-  
2 nated), by striking the period and in-  
3 serting “; and”; and

4 (V) by adding at the end the fol-  
5 lowing:

6 “(iv) the use and collection of data  
7 demonstrating the effectiveness of such  
8 program in decreasing infant mortality  
9 rates and improving perinatal outcomes, as  
10 applicable, or the process by which new ap-  
11 plicants plan to collect this data.”;

12 (3) in subsection (c)—

13 (A) by striking “Recipients of grants” and  
14 inserting the following:

15 “(1) IN GENERAL.—Recipients of grants”; and

16 (B) by adding at the end the following:

17 “(2) OTHER PROGRAMS.—The Secretary shall  
18 ensure coordination of the program carried out pur-  
19 suant to this section with other programs and activi-  
20 ties related to the reduction of the rate of infant  
21 mortality and improved perinatal and infant health  
22 outcomes supported by the Department.”;

23 (4) in subsection (e)—

24 (A) in paragraph (1), by striking “appro-  
25 priated—” and all that follows through the end

1 and inserting “appropriated \$122,500,000 for  
2 each of fiscal years 2020 through 2024.”; and

3 (B) in paragraph (2)(B), by adding at the  
4 end the following: “Evaluations may also in-  
5 clude, to the extent practicable, information re-  
6 lated to—

7 “(i) progress toward achieving any  
8 grant metrics or outcomes related to re-  
9 ducing infant mortality rates, improving  
10 perinatal outcomes, or reducing the dis-  
11 parity in health status;

12 “(ii) recommendations on potential  
13 improvements that may assist with ad-  
14 dressing gaps, as applicable and appro-  
15 priate; and

16 “(iii) the extent to which the grantee  
17 coordinated with the community in which  
18 the grantee is located in the development  
19 of the project and delivery of services, in-  
20 cluding with respect to technical assistance  
21 and mentorship programs.”; and

22 (5) by adding at the end the following:

23 “(f) GAO REPORT.—

24 “(1) IN GENERAL.—Not later than 4 years  
25 after the date of the enactment of this subsection,

1 the Comptroller General of the United States shall  
2 conduct an independent evaluation, and submit to  
3 the appropriate Committees of Congress a report,  
4 concerning the Healthy Start program under this  
5 section.

6 “(2) EVALUATION.—In conducting the evalua-  
7 tion under paragraph (1), the Comptroller General  
8 shall consider, as applicable and appropriate, infor-  
9 mation from the evaluations under subsection  
10 (e)(2)(B).

11 “(3) REPORT.—The report described in para-  
12 graph (1) shall review, assess, and provide rec-  
13 ommendations, as appropriate, on the following:

14 “(A) The allocation of Healthy Start pro-  
15 gram grants by the Health Resources and Serv-  
16 ices Administration, including considerations  
17 made by such Administration regarding dispari-  
18 ties in infant mortality or perinatal outcomes  
19 among urban and rural areas in making such  
20 awards.

21 “(B) Trends in the progress made toward  
22 meeting the evaluation criteria pursuant to sub-  
23 section (e)(2)(B), including programs which de-  
24 crease infant mortality rates and improve  
25 perinatal outcomes, programs that have not de-

1           creased infant mortality rates or improved  
2           perinatal outcomes, and programs that have  
3           made an impact on disparities in infant mor-  
4           tality or perinatal outcomes.

5           “(C) The ability of grantees to improve  
6           health outcomes for project participants, pro-  
7           mote the awareness of the Healthy Start pro-  
8           gram services, incorporate and promote family  
9           participation, facilitate coordination with the  
10          community in which the grantee is located, and  
11          increase grantee accountability through quality  
12          improvement, performance monitoring, evalua-  
13          tion, and the effect such metrics may have to-  
14          ward decreasing the rate of infant mortality  
15          and improving perinatal outcomes.

16          “(D) The extent to which such Federal  
17          programs are coordinated across agencies and  
18          the identification of opportunities for improved  
19          coordination in such Federal programs and ac-  
20          tivities.”.

## 21                   **Subtitle C—Innovation**

### 22   **SEC. 4301. REMOVING THE CAP ON OTA.**

23           Section 319L(c)(5)(A)(ii) of the Public Health Serv-  
24   ice Act (42 U.S.C. 247d–7e(c)(5)(A)(ii)) is amended to  
25   read as follows:

1                   “(ii) LIMITATIONS ON AUTHORITY.—  
2                   To the maximum extent practicable, com-  
3                   petitive procedures shall be used when en-  
4                   tering into transactions to carry out  
5                   projects under this subsection.”.

6 **SEC. 4302. EXTENDING THE PRIORITY REVIEW PROGRAM**  
7 **FOR AGENTS THAT PRESENT NATIONAL SE-**  
8 **CURITY THREATS.**

9           Section 565A of the Federal Food, Drug, and Cos-  
10       metic Act (21 U.S.C. 360bbb–4a) is amended by striking  
11       subsection (g).

12 **SEC. 4303. PRIORITY ZONOTIC ANIMAL DRUGS.**

13           Chapter V of the Federal Food, Drug, and Cosmetic  
14       Act (21 U.S.C. 351 et seq.) is amended by inserting after  
15       section 512 the following:

16 **“SEC. 512A. PRIORITY ZONOTIC ANIMAL DRUGS.**

17           “(a) IN GENERAL.—The Secretary shall, at the re-  
18       quest of the sponsor intending to submit an application  
19       for approval of a new animal drug under section 512(b)(1)  
20       or an application for conditional approval of a new animal  
21       drug under section 571, expedite the development and re-  
22       view of such new animal drug if preliminary clinical evi-  
23       dence indicates that the new animal drug, alone or in com-  
24       bination with 1 or more other animal drugs, has the poten-  
25       tial to prevent or treat a zoonotic disease in animals, in-

1 cluding a vector borne-disease, that has the potential to  
2 cause serious adverse health consequences for, or serious  
3 or life-threatening diseases in, humans.

4 “(b) REQUEST FOR DESIGNATION.—The sponsor of  
5 a new animal drug may request the Secretary to designate  
6 a new animal drug described in subsection (a) as a priority  
7 zoonotic animal drug. A request for the designation may  
8 be made concurrently with, or at any time after, the open-  
9 ing of an investigational new animal drug file under sec-  
10 tion 512(j) or the filing of an application under section  
11 512(b)(1) or 571.

12 “(c) DESIGNATION.—

13 “(1) IN GENERAL.—Not later than 60 calendar  
14 days after the receipt of a request under subsection  
15 (b), the Secretary shall determine whether the new  
16 animal drug that is the subject of the request meets  
17 the criteria described in subsection (a). If the Sec-  
18 retary determines that the new animal drug meets  
19 the criteria, the Secretary shall designate the new  
20 animal drug as a priority zoonotic animal drug and  
21 shall take such actions as are appropriate to expe-  
22 dite the development and review of the application  
23 for approval or conditional approval of such new ani-  
24 mal drug.

1           “(2) ACTIONS.—The actions to expedite the de-  
2           velopment and review of an application under para-  
3           graph (1) may include, as appropriate—

4                   “(A) taking steps to ensure that the design  
5                   of clinical trials is as efficient as practicable,  
6                   when scientifically appropriate, such as by uti-  
7                   lizing novel trial designs or drug development  
8                   tools (including biomarkers) that may reduce  
9                   the number of animals needed for studies;

10                   “(B) providing timely advice to, and inter-  
11                   active communication with, the sponsor (which  
12                   may include meetings with the sponsor and re-  
13                   view team) regarding the development of the  
14                   new animal drug to ensure that the develop-  
15                   ment program to gather the nonclinical and  
16                   clinical data necessary for approval is as effi-  
17                   cient as practicable;

18                   “(C) involving senior managers and review  
19                   staff with experience in zoonotic or vector-borne  
20                   disease to facilitate collaborative, cross-discipli-  
21                   nary review, including, as appropriate, across  
22                   agency centers; and

23                   “(D) implementing additional administra-  
24                   tive or process enhancements, as necessary, to



1 facilitate an efficient review and development  
2 program.”.

### 3 **Subtitle D—Finance Committee**

#### 4 **SEC. 4401. EXEMPTION FOR TELEHEALTH SERVICES.**

5 (a) IN GENERAL.—Paragraph (2) of section 223(c)  
6 of the Internal Revenue Code of 1986 is amended by add-  
7 ing at the end the following new subparagraph:

8 “(E) SAFE HARBOR FOR ABSENCE OF DE-  
9 DUCTIBLE FOR TELEHEALTH.—In the case of  
10 plan years beginning on or before December 31,  
11 2021, a plan shall not fail to be treated as a  
12 high deductible health plan by reason of failing  
13 to have a deductible for telehealth and other re-  
14 mote care services.”.

15 (b) CERTAIN COVERAGE DISREGARDED.—Clause (ii)  
16 of section 223(c)(1)(B) of the Internal Revenue Code of  
17 1986 is amended by striking “or long-term care” and in-  
18 serting “long-term care, or (in the case of plan years be-  
19 ginning on or before December 31, 2021) telehealth and  
20 other remote care”.

21 (c) EFFECTIVE DATE.—The amendments made by  
22 this section shall take effect on the date of the enactment  
23 of this Act.

1 **SEC. 4402. INCLUSION OF CERTAIN OVER-THE-COUNTER**  
2 **MEDICAL PRODUCTS AS QUALIFIED MEDICAL**  
3 **EXPENSES.**

4 (a) HSAs.—Section 223(d)(2) of the Internal Rev-  
5 enue Code of 1986 is amended—

6 (1) by striking the last sentence of subpara-  
7 graph (A) and inserting the following: “For pur-  
8 poses of this subparagraph, amounts paid for men-  
9 strual care products shall be treated as paid for  
10 medical care.”; and

11 (2) by adding at the end the following new sub-  
12 paragraph:

13 “(D) MENSTRUAL CARE PRODUCT.—For  
14 purposes of this paragraph, the term ‘menstrual  
15 care product’ means a tampon, pad, liner, cup,  
16 sponge, or similar product used by individuals  
17 with respect to menstruation or other genital-  
18 tract secretions.”.

19 (b) ARCHER MSAs.—Section 220(d)(2)(A) of such  
20 Code is amended by striking the last sentence and insert-  
21 ing the following: “For purposes of this subparagraph,  
22 amounts paid for menstrual care products (as defined in  
23 section 223(d)(2)(D)) shall be treated as paid for medical  
24 care.”.

25 (c) HEALTH FLEXIBLE SPENDING ARRANGEMENTS  
26 AND HEALTH REIMBURSEMENT ARRANGEMENTS.—Sec-

1 tion 106 of such Code is amended by striking subsection  
2 (f) and inserting the following new subsection:

3 “(f) REIMBURSEMENTS FOR MENSTRUAL CARE  
4 PRODUCTS.—For purposes of this section and section  
5 105, expenses incurred for menstrual care products (as  
6 defined in section 223(d)(2)(D)) shall be treated as in-  
7 curred for medical care.”.

8 (d) EFFECTIVE DATES.—

9 (1) DISTRIBUTIONS FROM SAVINGS AC-  
10 COUNTS.—The amendment made by subsections (a)  
11 and (b) shall apply to amounts paid after December  
12 31, 2019.

13 (2) REIMBURSEMENTS.—The amendment made  
14 by subsection (c) shall apply to expenses incurred  
15 after December 31, 2019.

16 **SEC. 4403. TREATMENT OF DIRECT PRIMARY CARE SERV-**  
17 **ICE ARRANGEMENTS.**

18 (a) IN GENERAL.—Section 223(c)(1) of the Internal  
19 Revenue Code of 1986 is amended by adding at the end  
20 the following new subparagraph:

21 “(D) TREATMENT OF DIRECT PRIMARY  
22 CARE SERVICE ARRANGEMENTS.—

23 “(i) IN GENERAL.—A direct primary  
24 care service arrangement shall not be

1 treated as a health plan for purposes of  
2 subparagraph (A)(ii).

3 “(ii) DIRECT PRIMARY CARE SERVICE  
4 ARRANGEMENT.—For purposes of this  
5 paragraph—

6 “(I) IN GENERAL.—The term ‘di-  
7 rect primary care service arrange-  
8 ment’ means, with respect to any indi-  
9 vidual, an arrangement under which  
10 such individual is provided medical  
11 care (as defined in section 213(d))  
12 consisting solely of primary care serv-  
13 ices provided by primary care practi-  
14 tioners (as defined in section  
15 1833(x)(2)(A) of the Social Security  
16 Act, determined without regard to  
17 clause (ii) thereof), if the sole com-  
18 pensation for such care is a fixed peri-  
19 odic fee.

20 “(II) LIMITATION.—With respect  
21 to any individual for any month, such  
22 term shall not include any arrange-  
23 ment if the aggregate fees for all di-  
24 rect primary care service arrange-  
25 ments (determined without regard to

1 this subclause) with respect to such  
2 individual for such month exceed  
3 \$150 (twice such dollar amount in the  
4 case of an individual with any direct  
5 primary care service arrangement (as  
6 so determined) that covers more than  
7 one individual).

8 “(iii) CERTAIN SERVICES SPECIFI-  
9 CALLY EXCLUDED FROM TREATMENT AS  
10 PRIMARY CARE SERVICES.—For purposes  
11 of this paragraph, the term ‘primary care  
12 services’ shall not include—

13 “(I) procedures that require the  
14 use of general anesthesia, and

15 “(II) laboratory services not typi-  
16 cally administered in an ambulatory  
17 primary care setting.

18 The Secretary, after consultation with the  
19 Secretary of Health and Human Services,  
20 shall issue regulations or other guidance  
21 regarding the application of this clause.”.

22 (b) DIRECT PRIMARY CARE SERVICE ARRANGEMENT  
23 FEES TREATED AS MEDICAL EXPENSES.—Section  
24 223(d)(2)(C) is amended by striking “or” at the end of  
25 clause (iii), by striking the period at the end of clause (iv)

1 and inserting “, or”, and by adding at the end the fol-  
2 lowing new clause:

3 “(v) any direct primary care service arrangement.”.

4 (c) INFLATION ADJUSTMENT.—Section 223(g)(1) of  
5 such Code is amended—

6 (1) by inserting “, (c)(1)(D)(ii)(II),” after  
7 “(b)(2),” each place such term appears, and

8 (2) in subparagraph (B), by inserting “and  
9 (iii)” after “clause (ii)” in clause (i), by striking  
10 “and” at the end of clause (i), by striking the period  
11 at the end of clause (ii) and inserting “, and”, and  
12 by inserting after clause (ii) the following new  
13 clause:

14 “(iii) in the case of the dollar amount  
15 in subsection (c)(1)(D)(ii)(II) for taxable  
16 years beginning in calendar years after  
17 2020, ‘calendar year 2019.’”.

18 (d) REPORTING OF DIRECT PRIMARY CARE SERVICE  
19 ARRANGEMENT FEES ON W-2.—Section 6051(a) of such  
20 Code is amended by striking “and” at the end of para-  
21 graph (16), by striking the period at the end of paragraph  
22 (17) and inserting “, and”, and by inserting after para-  
23 graph (17) the following new paragraph:

24 “(18) in the case of a direct primary care serv-  
25 ice arrangement (as defined in section

1 223(c)(1)(D)(ii) which is provided in connection  
2 with employment, the aggregate fees for such ar-  
3 rangement for such employee.”.

4 (e) EFFECTIVE DATE.—The amendments made by  
5 this section shall apply to months beginning after Decem-  
6 ber 31, 2019, in taxable years ending after such date.

7 **SEC. 4404. INCREASING MEDICARE TELEHEALTH FLEXI-**  
8 **BILITIES DURING EMERGENCY PERIOD.**

9 Section 1135 of the Social Security Act (42 U.S.C.  
10 1320b–5) is amended—

11 (1) in subsection (b)(8), by striking “to an indi-  
12 vidual by a qualified provider (as defined in sub-  
13 section (g)(3))” and all that follows through the pe-  
14 riod and inserting “, the requirements of section  
15 1834(m).”; and

16 (2) in subsection (g), by striking paragraph (3).

17 **SEC. 4405. ENHANCING MEDICARE TELEHEALTH SERVICES**  
18 **FOR FEDERALLY QUALIFIED HEALTH CEN-**  
19 **TERS AND RURAL HEALTH CLINICS DURING**  
20 **EMERGENCY PERIOD.**

21 Section 1834(m) of the Social Security Act (42  
22 U.S.C. 1395m(m)) is amended—

23 (1) in the first sentence of paragraph (1), by  
24 striking “The Secretary” and inserting “Subject to  
25 paragraph (8), the Secretary”;

1           (2) in paragraph (2)(A), by striking “The Sec-  
2           retary” and inserting “Subject to paragraph (8), the  
3           Secretary”;

4           (3) in paragraph (4)—

5                 (A) in subparagraph (A), by striking “The  
6                 term” and inserting “Subject to paragraph (8),  
7                 the term”; and

8                 (B) in subparagraph (F)(i), by striking  
9                 “The term” and inserting “Subject to para-  
10                graph (8), the term”; and

11           (4) by adding at the end the following new  
12           paragraph:

13                 “(8) ENHANCING TELEHEALTH SERVICES FOR  
14                 FEDERALLY QUALIFIED HEALTH CENTERS AND  
15                 RURAL HEALTH CLINICS DURING EMERGENCY PE-  
16                 RIOD.—

17                         “(A) IN GENERAL.—During the emergency  
18                         period described in section 1135(g)(1)(B)—

19                                 “(i) the Secretary shall pay for tele-  
20                                 health services that are furnished via a  
21                                 telecommunications system by a Federally  
22                                 qualified health center or a rural health  
23                                 clinic to an eligible telehealth individual en-  
24                                 rolled under this part notwithstanding that  
25                                 the Federally qualified health center or



1 rural clinic providing the telehealth service  
2 is not at the same location as the bene-  
3 ficiary;

4 “(ii) the amount of payment to a Fed-  
5 erally qualified health center or rural  
6 health clinic that serves as a distant site  
7 for such a telehealth service shall be deter-  
8 mined under subparagraph (B); and

9 “(iii) for purposes of this subsection—

10 “(I) the term ‘distant site’ in-  
11 cludes a Federally qualified health  
12 center or rural health clinic that fur-  
13 nishes a telehealth service to an eligi-  
14 ble telehealth individual; and

15 “(II) the term ‘telehealth serv-  
16 ices’ includes a rural health clinic  
17 service or Federally qualified health  
18 center service that is furnished using  
19 telehealth to the extent that payment  
20 codes corresponding to services identi-  
21 fied by the Secretary under clause (i)  
22 or (ii) of paragraph (4)(F) are listed  
23 on the corresponding claim for such  
24 rural health clinic service or Federally  
25 qualified health center service.

1           “(B) SPECIAL PAYMENT RULE.—The Sec-  
2           retary shall develop and implement payment  
3           methods that apply under this subsection to a  
4           Federally qualified health center or rural health  
5           clinic that serves as a distant site that furnishes  
6           a telehealth service to an eligible telehealth indi-  
7           vidual during such emergency period. Such pay-  
8           ment methods shall be based on a composite  
9           rate that is similar to the payment that applies  
10          to payment for comparable telehealth services  
11          under the physician fee schedule under section  
12          1848. Notwithstanding any other provision of  
13          law, the Secretary may implement such pay-  
14          ment methods through program instruction or  
15          otherwise.”.

16 **SEC. 4406. TEMPORARY WAIVER OF REQUIREMENT FOR**  
17                           **FACE-TO-FACE VISITS BETWEEN HOME DI-**  
18                           **ALYSIS PATIENTS AND PHYSICIANS.**

19          Section 1881(b)(3)(B) of the Social Security Act (42  
20 U.S.C. 1395rr(b)(3)(B)) is amended—

21           (1) in clause (i), by striking “clause (ii)” and  
22           inserting “clauses (ii) and (iii)”;

23           (2) in clause (ii), in the matter preceding sub-  
24           clause (I), by striking “Clause (i)” and inserting  
25           “Except as provided in clause (iii), clause (i)”;

1           (3) by adding at the end the following new  
2       clause:

3                       “(iii) The Secretary may waive the  
4                       provisions of clause (ii) during the emer-  
5                       gency period described in section  
6                       1135(g)(1)(B).”.

7       **SEC. 4407. IMPROVING CARE PLANNING FOR MEDICARE**  
8                       **HOME HEALTH SERVICES.**

9           (a) **PART A PROVISIONS.**—Section 1814(a) of the So-  
10       cial Security Act (42 U.S.C. 1395f(a)) is amended—

11               (1) in paragraph (2)—

12                       (A) in the matter preceding subparagraph  
13                       (A), by inserting “, a nurse practitioner or clin-  
14                       ical nurse specialist (as such terms are defined  
15                       in section 1861(aa)(5)) who is working in ac-  
16                       cordance with State law, or a physician assist-  
17                       ant (as defined in section 1861(aa)(5)) under  
18                       the supervision of a physician, who is” after “in  
19                       the case of services described in subparagraph  
20                       (C), a physician”; and

21                       (B) in subparagraph (C)—

22                               (i) by inserting “, a nurse practi-  
23                               tioner, a clinical nurse specialist, or a phy-  
24                               sician assistant (as the case may be)” after

1 “physician” the first 2 times it appears;  
2 and

3 (ii) by striking “, and, in the case of  
4 a certification made by a physician” and  
5 all that follows through “face-to-face en-  
6 counter” and inserting “, and, in the case  
7 of a certification made by a physician after  
8 January 1, 2010, or by a nurse practi-  
9 tioner, clinical nurse specialist, or physi-  
10 cian assistant (as the case may be) after a  
11 date specified by the Secretary (but in no  
12 case later than the date that is 6 months  
13 after the date of the enactment of the  
14 CARES Act), prior to making such certifi-  
15 cation a physician, nurse practitioner, clin-  
16 ical nurse specialist, or physician assistant  
17 must document that a physician, nurse  
18 practitioner, clinical nurse specialist, or  
19 physician assistant has had a face-to-face  
20 encounter”;

21 (2) in the third sentence—

22 (A) by striking “physician certification”  
23 and inserting “certification”;

24 (B) by inserting “(or in the case of regula-  
25 tions to implement the amendments made by

1 section 4407 of the CARES Act, the Secretary  
2 shall prescribe regulations, which shall become  
3 effective no later than 6 months after the enact-  
4 ment of such Act))” after “1981”; and

5 (C) by striking “a physician who” and in-  
6 serting “a physician, nurse practitioner, clinical  
7 nurse specialist, certified nurse-midwife, or phy-  
8 sician assistant who”; and

9 (3) in the fourth sentence, by inserting “, nurse  
10 practitioner, clinical nurse specialist, certified nurse-  
11 midwife, or physician assistant” after “physician”;  
12 and

13 (4) in the fifth sentence—

14 (A) by inserting “or no later than six  
15 months after the enactment of this legislation  
16 for purposes of documentation for certification  
17 and recertification made under paragraph (2)  
18 by a nurse practitioner, clinical nurse specialist,  
19 certified nurse-midwife, or physician assist-  
20 ant,”; and

21 (B) by inserting “, nurse practitioner, clin-  
22 ical nurse specialist, certified nurse-midwife, or  
23 physician assistant” after “of the physician”.

24 (b) PART B PROVISIONS.—Section 1835(a) of the So-  
25 cial Security Act (42 U.S.C. 1395n(a)) is amended—

1 (1) in paragraph (2)—

2 (A) in the matter preceding subparagraph  
3 (A), by inserting “, a nurse practitioner or clinical  
4 nurse specialist (as those terms are defined  
5 in section 1861(aa)(5)) who is working in accordance  
6 with State law, or a physician assistant (as defined in section 1861(aa)(5)) under  
7 the supervision of a physician, who is” after “in  
8 the case of services described in subparagraph  
9 (C), a physician”; and

11 (B) in subparagraph (A)—

12 (i) in each of clauses (ii) and (iii) of  
13 subparagraph (A) by inserting “, a nurse  
14 practitioner, a clinical nurse specialist, or a  
15 physician assistant (as the case may be)”  
16 after “physician”; and

17 (ii) in clause (iv), by striking “after  
18 January 1, 2010” and all that follows  
19 through “face-to-face encounter” and inserting  
20 “made by a physician after January  
21 1, 2010, or by a nurse practitioner,  
22 clinical nurse specialist, or physician assistant  
23 (as the case may be) after a date  
24 specified by the Secretary (but in no case  
25 later than the date that is 6 months after

1           the date of the enactment of the CARES  
2           Act), prior to making such certification a  
3           physician, nurse practitioner, clinical nurse  
4           specialist, certified nurse-midwife, or physi-  
5           cian assistant must document that a physi-  
6           cian, nurse practitioner, clinical nurse spe-  
7           cialist, or physician assistant has had a  
8           face-to-face encounter”;

9           (2) in the third sentence, by inserting “, nurse  
10          practitioner, clinical nurse specialist, or physician as-  
11          sistant (as the case may be)” after physician;

12          (3) in the fourth sentence—

13               (A) by striking “physician certification”  
14               and inserting “certification”;

15               (B) by inserting “(or in the case of regula-  
16               tions to implement the amendments made by  
17               section 4407 of the CARES Act the Secretary  
18               shall prescribe regulations which shall become  
19               effective no later than 6 months after the enact-  
20               ment of such Act))” after “1981”; and

21               (C) by striking “a physician who” and in-  
22               serting “a physician, nurse practitioner, clinical  
23               nurse specialist, or physician assistant who”;

1           (4) in the fifth sentence, by inserting “, nurse  
2 practitioner, clinical nurse specialist, or physician as-  
3 sistant” after “physician”; and

4           (5) in the sixth sentence—

5           (A) by inserting “or no later than six  
6 months after the enactment of this legislation  
7 for purposes of documentation for certification  
8 and recerification made under paragraph (2) by  
9 a nurse practitioner, clinical nurse specialist,  
10 certified nurse-midwife, or physician assistant,”  
11 after “January 1, 2019”; and

12           (B) by inserting “, nurse practitioner, clin-  
13 ical nurse specialist, certified nurse-midwife, or  
14 physician assistant” after “of the physician”.

15       (c) DEFINITION PROVISIONS.—

16           (1) HOME HEALTH SERVICES.—Section  
17 1861(m) of the Social Security Act (42 U.S.C.  
18 1395x(m)) is amended—

19           (A) in the matter preceding paragraph  
20 (1)—

21           (i) by inserting “, a nurse practitioner  
22 or a clinical nurse specialist (as those  
23 terms are defined in subsection (aa)(5)), or  
24 a physician assistant (as defined in sub-



1 section (aa)(5))” after “physician” the  
2 first place it appears; and

3 (ii) by inserting “, a nurse practi-  
4 tioner, a clinical nurse specialist, or a phy-  
5 sician assistant” after “physician” the sec-  
6 ond place it appears; and

7 (B) in paragraph (3), by inserting “, a  
8 nurse practitioner, a clinical nurse specialist, or  
9 a physician assistant” after “physician”.

10 (2) HOME HEALTH AGENCY.—Section  
11 1861(o)(2) of the Social Security Act (42 U.S.C.  
12 1395x(o)(2)) is amended—

13 (A) by inserting “, nurse practitioners or  
14 clinical nurse specialists (as those terms are de-  
15 fined in subsection (aa)(5)), certified nurse-mid-  
16 wives (as defined in subsection (gg)), or physi-  
17 cian assistants (as defined in subsection  
18 (aa)(5))” after “physicians”; and

19 (B) by inserting “, nurse practitioner, clin-  
20 ical nurse specialist, certified nurse-midwife,  
21 physician assistant,” after “physician”.

22 (3) COVERED OSTEOPOROSIS DRUG.—Section  
23 1861(kk)(1) of the Social Security Act (42 U.S.C.  
24 1395x(kk)(1)) is amended by inserting “, nurse  
25 practitioner or clinical nurse specialist (as those

1 terms are defined in subsection (aa)(5)), certified  
2 nurse-midwife (as defined in subsection (gg)), or  
3 physician assistant (as defined in subsection  
4 1820(aa)(5))” after “attending physician”.

5 (d) HOME HEALTH PROSPECTIVE PAYMENT SYSTEM  
6 PROVISIONS.—Section 1895 of the Social Security Act (42  
7 U.S.C. 1395fff) is amended—

8 (1) in subsection (c)(1)—

9 (A) by striking “(provided under section  
10 1842(r))”; and

11 (B) by inserting “the 1 nurse practitioner  
12 or clinical nurse specialist (as those terms are  
13 defined in section 1861(aa)(5)), or the physi-  
14 cian assistant (as defined in section  
15 1861(aa)(5))” after “physician”; and

16 (2) in subsection (e)—

17 (A) in paragraph (1)(A), by inserting “or  
18 a nurse practitioner or clinical nurse specialist  
19 (as those terms are defined in section  
20 1861(aa)(5))” after “physician”; and

21 (B) in paragraph (2)—

22 (i) in the heading, by striking “PHY-  
23 SICIAN CERTIFICATION” and inserting  
24 “RULE OF CONSTRUCTION REGARDING RE-  
25 QUIREMENT FOR CERTIFICATION”; and

1 (ii) by striking “physician”.

2 (e) APPLICATION TO MEDICAID.—The amendments  
3 made under this section shall apply under title XIX of the  
4 Social Security Act in the same manner and to the same  
5 extent as such requirements apply under title XVIII of  
6 such Act or regulations promulgated thereunder.

7 (f) EFFECTIVE DATE.—The Secretary of Health and  
8 Human Services shall prescribe regulations to apply the  
9 amendments made by this section to items and services  
10 furnished, which shall become effective no later than six  
11 months after the enactment of this legislation. The Sec-  
12 retary shall promulgate an interim final rule if necessary,  
13 to comply with the required effective date.

14 **SEC. 4408. ADJUSTMENT OF SEQUESTRATION.**

15 (a) TEMPORARY SUSPENSION OF MEDICARE SE-  
16 QUESTRATION.—During the period beginning on May 1,  
17 2020 and ending on December 31, 2020, the Medicare  
18 programs under title XVIII of the Social Security Act (42  
19 U.S.C. 1395 et seq.) shall be exempt from reduction under  
20 any sequestration order issued before, on, or after the date  
21 of enactment of this Act.

22 (b) EXTENSION OF DIRECT SPENDING REDUCTIONS  
23 THROUGH FISCAL YEAR 2030.—Section 251A(6) of the  
24 Balanced Budget and Emergency Deficit Control Act of  
25 1985 (2 U.S.C. 901a(6)) is amended—

1 (1) in subparagraph (B), in the matter pre-  
2 ceding clause (i), by striking “through 2029” and  
3 inserting “through 2030”; and

4 (2) in subparagraph (C), in the matter pre-  
5 ceding clause (i), by striking “fiscal year 2029” and  
6 inserting “fiscal year 2030”.

7 **SEC. 4409. MEDICARE HOSPITAL INPATIENT PROSPECTIVE**  
8 **PAYMENT SYSTEM ADD-ON PAYMENT FOR**  
9 **COVID-19 PATIENTS DURING EMERGENCY PE-**  
10 **RIOD.**

11 (a) IN GENERAL.—Section 1886(d)(4)(C) of the So-  
12 cial Security Act (42 U.S.C. 1395ww(d)(4)(C)) is amend-  
13 ed by adding at the end the following new clause:

14 “(iv)(I) For discharges occurring during the emer-  
15 gency period described in section 1135(g)(1)(B), in the  
16 case of a discharge that has a principal or secondary diag-  
17 nosis of COVID-19, the Secretary shall increase the  
18 weighting factor for each diagnosis-related group (with  
19 such a principal or secondary diagnosis) by 15 percent.

20 “(II) Any adjustment under subclause (I) shall not  
21 be taken into account in applying budget neutrality under  
22 clause (iii).”.

23 (b) IMPLEMENTATION.—Notwithstanding any other  
24 provision of law, the Secretary may implement the amend-

1 ment made by subsection (a) by program instruction or  
2 otherwise.

3 **SEC. 4410. REVISING PAYMENT RATES FOR DURABLE MED-**  
4 **ICAL EQUIPMENT UNDER THE MEDICARE**  
5 **PROGRAM THROUGH DURATION OF EMER-**  
6 **GENCY PERIOD.**

7 (a) RURAL AND NONCONTIGUOUS AREAS.—The Sec-  
8 retary of Health and Human Services shall implement sec-  
9 tion 414.210(g)(9)(iii) of title 42, Code of Federal Regula-  
10 tions (or any successor regulation), to apply the transition  
11 rule described in such section to all applicable items and  
12 services furnished in rural areas and noncontiguous areas  
13 (as such terms are defined for purposes of such section)  
14 as planned through December 31, 2020, and through the  
15 duration of the emergency period described in section  
16 1135(g)(1)(B) of the Social Security Act (42 U.S.C.  
17 1320b–5(g)(1)(B)), if longer.

18 (b) AREAS OTHER THAN RURAL AND NONCONTIG-  
19 UOUS AREAS.—With respect to items and services fur-  
20 nished on or after the date that is 30 days after the date  
21 of the enactment of this Act, the Secretary of Health and  
22 Human Services shall apply section 414.210(g)(9)(iv) of  
23 title 42, Code of Federal Regulations (or any successor  
24 regulation), as if the reference to “dates of service from  
25 June 1, 2018 through December 31, 2020, based on the

1 fee schedule amount for the area is equal to 100 percent  
2 of the adjusted payment amount established under this  
3 section” were instead a reference to “dates of service from  
4 March 6, 2020, through the remainder of the duration of  
5 the emergency period described in section 1135(g)(1)(B)  
6 of the Social Security Act (42 U.S.C. 1320b–5(g)(1)(B)),  
7 based on the fee schedule amount for the area is equal  
8 to 75 percent of the adjusted payment amount established  
9 under this section and 25 percent of the unadjusted fee  
10 schedule amount”.

11 **SEC. 4411. PROVIDING HOME AND COMMUNITY-BASED**  
12 **SERVICES IN ACUTE CARE HOSPITALS.**

13 Section 1902(h) of the Social Security Act (42 U.S.C.  
14 1396a(h)) is amended—

15 (1) by inserting “(1)” after “(h)”;

16 (2) by inserting “, home and community-based  
17 services provided under subsection (c), (d), or (i) of  
18 section 1915 or under a waiver under section 1115,  
19 self-directed personal assistance services provided  
20 pursuant to a written plan of care under section  
21 1915(j), and home and community-based attendant  
22 services and supports under section 1915(k)” before  
23 the period; and

24 (3) by adding at the end the following:

1           “(2) Nothing in this title, title XVIII, or title XI shall  
 2 be construed as prohibiting receipt of any care or services  
 3 specified in paragraph (1) in an acute care hospital that  
 4 are—

5           “(A) identified in an individual’s person-cen-  
 6 tered plan of services and supports (or comparable  
 7 plan of care);

8           “(B) provided to meet needs of the individual  
 9 that are not met through the provision of hospital  
 10 services;

11           “(C) not a substitute for services that the hos-  
 12 pital is obligated to provide through its conditions of  
 13 participation or under Federal or State law; and

14           “(D) designed to ensure smooth transitions be-  
 15 tween acute care settings and home and community-  
 16 based settings, and to preserve the individual’s func-  
 17 tions.”.

18 **SEC. 4412. TREATMENT OF TECHNOLOGY-ENABLED COL-**  
 19 **LABORATIVE LEARNING AND CAPACITY**  
 20 **BUILDING MODELS AS MEDICAL ASSISTANCE.**

21           Section 1915 of the Social Security Act (42 U.S.C.  
 22 1396n) is amended by adding at the end the following:

23           “(m) **TECHNOLOGY-ENABLED COLLABORATIVE**  
 24 **LEARNING AND CAPACITY BUILDING MODELS.—**

1           “(1) IN GENERAL.—A State may provide, as  
2           medical assistance, a technology-enabled collabo-  
3           rative learning and capacity building model used by  
4           a provider participating under the State plan (or a  
5           waiver of such plan) without regard to the require-  
6           ments of section 1902(a)(1) (relating to  
7           statewideness), section 1902(a)(10)(B) (relating to  
8           comparability), and section 1902(a)(23) (relating to  
9           freedom of choice of providers).

10           “(2) REQUIREMENTS.—A State shall be eligible  
11           for Federal financial assistance for providing such  
12           medical assistance under the following conditions:

13                   “(A) A participating provider uses the  
14                   technology-enabled collaborative learning and  
15                   capacity building model to train health profes-  
16                   sionals (which may include medical students) in  
17                   protocols for responding to a public health  
18                   emergency during an emergency period, includ-  
19                   ing any period relating to an outbreak of  
20                   coronavirus disease 2019 (COVID–19).

21                   “(B) In accordance with section  
22                   1902(a)(25), there are no other third parties  
23                   liable to pay for the use of such model by a par-  
24                   ticipating provider, including as reimbursement



1 under a medical, social, educational, or other  
2 program.

3 “(C) The State allocates the costs of any  
4 part of the use such model which is reimburs-  
5 able under another federally funded program in  
6 accordance with OMB Circular A-87 (or any  
7 related or successor guidance or regulations re-  
8 garding allocation of costs among federally  
9 funded programs) under an approved cost allo-  
10 cation program.

11 “(3) NONAPPLICATION OF TIME LIMITS.—Sub-  
12 section (h) shall not apply to the provision of med-  
13 ical assistance for technology-enabled collaborative  
14 learning and capacity building models under this  
15 subsection.

16 “(4) DEFINITIONS.—In this subsection:

17 “(A) EMERGENCY PERIOD.—The term  
18 ‘emergency period’ has the meaning given that  
19 term in section 1135(g)(1).

20 “(B) TECHNOLOGY-ENABLED COLLABO-  
21 RATIVE LEARNING AND CAPACITY BUILDING  
22 MODEL.—The term ‘technology-enabled col-  
23 laborative learning and capacity building model’  
24 has the meaning given that term in section 2(7)  
25 of the Expanding Capacity for Health Out-

1 comes Act (Public Law 114–270, 130 Stat.  
2 1395).”.

3 **SEC. 4413. ENCOURAGING THE DEVELOPMENT AND USE OF**  
4 **DISARM ANTIMICROBIAL DRUGS.**

5 (a) ADDITIONAL PAYMENT FOR DISARM ANTI-  
6 MICROBIAL DRUGS UNDER MEDICARE.—

7 (1) IN GENERAL.—Section 1886(d)(5) of the  
8 Social Security Act (42 U.S.C. 1395ww(d)(5)) is  
9 amended by adding at the end the following new  
10 subparagraph:

11 “(M)(i)(I) In the case of discharges occurring on or  
12 after October 1, 2021, and before October 1, 2026, subject  
13 to subclause (II), the Secretary shall, after notice and op-  
14 portunity for public comment (in the publications required  
15 by subsection (e)(5) for a fiscal year or otherwise), provide  
16 for an additional payment under a mechanism (separate  
17 from the mechanism established under subparagraph (K)),  
18 with respect to such discharges involving any DISARM  
19 antimicrobial drug, in an amount equal to—

20 “(aa) the amount payable under section 1847A  
21 for such drug during the calendar quarter in which  
22 the discharge occurred; or

23 “(bb) if no amount for such drug is determined  
24 under section 1847A, an amount to be determined  
25 by the Secretary in a manner similar to the manner

1 in which payment amounts are determined under  
2 section 1847A based on information submitted by  
3 the manufacturer or sponsor of such drug (as re-  
4 quired under clause (v)).

5 “(II) In determining the amount payable under sec-  
6 tion 1847A for purposes of items (aa) and (bb) of sub-  
7 clause (I), subparagraphs (A) and (B) of subsection (b)(1)  
8 of such section shall be applied by substituting ‘100 per-  
9 cent’ for ‘106 percent’ each place it appears and para-  
10 graph (8)(B) of such section shall be applied by sub-  
11 stituting ‘0 percent’ for ‘6 percent’.

12 “(ii) For purposes of this subparagraph, a DISARM  
13 antimicrobial drug is—

14 “(I) a drug—

15 “(aa) that—

16 “(AA) is approved by the Food and  
17 Drug Administration;

18 “(BB) is designated by the Food and  
19 Drug Administration as a qualified infec-  
20 tious disease product under subsection (d)  
21 of section 505E of the Federal Food,  
22 Drug, and Cosmetic Act; and

23 “(CC) has received an extension of its  
24 exclusivity period pursuant to subsection  
25 (a) of such section; and

1           “(bb) that has been designated by the Sec-  
2           retary pursuant to the process established  
3           under clause (iv)(I)(bb); or

4           “(II) an antibacterial or antifungal biological  
5           product—

6           “(aa) that is licensed for use, or an anti-  
7           bacterial or antifungal biological product for  
8           which an indication is first licensed for use, by  
9           the Food and Drug Administration on or after  
10          June 5, 2014, under section 351(a) of the Pub-  
11          lic Health Service Act for human use to treat  
12          serious or life-threatening infections, as deter-  
13          mined by the Food and Drug Administration,  
14          including those caused by, or likely to be caused  
15          by—

16          “(AA) an antibacterial or antifungal  
17          resistant pathogen, including novel or  
18          emerging infectious pathogens; or

19          “(BB) a qualifying pathogen (as de-  
20          fined under section 505E(f) of the Federal  
21          Food, Drug, and Cosmetic Act); and

22          “(bb) has been designated by the Secretary  
23          pursuant to the process established under  
24          clause (iv)(I)(bb).

1           “(iii) The mechanism established pursuant to clause  
2 (i) shall provide that the additional payment under clause  
3 (i) shall—

4           “(I) with respect to a discharge, only be made  
5 to a subsection (d) hospital that, as determined by  
6 the Secretary—

7           “(aa) is participating in the National  
8 Healthcare Safety Network Antimicrobial Use  
9 and Resistance Module of the Centers for Dis-  
10 ease Control and Prevention or a similar report-  
11 ing program, as specified by the Secretary, re-  
12 lating to antimicrobial drugs; and

13           “(bb) has an antimicrobial stewardship  
14 program that aligns with the Core Elements of  
15 Hospital Antibiotic Stewardship Programs of  
16 the Centers for Disease Control and Prevention  
17 or the Antimicrobial Stewardship Standard set  
18 by the Joint Commission; and

19           “(II) apply to discharges occurring on or after  
20 October 1 of the year in which the drug or biological  
21 product is designated by the Secretary as a DIS-  
22 ARM antimicrobial drug.

23           “(iv)(I) The mechanism established pursuant to  
24 clause (i) shall provide for a process for—

1           “(aa) a manufacturer or sponsor of a drug or  
2 biological product to request the Secretary to des-  
3 ignate the drug or biological product as a DISARM  
4 antimicrobial drug; and

5           “(bb) the designation by the Secretary of drugs  
6 and biological products as DISARM antimicrobial  
7 drugs.

8           “(II) A designation of a drug or biological product  
9 as a DISARM antimicrobial drug may be revoked by the  
10 Secretary if the Secretary determines that—

11           “(aa) the drug or biological product no longer  
12 meets the requirements for a DISARM antimicrobial  
13 drug under clause (ii);

14           “(bb) the request for such designation con-  
15 tained an untrue statement of material fact; or

16           “(cc) clinical or other information that was not  
17 available to the Secretary at the time such designa-  
18 tion was made shows that—

19           “(AA) such drug or biological product is  
20 unsafe for use or not shown to be safe for use  
21 for individuals who are entitled to benefits  
22 under part A; or

23           “(BB) an alternative to such drug or bio-  
24 logical product is an advance that substantially

1 improves the diagnosis or treatment of such in-  
2 dividuals.

3 “(III) Not later than October 1, 2021, and annually  
4 thereafter through October 1, 2025, the Secretary shall  
5 publish in the Federal Register a list of the DISARM anti-  
6 microbial drugs designated under this subparagraph pur-  
7 suant to the process established under clause (iv)(I)(bb).

8 “(v)(I) For purposes of determining additional pay-  
9 ment amounts under clause (i), a manufacturer or sponsor  
10 of a drug or biological product that submits a request de-  
11 scribed in clause (iv)(I)(aa) shall submit to the Secretary  
12 information described in section 1927(b)(3)(A)(iii).

13 “(II) The penalties for failure to provide timely infor-  
14 mation under clause (i) of subparagraph (C) of section  
15 1927(b)(3) and for providing false information under  
16 clause (ii) of such subparagraph shall apply to manufac-  
17 turers and sponsors of a drug or biological product under  
18 this section with respect to information under subclause  
19 (I) in the same manner as such penalties apply to manu-  
20 facturers under such clauses with respect to information  
21 under subparagraph (A) of such section.

22 “(vi) The mechanism established pursuant to clause  
23 (i) shall provide that—

24 “(I) except as provided in subclause (II), no ad-  
25 ditional payment shall be made under this subpara-

1 graph for discharges involving a DISARM anti-  
2 microbial drug if any additional payments have been  
3 made for discharges involving such drug as a new  
4 medical service or technology under subparagraph  
5 (K);

6 “(II) additional payments may be made under  
7 this subparagraph for discharges involving a DIS-  
8 ARM antimicrobial drug if any additional payments  
9 have been made for discharges occurring prior to the  
10 date of enactment of this subparagraph involving  
11 such drug as a new medical service or technology  
12 under subparagraph (K); and

13 “(III) no additional payment shall be made  
14 under subparagraph (K) for discharges involving a  
15 DISARM antimicrobial drug as a new medical serv-  
16 ice or technology if any additional payments for dis-  
17 charges involving such drug have been made under  
18 this subparagraph.”.

19 (2) CONFORMING AMENDMENT.—Section  
20 1886(d)(5)(K)(ii)(III) of the Social Security Act (42  
21 U.S.C. 1395ww(d)(5)(K)(ii)(III)) is amended by  
22 striking “provide” and inserting “subject to sub-  
23 paragraph (M)(vi), provide”.



1 (b) STUDY AND REPORTS ON REMOVING BARRIERS  
2 TO THE DEVELOPMENT OF DISARM ANTIMICROBIAL  
3 DRUGS.—

4 (1) STUDY.—The Comptroller General of the  
5 United States (in this subsection referred to as the  
6 “Comptroller General”) shall, in consultation with  
7 the Director of the National Institutes of Health,  
8 the Commissioner of Food and Drugs, the Adminis-  
9 trator of the Centers for Medicare & Medicaid Serv-  
10 ices, and the Director of the Centers for Disease  
11 Control and Prevention, conduct a study to—

12 (A) identify and examine the barriers that  
13 prevent the development of DISARM anti-  
14 microbial drugs (as defined in section  
15 1886(d)(5)(M)(ii) of the Social Security Act, as  
16 added by subsection (a)); and

17 (B) develop recommendations for actions  
18 to be taken in order to overcome any barriers  
19 identified under subparagraph (A).

20 (2) REPORT.—October 1, 2025, the Comp-  
21 troller General shall submit to Congress a report  
22 containing the preliminary results of the study con-  
23 ducted under paragraph (1), together with rec-  
24 ommendations for such legislation and administra-

1           tive action as the Comptroller General determines  
2           appropriate.

3 **SEC. 4414. NOVEL MEDICAL PRODUCTS.**

4           (a) EXPEDITED CODING OF NOVEL MEDICAL PROD-  
5 UCTS.—Section 1174(b)(2)(B) of the Social Security Act  
6 (42 U.S.C. 1320d–3(b)(2)(B)) is amended by adding at  
7 the end the following new clauses:

8                           “(iii) EXPEDITED CODING OF NOVEL  
9                           MEDICAL PRODUCTS.—

10                           “(I) IN GENERAL.—Notwith-  
11                           standing paragraph (1), in the case of  
12                           a novel medical product (as defined in  
13                           clause (iv)), the Secretary shall make  
14                           modifications to the HCPCS code set  
15                           at least once every quarter.

16                           “(II) REQUEST.—Upon the writ-  
17                           ten confidential request of a manufac-  
18                           turer of a novel medical product, the  
19                           Secretary shall make a determination  
20                           whether to assign a HCPCS code to  
21                           such product. Such request may occur  
22                           on or after the date on which the  
23                           product receives a designation as a  
24                           breakthrough therapy under section  
25                           506(a) of the Federal Food, Drug,

1 and Cosmetic Act (21 U.S.C. 356(a)),  
2 a breakthrough device under section  
3 515B of such Act (21 U.S.C. 360e–  
4 3), or a regenerative advanced therapy  
5 under section 506(g) of such Act (21  
6 U.S.C. 356(g)).

7 “(III) DEADLINE FOR DETER-  
8 MINATION; NOTIFICATION.—The Sec-  
9 retary shall—

10 “(aa) not later than 180 cal-  
11 endar days after receiving the re-  
12 quest of a manufacturer under  
13 subclause (II), make a deter-  
14 mination under such subclause  
15 with respect to the request; and

16 “(bb) not later than 30 cal-  
17 endar days after making such de-  
18 termination, notify the manufac-  
19 turer of the determination.

20 “(IV) MONITORING UTILIZATION  
21 AND OUTCOMES.—A HCPCS code as-  
22 signed under this clause shall allow  
23 for the reliable monitoring of utiliza-  
24 tion and outcomes of the novel med-

1 ical product as described in clause  
2 (vi).

3 “(V) EFFECTIVE DATE OF CODE  
4 ASSIGNMENT.—If the Secretary makes  
5 a determination to assign a HCPCS  
6 code to a product under subclause  
7 (II), such code—

8 “(aa) may be assigned with-  
9 in the first quarter after the  
10 manufacturer files, with respect  
11 to such product, a new drug ap-  
12 plication under section 505(b) of  
13 the Federal Food, Drug, and  
14 Cosmetic Act (21 U.S.C. 355(b)),  
15 a biological product license appli-  
16 cation under section 351(a) of  
17 the Public Health Service Act  
18 (42 U.S.C. 262(a)), a premarket  
19 application under section 515(c)  
20 of the Federal Food, Drug, and  
21 Cosmetic Act (21 U.S.C.  
22 360e(c)), a report under section  
23 510(k) of such Act (21 U.S.C.  
24 360k), or a request for classifica-  
25 tion under section 513(f)(2) of

205

1 such Act (21 U.S.C. 360c(f)(2));

2 and

3 “(bb) may not take effect  
4 before the date the product is ap-  
5 proved, cleared, or licensed by  
6 the Food and Drug Administra-  
7 tion.

8 “(VI) TRADE SECRETS AND CON-  
9 FIDENTIAL INFORMATION.—No infor-  
10 mation submitted under subclause (II)  
11 shall be construed as authorizing the  
12 Secretary to disclose any information  
13 that is a trade secret or confidential  
14 information subject to section  
15 552(b)(4) of title 5, United States  
16 Code.

17 “(iv) NOVEL MEDICAL PRODUCT DE-  
18 FINED.—For purposes of this subpara-  
19 graph, the term ‘novel medical product’  
20 means a drug, biological product, or med-  
21 ical device—

22 “(I) that has not been assigned a  
23 HCPCS code; and

24 “(II) that has been designated as  
25 a breakthrough therapy under section

1 506(a) of the Federal Food, Drug,  
2 and Cosmetic Act (21 U.S.C. 356(a)),  
3 a breakthrough device under section  
4 515B of such Act (21 U.S.C. 360e–  
5 3), or a regenerative advanced therapy  
6 under section 506(g) of such Act (21  
7 U.S.C. 356(g)).

8 “(v) HCPCS DEFINED.—For pur-  
9 poses of this subparagraph, the term  
10 ‘HCPCS’ means the Healthcare Common  
11 Procedure Coding System.

12 “(vi) INPATIENT PRODUCTS.—The  
13 Secretary shall establish a code modifier  
14 within the hospital inpatient prospective  
15 payment system under section 1886(d) to  
16 track the utilization and outcomes of novel  
17 medical products that are assigned a  
18 HCPCS code pursuant to the expedited  
19 coding process under clause (iii) and are  
20 furnished by hospitals in inpatient set-  
21 tings.”.

22 (b) COVERAGE DETERMINATIONS FOR NOVEL MED-  
23 ICAL PRODUCTS.—Section 1862(l) of the Social Security  
24 Act (42 U.S.C. 1395y(l)) is amended by adding at the end  
25 the following new paragraph:

1           “(7) COVERAGE PATHWAY FOR NOVEL MEDICAL  
2 PRODUCTS.—

3           “(A) IN GENERAL.—The Secretary shall  
4 facilitate an efficient coverage pathway to expedite  
5 a national coverage decision for coverage  
6 with evidence development process under this  
7 title for novel medical products described in  
8 subparagraph (D). The Secretary shall review  
9 such novel medical products for the coverage  
10 process on an expedited basis, beginning as  
11 soon as the Secretary assigns a HCPCS code to  
12 the product under clause (iii)(V)(aa) of section  
13 1174(b)(2)(B).

14           “(B) DETERMINATION OF COVERAGE WITH  
15 EVIDENCE DEVELOPMENT.—Such coverage  
16 pathway shall include, with respect to such  
17 novel medical products, if the Secretary deter-  
18 mines coverage with evidence development is  
19 appropriate, issuance of a national coverage de-  
20 termination of coverage with evidence develop-  
21 ment for a period up to, but not to exceed, 4  
22 years from the date of such determination.

23           “(C) MODERNIZING PAYMENT OPTIONS  
24 FOR NOVEL MEDICAL PRODUCTS.—Not later  
25 than 4 years after issuing such national cov-

1           erage determination, the Secretary shall submit  
2           to Congress and to the manufacturer of the  
3           novel medical product a report providing op-  
4           tions for alternative payment models under this  
5           title for the novel medical product or class of  
6           such products, which may include the utilization  
7           of existing models in the commercial health in-  
8           surance market. Such report shall include any  
9           recommendations for legislation and adminis-  
10          trative action as the Secretary determines ap-  
11          propriate to facilitate such payment arrange-  
12          ments.

13                 “(D) NOVEL MEDICAL PRODUCTS DE-  
14          SCRIBED.—For purposes of this paragraph, a  
15          novel medical product described in this subpara-  
16          graph is a novel medical product, as defined in  
17          clause (iv) of section 1174(b)(2)(B), that is as-  
18          signed a HCPCS code pursuant to the expe-  
19          dited coding process under clause (iii) of such  
20          section.

21                 “(E) CLARIFICATION.—Nothing in this  
22          paragraph shall prevent the Secretary from  
23          issuing a noncoverage or a national coverage  
24          determination for a novel medical product.”.



1           (c) ENHANCING COORDINATION WITH THE FOOD  
2 AND DRUG ADMINISTRATION.—

3           (1) PUBLIC MEETING.—

4                   (A) IN GENERAL.—Not later than 12  
5 months after the date of the enactment of this  
6 Act, the Secretary shall convene a public meet-  
7 ing for the purposes of discussing and providing  
8 input on improvements to coordination between  
9 the Food and Drug Administration and the  
10 Centers for Medicare & Medicaid Services in  
11 preparing for the availability of novel medical  
12 products (as defined in section  
13 1174(b)(2)(B)(iv) of the Social Security Act, as  
14 added by subsection (a)) on the market in the  
15 United States.

16                   (B) ATTENDEES.—The public meeting  
17 shall include—

18                           (i) representatives of relevant Federal  
19 agencies, including representatives from  
20 each of the medical product centers within  
21 the Food and Drug Administration and  
22 representatives from the coding, coverage,  
23 and payment offices within the Centers for  
24 Medicare & Medicaid Services;

1 (ii) stakeholders with expertise in the  
2 research and development of novel medical  
3 products, including manufacturers of such  
4 products;

5 (iii) representatives of commercial  
6 health insurance payers;

7 (iv) stakeholders with expertise in the  
8 administration and use of novel medical  
9 products, including physicians; and

10 (v) stakeholders representing patients  
11 and with expertise in the utilization of pa-  
12 tient experience data in medical product  
13 development.

14 (C) TOPICS.—The public meeting shall in-  
15 clude a discussion of—

16 (i) the status of the drug and medical  
17 device development pipeline related to the  
18 availability of novel medical products;

19 (ii) the anticipated expertise necessary  
20 to review the safety and effectiveness of  
21 such products at the Food and Drug Ad-  
22 ministration and current gaps in such ex-  
23 pertise, if any;

24 (iii) the expertise necessary to make  
25 coding, coverage, and payment decisions

1 with respect to such products within the  
2 Centers for Medicare & Medicaid Services,  
3 and current gaps in such expertise, if any;

4 (iv) trends in the differences in the  
5 data necessary to determine the safety and  
6 effectiveness of a novel medical product  
7 and the data necessary to determine  
8 whether a novel medical product meets the  
9 reasonable and necessary requirements for  
10 coverage and payment under title XVIII of  
11 the Social Security Act pursuant to section  
12 1862(a)(1)(A) of such Act (42 U.S.C.  
13 1395y(a)(1)(A));

14 (v) the availability of information for  
15 sponsors of such novel medical products to  
16 meet each of those requirements; and

17 (vi) the coordination of information  
18 related to significant clinical improvement  
19 over existing therapies for patients between  
20 the Food and Drug Administration and the  
21 Centers for Medicare & Medicaid Services  
22 with respect to novel medical products.

23 (D) TRADE SECRETS AND CONFIDENTIAL  
24 INFORMATION.—No information discussed as a  
25 part of the public meeting under this paragraph

1 shall be construed as authorizing the Secretary  
2 to disclose any information that is a trade se-  
3 cret or confidential information subject to sec-  
4 tion 552(b)(4) of title 5, United States Code.

5 (2) IMPROVING TRANSPARENCY OF CRITERIA  
6 FOR MEDICARE COVERAGE.—

7 (A) UPDATING GUIDANCE.—Not later than  
8 18 months after the public meeting under para-  
9 graph (1), the Secretary of Health and Human  
10 Services shall update the final guidance entitled  
11 “National Coverage Determinations with Data  
12 Collection as a Condition of Coverage: Coverage  
13 with Evidence Development” to improve the  
14 availability and coordination of information as  
15 described in clauses (iv) through (vi) of para-  
16 graph (1)(C), and clarify novel medical product  
17 clinical data requirements to meet reasonable  
18 and necessary requirements for coverage and  
19 payment under title XVIII of the Social Secu-  
20 rity Act.

21 (B) FINALIZING UPDATED GUIDANCE.—  
22 Not later than 12 months after issuing draft  
23 guidance under subparagraph (A), the Sec-  
24 retary shall finalize the updated guidance.

1 (d) REPORT ON CODING, COVERAGE, AND PAYMENT  
2 PROCESSES UNDER MEDICARE FOR NEW MEDICAL  
3 PRODUCTS.—

4 (1) IN GENERAL.—Not later than 12 months  
5 after the date of enactment of this Act, the Sec-  
6 retary of Health and Human Services shall publish  
7 a report on the internet website of the Department  
8 of Health and Human Services regarding processes  
9 under the Medicare program under title XVIII of  
10 the Social Security Act (42 U.S.C. 1395 et seq.)  
11 with respect to the coding, coverage, and payment of  
12 medical products described in paragraph (2). Such  
13 report shall include the following:

14 (A) A description of challenges in the cod-  
15 ing, coverage, and payment processes under the  
16 Medicare program for medical products de-  
17 scribed in such paragraph.

18 (B) Recommendations to—

19 (i) incorporate patient experience data  
20 (such as the impact of a disease or condi-  
21 tion on the lives of patients and patient  
22 treatment preferences) into the coverage  
23 and payment processes within the Centers  
24 for Medicare & Medicaid Services;

1                   (ii) decrease the length of time to  
2                   make national and local coverage deter-  
3                   minations under the Medicare program (as  
4                   those terms are defined in subparagraph  
5                   (A) and (B), respectively, of section  
6                   1862(l)(6) of the Social Security Act (42  
7                   U.S.C. 1395y(l)(6)));

8                   (iii) streamline the coverage process  
9                   under the Medicare program and incor-  
10                  porate input from relevant stakeholders  
11                  into such coverage determinations; and

12                  (iv) identify potential mechanisms to  
13                  incorporate novel payment designs similar  
14                  to those in development in commercial in-  
15                  surance plans and State plans under title  
16                  XIX of the Social Security Act (42 U.S.C.  
17                  1396r et seq.) into the Medicare program.

18                  (2) MEDICAL PRODUCTS DESCRIBED.—For pur-  
19                  poses of paragraph (1), a medical product described  
20                  in this paragraph is a medical product, including a  
21                  drug, biological (including gene and cell therapy and  
22                  gene editing), or medical device, that has been des-  
23                  ignated as a breakthrough therapy under section  
24                  506(a) of the Federal Food, Drug, and Cosmetic Act  
25                  (21 U.S.C. 356(a)), a breakthrough device under

1 section 515B of such Act (21 U.S.C. 360e–3), or a  
2 regenerative advanced therapy under section 506(g)  
3 of such Act (21 U.S.C. 356(g)).

## 4 **TITLE II—EDUCATION** 5 **PROVISIONS**

### 6 **SEC. 4501. SHORT TITLE.**

7 This title may be cited as the “COVID-19 Pandemic  
8 Education Relief Act of 2020”.

### 9 **SEC. 4502. DEFINITIONS.**

10 (a) DEFINITIONS.—In this title:

11 (1) QUALIFYING EMERGENCY.—The term  
12 “qualifying emergency” means—

13 (A) a public health emergency declared by  
14 the Secretary of Health and Human Services  
15 pursuant to section 319 of the Public Health  
16 Service Act (42 U.S.C. 247d);

17 (B) an event for which the President de-  
18 clared a major disaster or an emergency under  
19 section 401 or 501, respectively, of the Robert  
20 T. Stafford Disaster Relief and Emergency As-  
21 sistance Act (42 U.S.C. 5170 and 5191); or

22 (C) a national emergency declared by the  
23 President under section 201 of the National  
24 Emergencies Act (50 U.S.C. 1601 et seq.).

1           (2) INSTITUTION OF HIGHER EDUCATION.—The  
2           term “institution of higher education” has the  
3           meaning of the term under section 102 of the High-  
4           er Education Act of 1965 (20 U.S.C. 1002).

5           (3) SECRETARY.—The term “Secretary” means  
6           the Secretary of Education.

7   **SEC. 4503. CAMPUS-BASED AID WAIVERS.**

8           (a) WAIVER OF NON-FEDERAL SHARE REQUIRE-  
9           MENT.—Notwithstanding sections 413C(a)(2) and  
10          443(b)(5) of the Higher Education Act of 1965 (20  
11          U.S.C. 1070b–2(a)(2) and 1087–53(b)(5)), with respect  
12          to funds made available for award years 2019-2020 and  
13          2020-2021, the Secretary shall waive the requirement that  
14          a participating institution of higher education provide a  
15          non-Federal share to match Federal funds provided to the  
16          institution for the programs authorized pursuant to sub-  
17          part 3 of part A and part C of title IV of the Higher  
18          Education Act of 1965 (20 U.S.C. 1070b et seq. and  
19          1087–51 et seq.).

20          (b) AUTHORITY TO REALLOCATE.—Notwithstanding  
21          sections 413D, 442, and 488 of the Higher Education Act  
22          of 1965 (20 U.S.C. 1070b–3, 1087–52, and 1095), during  
23          a period of a qualifying emergency, an institution may  
24          transfer up to 100 percent of the institution’s unexpended  
25          allotment under section 442 of such Act to the institu-



1 tion's allotment under section 413D of such Act, but may  
2 not transfer any funds from the institution's unexpended  
3 allotment under section 413D of such Act to the institu-  
4 tion's allotment under section 442 of such Act.

5 **SEC. 4504. USE OF SUPPLEMENTAL EDUCATIONAL OPPOR-**  
6 **TUNITY GRANTS FOR EMERGENCY AID.**

7 (a) IN GENERAL.—Notwithstanding section 413B of  
8 the Higher Education Act of 1965 (20 U.S.C. 1070b–1),  
9 an institution of higher education may reserve any amount  
10 of an institution's allocation under subpart 3 of part A  
11 of title IV of the Higher Education Act of 1965 (20 U.S.C.  
12 1070b et seq.) for a fiscal year to award, in such fiscal  
13 year, emergency financial aid grants to assist under-  
14 graduate or graduate students for unexpected expenses  
15 and unmet financial need as the result of a qualifying  
16 emergency.

17 (b) DETERMINATIONS.—In determining eligibility for  
18 and awarding emergency financial aid grants under this  
19 section, an institution of higher education may—

20 (1) waive the amount of need calculation under  
21 section 471 of the Higher Education Act of 1965  
22 (20 U.S.C. 1087kk);

23 (2) allow for a student affected by a qualifying  
24 emergency to receive funds in an amount that is not

1 more than the maximum Federal Pell Grant for the  
2 applicable award year; and

3 (3) utilize a contract with a scholarship-grant-  
4 ing organization designated for the sole purpose of  
5 accepting applications from or disbursing funds to  
6 students enrolled in the institution of higher edu-  
7 cation, if such scholarship-granting organization dis-  
8 burses the full allocated amount provided to the in-  
9 stitution of higher education to the recipients.

10 (c) SPECIAL RULE.—Any emergency financial aid  
11 grants to students under this section shall not be treated  
12 as other financial assistance for the purposes of section  
13 471 of the Higher Education Act of 1965 (20 U.S.C.  
14 1087kk).

15 **SEC. 4505. FEDERAL WORK-STUDY DURING A QUALIFYING**  
16 **EMERGENCY.**

17 (a) IN GENERAL.—In the event of a qualifying emer-  
18 gency, an institution of higher education participating in  
19 the program under part C of title IV of the Higher Edu-  
20 cation Act of 1965 (20 U.S.C. 1087–51 et seq.) may make  
21 payments under such part to affected work-study stu-  
22 dents, for the period of time (not to exceed one academic  
23 year) in which affected students were unable to fulfill the  
24 students' work-study obligation for all or part of such aca-  
25 demic year due to such qualifying emergency, as follows:

1           (1) Payments may be made under such part to  
2           affected work-study students in an amount equal to  
3           or less than the amount of wages such students  
4           would have been paid under such part had the stu-  
5           dents been able to complete the work obligation nec-  
6           essary to receive work study funds, as a one time  
7           grant or as multiple payments.

8           (2) Payments shall not be made to any student  
9           who was not eligible for work study or was not com-  
10          pleting the work obligation necessary to receive work  
11          study funds under such part prior to the occurrence  
12          of the qualifying emergency.

13          (3) Any payments made to affected work-study  
14          students under this subsection shall meet the match-  
15          ing requirements of section 443 of the Higher Edu-  
16          cation Act of 1965 (20 U.S.C. 1087-53), unless  
17          such matching requirements are waived by the Sec-  
18          retary of Education.

19          (b) DEFINITION OF AFFECTED WORK-STUDY STU-  
20          DENT.—In this section, the term “affected work-study  
21          student” means a student enrolled at an eligible institu-  
22          tion participating in the program under part C of title IV  
23          of the Higher Education Act of 1965 (20 U.S.C. 1087-  
24          51 et seq.) who—

1           (1) received a work-study award under section  
2           443 of the Higher Education Act of 1965 (20  
3           U.S.C. 1087–53) for the academic year during which  
4           a qualifying emergency occurred;

5           (2) earned Federal work-study wages from such  
6           eligible institution for such academic year; and

7           (3) was prevented from fulfilling the student’s  
8           work-study obligation for all or part of such aca-  
9           demic year due to such qualifying emergency.

10 **SEC. 4506. ADJUSTMENT OF SUBSIDIZED LOAN USAGE LIM-**  
11 **ITS.**

12           Notwithstanding section 455(q)(3) of the Higher  
13           Education Act of 1965 (20 U.S.C. 1087e(q)(3)), the Sec-  
14           retary shall exclude from a student’s period of enrollment  
15           for purposes of loans made under part D of title IV of  
16           the Higher Education Act of 1965 (20 U.S.C. 1087a et  
17           seq.) any semester (or the equivalent) during which the  
18           student was unable to remain enrolled in school as a result  
19           of a qualifying emergency, if the Secretary is able to ad-  
20           minister such policy in a manner that limits complexity  
21           and the burden on the student.

22 **SEC. 4507. EXCLUSION FROM FEDERAL PELL GRANT DURA-**  
23 **TION LIMIT.**

24           The Secretary shall exclude from a student’s Federal  
25           Pell Grant duration limit under section 401(c)(5) of the

1 Higher Education Act of 1965 (2 U.S.C. 1070a(e)(5)) any  
2 semester (or the equivalent) that the student does not  
3 complete due to a qualifying emergency if the Secretary  
4 is able to administer such policy in a manner that limits  
5 complexity and the burden on the student.

6 **SEC. 4508. INSTITUTIONAL REFUNDS AND FEDERAL STU-**  
7 **DENT LOAN FLEXIBILITY.**

8 (a) INSTITUTIONAL WAIVER.—The Secretary may  
9 waive the institutional requirement in section 484B of the  
10 Higher Education Act of 1965 (20 U.S.C. 1091b) with  
11 respect to the amount of grant or loan assistance (other  
12 than assistance received under part C of title IV of such  
13 Act) to be returned to the title IV programs if a recipient  
14 of assistance under title IV of the Higher Education Act  
15 of 1965 (20 U.S.C. 1070 et seq.) withdraws from the in-  
16 stitution during the payment period or period of enroll-  
17 ment as a result of a qualifying emergency.

18 (b) STUDENT WAIVER.—The Secretary may waive  
19 the amounts that students are required to return in sec-  
20 tion 484B of the Higher Education Act of 1965 (20  
21 U.S.C. 1091b) with respect to Federal Pell Grants or  
22 other grant assistance if the withdrawals on which the re-  
23 turns are based on withdrawals by students who withdrew  
24 from the institution as a result of a qualifying emergency.

1           (c) CANCELING LOAN OBLIGATION.—Notwith-  
2 standing any other provision of the Higher Education Act  
3 of 1965 (20 U.S.C. 1001 et seq.), the Secretary shall can-  
4 cel the borrower’s obligation to repay the portion of a loan  
5 made under part D of title IV of such Act for a recipient  
6 of assistance who withdraws from the institution during  
7 the payment period as a result of a qualifying emergency.

8           (d) APPROVED LEAVE OF ABSENCE.—Notwith-  
9 standing any other provision of law, for purposes of receiv-  
10 ing assistance under title IV of the Higher Education Act  
11 of 1965 (20 U.S.C. 1070 et seq.), an institution of higher  
12 education may, as a result of a qualifying emergency, pro-  
13 vide a student with an approved leave of absence that does  
14 not require the student to return at the same point in the  
15 academic program that the student began the leave of ab-  
16 sence if the student returns within the same semester (or  
17 the equivalent).

18 **SEC. 4509. SATISFACTORY PROGRESS.**

19           Notwithstanding section 484 of the Higher Education  
20 Act of 1965 (20 U.S.C. 1091), in determining whether a  
21 student is maintaining satisfactory progress for purposes  
22 of title IV of the Higher Education Act of 1965 (20 U.S.C.  
23 1070 et seq.), an institution of higher education may, as  
24 a result of a qualifying emergency, exclude from the quan-  
25 titative component of the calculation any attempted cred-

1 its that were not completed by such student without re-  
2 quiring an appeal by such student.

3 **SEC. 4510. CONTINUING EDUCATION AT AFFECTED FOR-**  
4 **EIGN INSTITUTIONS.**

5 (a) IN GENERAL.—Notwithstanding section 481(b)  
6 of the Higher Education Act of 1965 (20 U.S.C. 1088(b)),  
7 with respect to a foreign institution, in the case of a public  
8 health emergency, major disaster or emergency, or na-  
9 tional emergency declared by the applicable government  
10 authorities in the country in which the foreign institution  
11 is located, the Secretary may permit any part of an other-  
12 wise eligible program to be offered via distance education  
13 for the duration of such emergency or disaster and the  
14 following payment period for purposes of title IV of the  
15 Higher Education Act of 1965 (20 U.S.C. 1070 et seq.).

16 (b) ELIGIBILITY.—An otherwise eligible program  
17 that is offered in whole or in part through distance edu-  
18 cation by a foreign institution between March 1, 2020, and  
19 the date of enactment of this Act shall be deemed eligible  
20 for the purposes of part D of title IV of the Higher Edu-  
21 cation Act of 1965 (20 U.S.C. 1087a et seq.) for the dura-  
22 tion of the qualifying emergency and the following pay-  
23 ment period for purposes of title IV of the Higher Edu-  
24 cation Act of 1965 (20 U.S.C. 1070 et seq.). Not later  
25 than June 30, 2020, an institution of higher that uses

1 the authority provided in the previous sentence shall re-  
2 port such use to the Secretary.

3 (c) REPORT.—Not later than 180 days after the date  
4 of enactment of this Act, and every 180 days thereafter  
5 for the duration of the qualifying emergency and the fol-  
6 lowing payment period, the Secretary shall submit to the  
7 authorizing committees (as defined in section 103 of the  
8 Higher Education Act of 1965 (20 U.S.C. 1003)) a report  
9 that identifies each foreign institution that carried out a  
10 distance education program authorized under this section.

11 (d) WRITTEN ARRANGEMENTS.—

12 (1) IN GENERAL.—Notwithstanding section 102  
13 of the Higher Education Act of 1965 (20 U.S.C.  
14 1002), for the duration of a qualifying emergency  
15 and the following payment period, the Secretary may  
16 allow a foreign institution to enter into a written ar-  
17 rangement with an institution of higher education  
18 located in the United States that participates in the  
19 Federal Direct Loan Program under part D of title  
20 IV of the Higher Education Act of 1965 (20 U.S.C.  
21 1087a et seq.) for the purpose of allowing a student  
22 of the foreign institution who is a borrower of a loan  
23 made under such part to take courses from the insti-  
24 tution of higher education located in the United  
25 States.



1 (2) FORM OF ARRANGEMENTS.—

2 (A) PUBLIC OR OTHER NONPROFIT INSTI-  
3 TUTIONS.—A foreign institution that is a public  
4 or other nonprofit institution may enter into a  
5 written arrangement under subsection (a) only  
6 with an institution of higher education de-  
7 scribed in section 101 of such Act (20 U.S.C.  
8 1001).

9 (B) OTHER INSTITUTIONS.—A foreign in-  
10 stitution that is a graduate medical school,  
11 nursing school, or a veterinary school and that  
12 is not a public or other nonprofit institution  
13 may enter into a written arrangement under  
14 subsection (a) with an institution of higher edu-  
15 cation described in section 101 or section 102  
16 of such Act (20 U.S.C. 1001 and 1002).

17 (3) REPORT USE.—Not later than June 30,  
18 2020, an institution of higher that uses the author-  
19 ity described in paragraph (2) shall report such use  
20 to the Secretary.

21 (4) REPORT FROM THE SECRETARY.—Not later  
22 than 180 days after the date of enactment of this  
23 Act, and every 180 days thereafter for the duration  
24 of the qualifying emergency and the following pay-  
25 ment period, the Secretary shall submit to the au-

1       thorizing committees (as defined in section 103 of  
2       the Higher Education Act of 1965 (20 U.S.C.  
3       1003)) a report that identifies each foreign institu-  
4       tion that entered into a written arrangement author-  
5       ized under subsection (a).

6       **SEC. 4511. NATIONAL EMERGENCY EDUCATIONAL WAIVERS.**

7       (a) IN GENERAL.—Notwithstanding any other provi-  
8       sion of law, the Secretary of Education may waive any  
9       statutory or regulatory provision described under subpara-  
10      graphs (A) through (C) of subsection (b)(1) if the Sec-  
11      retary determines that such a waiver is necessary and ap-  
12      propriate due to the emergency involving Federal primary  
13      responsibility determined to exist by the President under  
14      the section 501(b) of the Robert T. Stafford Disaster Re-  
15      lief and Emergency Assistance Act (42 U.S.C. 5191(b))  
16      with respect to the Coronavirus Disease 2019 (COVID-  
17      19).

18      (b) APPLICABLE PROVISIONS OF LAW.—

19           (1) IN GENERAL.—The Secretary of Education  
20      may waive any statutory or regulatory requirement  
21      (such as those requirements related to assessments,  
22      accountability, allocation of funds, and reporting),  
23      for which a waiver request is submitted under sub-  
24      section (c), if the Secretary determines that such a

1 waiver is necessary and appropriate as described in  
2 subsection (a), under the following provisions of law:

3 (A) The Elementary and Secondary Edu-  
4 cation Act of 1965 (20 U.S.C. 6301 et seq.).

5 (B) The Carl D. Perkins Career and Tech-  
6 nical Education Act of 2006 (20 U.S.C. 2301  
7 et seq.).

8 (C) The Higher Education Act of 1965  
9 (20 U.S.C. 1001 et seq.).

10 (2) LIMITATION.—The Secretary of Education  
11 shall not waive under this section any statutory or  
12 regulatory requirements relating to applicable civil  
13 rights laws.

14 (c) REQUESTS FOR WAIVERS.—

15 (1) IN GENERAL.—In addition to any provision  
16 waived by the Secretary under subsection (a), a  
17 State, State educational agency, local educational  
18 agency, Indian tribe, or institution of higher edu-  
19 cation that desires a waiver from any statutory or  
20 regulatory provision described under subparagraphs  
21 (A) through (C) of subsection (b)(1) that the Sec-  
22 retary has not already waived in accordance with  
23 subsection (a), may submit a waiver request to the  
24 Secretary in accordance with this subsection.

1           (2) REQUESTS SUBMITTED.—A request for a  
2           waiver under this subsection shall—

3                   (A) identify the Federal programs affected  
4                   by the requested waiver;

5                   (B) describe which Federal statutory or  
6                   regulatory requirements are to be waived; and

7                   (C) describe how the emergency involving  
8                   Federal primary responsibility determined to  
9                   exist by the President under the section 501(b)  
10                  of the Robert T. Stafford Disaster Relief and  
11                  Emergency Assistance Act (42 U.S.C. 5191(b))  
12                  with respect to the Coronavirus Disease 2019  
13                  (COVID-19) prevents or otherwise restricts the  
14                  ability of the State, State educational agency,  
15                  local educational agency, Indian tribe, or insti-  
16                  tution of higher education to comply with such  
17                  statutory or regulatory requirements.

18           (3) SECRETARY APPROVAL.—

19                   (A) IN GENERAL.—Except as provided  
20                   under subparagraph (B), the Secretary of Edu-  
21                   cation shall approve or disapprove a waiver re-  
22                   quest submitted under paragraph (1) not more  
23                   than 15 days after the date on which such re-  
24                   quest is submitted.

1 (B) EXCEPTIONS.—The Secretary of Edu-  
2 cation may disapprove a waiver request sub-  
3 mitted under paragraph (1), only if the Sec-  
4 retary determines that—

5 (i) the waiver request does not meet  
6 the requirements of this section;

7 (ii) the waiver is not permitted pursu-  
8 ant to subsection (b)(2); or

9 (iii) the description required under  
10 paragraph (2)(C) provides insufficient in-  
11 formation to demonstrate that the waiving  
12 of such requirements is necessary or ap-  
13 propriate consistent with subsection (a).

14 (4) DURATION.—

15 (A) IN GENERAL.—Except as provided in  
16 paragraph (B), a waiver approved by the Sec-  
17 retary of Education under this subsection may  
18 be for a period not to exceed 1 academic year.

19 (B) EXTENSION.—The Secretary of Edu-  
20 cation may extend the period described under  
21 subparagraph (A) if the State, State edu-  
22 cational agency, local educational agency, In-  
23 dian tribe, or institution of higher education  
24 demonstrates to the Secretary that extending

1           the waiving of such requirements is necessary  
2           and appropriate consistent with subsection (a).

3           (d) REPORTING AND PUBLICATION.—

4           (1) NOTIFYING CONGRESS.—Not later than 7  
5           days after granting a waiver under this section, the  
6           Secretary of Education shall notify the Committee  
7           on Health, Education, Labor, and Pensions of the  
8           Senate, the Committee on Appropriations of the  
9           Senate, the Committee on Education and Labor of  
10          the House of Representatives, and the Committee on  
11          Appropriations of the House of Representatives of  
12          such waiver.

13          (2) PUBLICATION.—Not later than 30 days  
14          after granting a waiver under this section, the Sec-  
15          retary of Education shall publish a notice of the Sec-  
16          retary's decision in the Federal Register and on the  
17          website of the Department of Education.

18          (3) IDEA REPORT.—Not later than 30 days  
19          after the date of enactment of this Act, the Sec-  
20          retary of Education shall prepare and submit a re-  
21          port to the Committee on Health, Education, Labor,  
22          and Pensions and the Committee on Appropriations  
23          of the Senate, and the Committee on Education and  
24          Labor and the Committee on Appropriations of the  
25          House of Representatives, with recommendations on

1 any additional waivers the Secretary believes are  
2 necessary to be enacted into law under the Individ-  
3 uals with Disabilities Education Act (20 U.S.C.  
4 1401 et seq.) and the Rehabilitation Act of 1973 (29  
5 U.S.C. 701 et seq.) to provide limited flexibility to  
6 States and local educational agencies to meet the  
7 unique needs of students with disabilities during the  
8 emergency involving Federal primary responsibility  
9 determined to exist by the President under the sec-  
10 tion 501(b) of the Robert T. Stafford Disaster Relief  
11 and Emergency Assistance Act (42 U.S.C. 5191(b))  
12 with respect to the Coronavirus Disease 2019  
13 (COVID-19).

14 **SEC. 4512. HBCU CAPITAL FINANCING.**

15 (a) DEFERMENT PERIOD.—

16 (1) IN GENERAL.—Notwithstanding any provi-  
17 sion of title III of the Higher Education Act of 1965  
18 (20 U.S.C. 1051 et seq.), or any regulation promul-  
19 gated under such title, the Secretary may grant a  
20 deferment, for a period of a qualifying emergency to  
21 an institution that has received a loan under part D  
22 of title III of such Act (20 U.S.C. 1066 et seq.).

23 (2) TERMS.—During the deferment period  
24 granted under this subsection—

1           (A) the institution shall not be required to  
2           pay any periodic installment of principal re-  
3           quired under the loan agreement for such loan;  
4           and

5           (B) the Secretary shall make principal pay-  
6           ments otherwise due under the loan agreement.

7           (3) CLOSING.—At the closing of a loan deferred  
8           under this subsection, terms shall be set under  
9           which the institution shall be required to repay the  
10          Secretary for the payments of principal made by the  
11          Secretary during the deferment, on a schedule that  
12          begins upon repayment to the lender in full on the  
13          loan agreement.

14          (b) TERMINATION DATE.—

15           (1) IN GENERAL.—Except as provided in para-  
16           graph (2), the authority provided under this section  
17           to grant a loan deferment under subsection (a), shall  
18           terminate on the date that is the end of the quali-  
19           fying emergency.

20           (2) DURATION.—Any provision of a loan agree-  
21           ment or insurance agreement modified or waived by  
22           the authority under this section shall remain so  
23           modified or waived for the duration of the period  
24           covered by the loan agreement or insurance agree-  
25           ment.



1 (c) REPORT.—Not later than 180 days after the date  
2 of enactment of this Act, and every 180 days thereafter  
3 during the period beginning on the first day of the quali-  
4 fying emergency and ending on September 30 of the fiscal  
5 year following the end of the qualifying emergency, the  
6 Secretary shall submit to the authorizing committees (as  
7 defined in section 103 of the Higher Education Act of  
8 1965 (20 U.S.C. 1003)) a report that identifies each insti-  
9 tution that received assistance or a waiver under this sec-  
10 tion.

11 **SEC. 4513. TEMPORARY RELIEF FOR FEDERAL STUDENT**  
12 **LOAN BORROWERS.**

13 (a) IN GENERAL.—The Secretary shall suspend all  
14 payments due for loans made under part D of title IV  
15 of the Higher Education Act of 1965 (20 U.S.C. 1087a  
16 et seq.) for 3 months.

17 (b) NO ACCRUAL OF INTEREST.—Notwithstanding  
18 any other provision of the Higher Education Act of 1965  
19 (20 U.S.C. 1001 et seq.), interest shall not accrue on a  
20 loan described under subsection (a) for which payment  
21 was suspended for the period of the suspension.

22 (c) CONSIDERATION OF PAYMENTS.—The Secretary  
23 shall deem each month for which a loan payment was sus-  
24 pended under this section as if the borrower of the loan  
25 had made a payment for the purpose of any loan forgive-

1 ness program authorized under part D of title IV of the  
2 Higher Education Act of 1965 (20 U.S.C. 1087a et seq.)  
3 for which the borrower would have otherwise qualified.

4 (d) EXTENSION.—The Secretary may extend the pe-  
5 riod of suspension described under subsection (a) for an  
6 additional 3 months.

7 **SEC. 4514. PROVISIONS RELATED TO THE CORPORATION**  
8 **FOR NATIONAL AND COMMUNITY SERVICE.**

9 (a) ACCRUAL OF SERVICE HOURS.—

10 (1) ACCRUAL THROUGH OTHER SERVICE  
11 HOURS.—

12 (A) IN GENERAL.—Notwithstanding any  
13 other provision of the Domestic Volunteer Serv-  
14 ice Act of 1973 (42 U.S.C. 4950 et seq.) or the  
15 National and Community Service Act of 1990  
16 (42 U.S.C. 12501 et seq.), the Corporation for  
17 National and Community Service shall allow an  
18 individual described in subparagraph (B) to ac-  
19 crue other service hours that will count toward  
20 the number of hours needed for the individual's  
21 education award.

22 (B) AFFECTED INDIVIDUALS.—Subpara-  
23 graph (A) shall apply to any individual serving  
24 in a position eligible for an educational award  
25 under subtitle D of title I of the National and

1           Community Service Act of 1990 (42 U.S.C.  
2           12601 et seq.)—

3                   (i) who is performing limited service  
4                   due to COVID-19; or

5                   (ii) whose position has been suspended  
6                   or placed on hold due to COVID-19.

7           (2) PROVISIONS IN CASE OF EARLY EXIT.—In  
8           any case where an individual serving in a position el-  
9           igible for an educational award under subtitle D of  
10          title I of the National and Community Service Act  
11          of 1990 (42 U.S.C. 12601 et seq.) was required to  
12          exit the position early at the direction of the Cor-  
13          poration for National and Community Service, the  
14          Chief Executive Officer of the Corporation for Na-  
15          tional and Community Service may—

16                   (A) deem such individual as having met  
17                   the requirements of the position; and

18                   (B) award the individual the full value of  
19                   the educational award under such subtitle for  
20                   which the individual would otherwise have been  
21                   eligible.

22          (b) AVAILABILITY OF FUNDS.—Notwithstanding any  
23          other provision of law, all funds made available to the Cor-  
24          poration for National and Community Service under any  
25          Act, including the amounts appropriated to the Corpora-

1 tion under the headings “OPERATING EXPENSES”, “SALA-  
2 RIES AND EXPENSES”, and “OFFICE OF THE INSPECTOR  
3 GENERAL” under the heading “CORPORATION FOR NA-  
4 TIONAL AND COMMUNITY SERVICE” under title IV of Divi-  
5 sion A of the Further Consolidated Appropriations Act,  
6 2020 (Public Law 116–94), shall remain available for the  
7 fiscal year ending September 30, 2021.

8 (c) NO REQUIRED RETURN OF GRANT FUNDS.—  
9 Notwithstanding section 129(l)(3)(A)(i) of the National  
10 and Community Service Act of 1990 (42 U.S.C.  
11 12581(l)(3)(A)(i)), the Chief Executive Officer of the Cor-  
12 poration for National and Community Service may permit  
13 fixed-amount grant recipients under such section 129(l)  
14 to maintain a pro rata amount of grant funds, at the dis-  
15 cretion of the Corporation for National and Community  
16 Service, for participants who exited or are serving in a  
17 limited capacity due to COVID-19, to enable the grant re-  
18 cipients to maintain operations and to accept participants.

19 (d) EXTENSION OF TERMS AND AGE LIMITS.—Not-  
20 withstanding any other provision of law, the Corporation  
21 for National and Community Service may extend the term  
22 of service (for a period not to exceed the 1-year period  
23 immediately following the end of the national emergency)  
24 or waive any upper age limit (except in no case shall the  
25 maximum age exceed 26 years of age) for national service

1 programs carried out by the National Civilian Community  
2 Corps under subtitle E of title I of the National and Com-  
3 munity Service Act of 1990 (42 U.S.C. 12611 et seq.),  
4 and the participants in such programs, for the purposes  
5 of—

- 6 (1) addressing disruptions due to COVID-19;
- 7 and
- 8 (2) minimizing the difficulty in returning to full  
9 operation due to COVID-19 on such programs and  
10 participants.

11 **SEC. 4515. WORKFORCE RESPONSE ACTIVITIES.**

12 (a) ADMINISTRATIVE COSTS.—Of the total amount  
13 allocated to a local area under section 128(b) of the Work-  
14 force Innovation and Opportunity Act (29 U.S.C.  
15 3163(b)) and section 133(b) of such Act (29 U.S.C.  
16 3173(b)) and available for administrative costs for pro-  
17 gram year 2019, not more than 20 percent of the total  
18 amount may be used by the local board involved for the  
19 administrative costs of carrying out local workforce invest-  
20 ment activities under chapter 2 or chapter 3 of subtitle  
21 B of title I of such Act (29 U.S.C. 3151 et seq.), if the  
22 portion of the total amount that exceeds 10 percent of the  
23 total amount as described under section 128(b)(4)(A) of  
24 such Act is used to respond to the COVID-19 national  
25 emergency.

1 (b) RAPID RESPONSE ACTIVITIES.—

2 (1) STATEWIDE RAPID RESPONSE.—Of the  
3 funds available for program year 2019 for statewide  
4 activities under section 128(a) of the Workforce In-  
5 novation and Opportunity Act (29 U.S.C. 3163(a)),  
6 such funds may be used for statewide rapid response  
7 activities as described in section 134(a)(2)(A) (29  
8 U.S.C. 3174(a)(2)(A)) for responding to the  
9 COVID-19 national emergency.

10 (2) LOCAL BOARDS.—Of the funds available to  
11 a Governor under section 133(a)(2) of such Act (29  
12 U.S.C. 3173(a)(2)) such funds may be released  
13 within 30 days to local boards most impacted by the  
14 coronavirus at the determination of the Governor for  
15 rapid response activities related to responding to the  
16 COVID-19 national emergency.

17 (c) DEFINITIONS.—In this section:

18 (1) CORONAVIRUS.—The term “coronavirus”  
19 means coronavirus as defined in section 506 of the  
20 Coronavirus Preparedness and Response Supple-  
21 mental Appropriations Act, 2020 (Public Law 116–  
22 123).

23 (2) COVID-19 NATIONAL EMERGENCY.—The  
24 term “COVID-19 national emergency” means the  
25 national emergency declared by the President under

1 the National Emergencies Act (50 U.S.C. 1601 et  
2 seq.) on March 13, 2020, with respect to the  
3 coronavirus.

4 (3) WIOA TERMS.—Except as otherwise pro-  
5 vided, the terms in this section have the meanings  
6 given the terms in section 3 of the Workforce Inno-  
7 vation and Opportunity Act (29 U.S.C. 3102).

8 **SEC. 4516. TECHNICAL AMENDMENTS.**

9 (a) IN GENERAL.—

10 (1) Section 6103(a)(3) of the Internal Revenue  
11 Code of 1986, as amended by the FUTURE Act  
12 (Public Law 116-91), is further amended by striking  
13 “(13), (16)” and inserting “(13)(A), (13)(B),  
14 (13)(C), (13)(D)(i), (16)”.

15 (2) Section 6103(p)(3)(A) of such Code, as so  
16 amended, is further amended by striking “(12),”  
17 and inserting “(12), (13)(A), (13)(B), (13)(C),  
18 (13)(D)(i)”.

19 (3) Section 6103(p)(4) of such Code, as so  
20 amended, is further amended by striking “(13) or  
21 (16)” each place it appears and inserting “(13), or  
22 (16)”.

23 (4) Section 6103(p)(4) of such Code, as so  
24 amended and as amended by paragraph (3), is fur-  
25 ther amended by striking “(13)” each place it ap-

1       pears and inserting “(13)(A), (13)(B), (13)(C),  
2       (13)(D)(i)”.

3               (5) Section 6103(l)(13)(C)(ii) of such Code, as  
4       added by the FUTURE Act (Public Law 116-91), is  
5       amended by striking “section 236A(e)(4)” and in-  
6       serting “section 263A(e)(4)”.

7       (b) EFFECTIVE DATE.—The amendments made by  
8       this section shall apply as if included in the enactment  
9       of the FUTURE Act (Public Law 116-91).

## 10       **TITLE III—LABOR PROVISIONS**

### 11       **SEC. 4601. LIMITATION ON PAID LEAVE.**

12       Section 110(b)(2)(B) of the Family and Medical  
13       Leave Act of 1993 (as added by the Emergency Family  
14       and Medical Leave Expansion Act) is amended by striking  
15       clause (ii) and inserting the following:

16                       “(ii) LIMITATION.—An employer shall  
17                       not be required to pay more than \$200 per  
18                       day and \$10,000 in the aggregate for each  
19                       employee for paid leave under this sec-  
20                       tion.”.

### 21       **SEC. 4602. EMERGENCY PAID SICK LEAVE ACT LIMITATION.**

22       Section 5102 of the Emergency Paid Sick Leave Act  
23       (division E of the Families First Coronavirus Response  
24       Act) is amended by adding at the end the following:

25       “(f) LIMITATIONS.—



1           “(1) IN GENERAL.—An employer shall not be  
2 required to pay more than either—

3           “(A) \$511 per day and \$5,110 in the ag-  
4 gregate for each employee, when the employee  
5 is taking leave for a reason described in para-  
6 graph (1), (2), or (3) of section 5102(a); or

7           “(B) \$200 per day and \$2,000 in the ag-  
8 gregate for each employee, when the employee  
9 is taking leave for a reason described in para-  
10 graph (4), (5), or (6) of section 5102(a).

11           “(2) EXPIRATION OF REQUIREMENT.— An em-  
12 ployer’s requirement to provide paid leave with re-  
13 spect to a specific employee shall expire at the ear-  
14 lier of—

15           “(A) the time when the employer has paid  
16 that employee for paid leave under this section  
17 for an equivalent of 80 hours of work; or

18           “(B) upon the employee’s return to work  
19 after taking paid leave under this section.”.

20 **SEC. 4603. REGULATORY AUTHORITIES UNDER THE EMER-**  
21 **GENCY PAID SICK LEAVE ACT.**

22           Section 5111(2) of the Emergency Paid Sick Leave  
23 Act (division E of the Families First Coronavirus Re-  
24 sponse Act) is amended by striking “section 5102(a)(5)”

1 and inserting “paragraphs (4) and (5) of section  
2 5102(a)(5)”.

3 **SEC. 4604. UNEMPLOYMENT INSURANCE.**

4 Section 903(h)(2)(B) of the Social Security Act (42  
5 U.S.C. 1103(h)(2)(B)), as added by section 4102 of the  
6 Emergency Unemployment Insurance Stabilization and  
7 Access Act of 2020, is amended to read as follows:

8 “(B) The State ensures that applications  
9 for unemployment compensation, and assistance  
10 with the application process, are accessible in  
11 person, by phone, or online.”.

12 **SEC. 4605. OMB WAIVER OF PAID FAMILY AND PAID SICK  
13 LEAVE.**

14 (a) FAMILY AND MEDICAL LEAVE ACT OF 1993.—  
15 Section 110(a) of title I of the Family and Medical Leave  
16 Act of 1993 (29 U.S.C. 2611 et seq.) (as added by division  
17 C of the Families First Coronavirus Response Act) is  
18 amended by adding at the end the following new para-  
19 graph:

20 “(4) The Director of the Office of Management  
21 and Budget shall have the authority to exclude for  
22 good cause from the requirements under subsection  
23 (b) certain employers of the United States Govern-  
24 ment with respect to certain categories of Executive  
25 Branch employees.”.

1 (b) EMERGENCY PAID SICK LEAVE ACT.—The  
 2 Emergency Paid Sick Leave Act (division E of the Fami-  
 3 lies First Coronavirus Response Act) is amended by add-  
 4 ing at the end the following new section:

5 **“SEC. 5112. AUTHORITY TO EXCLUDE CERTAIN EMPLOYEES.**

6 “The Director of the Office of Management and  
 7 Budget shall have the authority to exclude for good cause  
 8 from the definition of employee under section 5110(1) cer-  
 9 tain employees described in subparagraphs (E) and (F)  
 10 of such section, including by exempting certain United  
 11 States Government employers covered by section  
 12 5110(2)(A)(i)(V) from the requirements of this title with  
 13 respect to certain categories of Executive Branch employ-  
 14 ees.”.

15 **SEC. 4606. PAID LEAVE FOR REHIRED EMPLOYEES.**

16 Section 110(a)(1)(A) of the Family and Medical  
 17 Leave Act of 1993, as added by section 3102 of the Emer-  
 18 gency Family and Medical Leave Expansion Act, is  
 19 amended to read as follows:

20 “(A) ELIGIBLE EMPLOYEE.—

21 “(i) IN GENERAL.—In lieu of the defi-  
 22 nition in sections 101(2)(A) and  
 23 101(2)(B)(ii), the term ‘eligible employee’  
 24 means an employee who has been employed  
 25 for at least 30 calendar days by the em-

1            employer with respect to whom leave is re-  
2            requested under section 102(a)(1)(F).

3            “(ii) **RULE REGARDING REHIRED EM-**  
4            **PLOYEES.**—For purposes of clause (i), the  
5            term ‘employed for at least 30 calendar  
6            days’, used with respect to an employee  
7            and an employer described in clause (i), in-  
8            cludes an employee who was laid off by  
9            that employer not earlier than March 1,  
10           2020, had worked for the employer for not  
11           less than 30 of the last 60 calendar days  
12           prior to the employee’s layoff, and was re-  
13           hired by the employer.”.

14    **SEC. 4607. ADVANCE REFUNDING OF CREDITS.**

15            (a) **PAYROLL CREDIT FOR REQUIRED PAID SICK**  
16            **LEAVE.**—Section 7001 of division G of the Families First  
17            Coronavirus Response Act is amended by inserting after  
18            subsection (g) the following new subsection:

19            “(h) **TREATMENT OF DEPOSITS.**—The Secretary of  
20            the Treasury (or the Secretary’s delegate) shall waive any  
21            penalty under section 6656 of the Internal Revenue Code  
22            of 1986 for any failure to make a deposit of the tax im-  
23            posed by section 3111(a) or 3221(a) of such Code if the  
24            Secretary determines that such failure was due to the an-  
25            ticipation of the credit allowed under this section.”.

1 (b) CREDIT FOR SICK LEAVE FOR CERTAIN SELF-  
2 EMPLOYED INDIVIDUALS.—Section 7002 of division G of  
3 the Families First Coronavirus Response Act is amended  
4 by inserting after subsection (g) the following new sub-  
5 section:

6 “(h) ADVANCING CREDIT.—The Secretary of the  
7 Treasury (or the Secretary’s delegate) shall issue such  
8 forms and instructions as are necessary—

9 “(1) to allow the advance payment of the credit  
10 under subsection (a), subject to the limitations pro-  
11 vided in this section, based on such information as  
12 the Secretary shall require, and

13 “(2) to provide for the reconciliation of such  
14 advance payment with the amount advanced at the  
15 time of filing the return of tax for the taxable  
16 year.”.

17 (c) PAYROLL CREDIT FOR REQUIRED PAID FAMILY  
18 LEAVE.—Section 7003 of division G of the Families First  
19 Coronavirus Response Act is amended by inserting after  
20 subsection (g) the following new subsection:

21 “(h) TREATMENT OF DEPOSITS.—The Secretary of  
22 the Treasury (or the Secretary’s delegate) shall waive any  
23 penalty under section 6656 of the Internal Revenue Code  
24 of 1986 for any failure to make a deposit of the tax im-  
25 posed by section 3111(a) or 3221(a) of such Code if the

1 Secretary determines that such failure was due to the an-  
2 ticipation of the credit allowed under this section.”.

3 (d) CREDIT FOR FAMILY LEAVE FOR CERTAIN SELF-  
4 EMPLOYED INDIVIDUALS.—Section 7004 of division G of  
5 the Families First Coronavirus Response Act is amended  
6 by inserting after subsection (e) the following new sub-  
7 section:

8 “(f) ADVANCING CREDIT.—The Secretary of the  
9 Treasury (or the Secretary’s delegate) shall issue such  
10 forms and instructions as are necessary—

11 “(1) to allow the advance payment of the credit  
12 under subsection (a), subject to the limitations pro-  
13 vided in this section, based on such information as  
14 the Secretary shall require, and

15 “(2) to provide for the reconciliation of such  
16 advance payment with the amount advanced at the  
17 time of filing the return of tax for the taxable  
18 year.”.

1 **DIVISION E—TEMPORARY PER-**  
2 **MIT USE TO GUARANTEE**  
3 **MONEY MARKET MUTUAL**  
4 **FUNDS**

5 **SEC. 5001. NON-APPLICABILITY OF RESTRICTIONS ON ESF**  
6 **DURING NATIONAL EMERGENCY.**

7 Section 131 of the Emergency Economic Stabilization  
8 Act of 2008 (12 U.S.C. 5236) shall not apply during the  
9 national emergency concerning the novel coronavirus dis-  
10 ease (COVID–19) outbreak declared by the President  
11 under the National Emergencies Act (50 U.S.C. 1601 et  
12 seq.).

13 **DIVISION F—BUDGETARY**  
14 **PROVISIONS**

15 **SEC. 6001. EMERGENCY DESIGNATION.**

16 (a) **IN GENERAL.**—The amounts provided under this  
17 Act are designated as an emergency requirement pursuant  
18 to section 4(g) of the Statutory Pay-As-You-Go Act of  
19 2010 (2 U.S.C. 933(g)).

20 (b) **DESIGNATION IN SENATE.**—In the Senate, this  
21 Act is designated as an emergency requirement pursuant  
22 to section 4112(a) of H. Con. Res. 71 (115th Congress),  
23 the concurrent resolution on the budget for fiscal year  
24 2018.